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5Summary
An effective type I interferon (IFN-α/β) response is critical for the control of many viral
infections. In vivo, the majority of type I IFN is produced by a rare cell type, referred to as
professional interferon producing cell (IPC). The phenotype of the murine IPC in viral
pathogenesis in vivo, and the molecular mechanism by which high-level IFN-α production
is regulated in IPCs have not been characterized previously.
Recent analysis of Newcastle disease virus (NDV) infected fibroblasts (MEFs) in cell
culture established the model of autocrine feedback regulation of type I IFN production. In
this model, induction of IFN-α subtype genes - except α4 - was dependent on type I IFN
receptor (IFNAR) triggering and interferon regulatory factor (IRF)-7 upregulation. Since in
an acutely infected host, fibroblasts presumably do not produce the majority of type I IFN,
we investigated the role of positive feedback regulation of type I IFN induction in viral
pathogenesis in vivo. Surprisingly, vesicular stomatitis virus (VSV) and UV-inactivated
herpes simplex virus (UV-HSV) treated mice mounted early IFN-α responses, largely
independent of IFNAR feedback signaling and IRF-7 upregulation. Type I IFN was
produced at high level by few cells located in the marginal zone (MZ) of the spleen.
In contrast, high-level IFN production by cells in the MZ was not detected in mice
stimulated with synthetic double stranded RNA (poly(I:C)). Moreover, IFN-α production in
poly(I:C) treated mice was IFNAR dependent. These data are discussed in the context of an
extended model of IFN-α induction based on the cell type involved in the production of
IFN-α.
To identify professional IFN-α producing cell type(s) in the mouse, IFN-α2 or IRF-7
promoter driven reporter constructs based on bacterial artificial chromosomes (BACs) were
generated by homologous recombination (ET-cloning). Currently transgenic mice,
expressing these BAC reporters, are being made that will allow to trace the fate of IPCs in
vivo and may give insights whether differentiated IPCs function as antigen presenting cells.
In a second approach to identify mouse IPCs, numerous populations of CD11c positive
dendritic cells (DC) have been isolated from VSV infected mice and screened for IFN-α
expression. Unlike all other fractions tested, the population of CD11cintCD11b-GR-1+ DC
was a major IFN-α producer. This DC subset had a morphology similar to the human
plasmacytoid dendritic cells. Interestingly, these cells expressed IFN-α, irrespective of
whether they were isolated from VSV infected IFNAR competent or deficient mice. Thus,
VSV preferentially activates a specialized DC subset of mouse IPCs to produce high-level
IFN-α largely independent of IFNAR feedback signaling.
6VSV infection led to a prompt upregulation of MHC class II and CD86 molecules on the
IPCs; a hallmark of DC maturation. However, the IPCs of acutely virus-infected mice
rapidly disappeared from secondary lymphoid tissues. At the same time IPC counts were
markedly increased in the bone marrow and slightly enhanced in several peripheral organs.
IPC repopulation of the spleen occurred during the recovery phase from acute virus
infection.
In conclusion, the mouse IPCs described here are capable of immediate IFN-α production
upon viral stimulation and show several characteristics of dendritic cell types. However,
activated IPCs disappear from secondary lymphoid tissues and are therefore unlikely to
constitute a major antigen presenting cell during the initial activation of the adaptive
immune response.
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Cover picture: Rapid expression of type I interferon (IFN-α/β) is the key innate immune response to many
viral infections. Type I IFN-producing cells in the marginal zone of the spleen were stained with polyclonal
antibody directed against type I IFN within hours after viral infection (lower right panel). Unlike fibroblasts in
cell culture, type I IFN-producing cells in the mouse are able to produce IFN-α independent of type I IFN
receptor (IFNAR) feedback signaling. In both wild-type and IFNAR-/- mice the subset of CD11c+GR-1+
dendritic cells has been shown to be a major producer of type I IFNs after viral infection in vivo.
See also figures 3.14 and 3.26f.
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1 Introduction
1.1 The Immune System
It is the task of the immune system to protect the host against invading infectious agents
and thereby to prevent infectious disease. A plethora of microbial pathogens exists (viruses,
bacteria, fungi, parasites and helminths). The successful combat of an invading infectious
agent largely depends on the host's capacity to mount an appropriate protective immune
response.
Classic definition divides the immune system into an innate and an adaptive branch. Innate
immunity depends upon germline-encoded receptors to recognize features that are common
to many pathogens. These receptors are referred to as pattern-recognition receptors (PRRs)
and are expressed differentially by lineages or subtypes of cells. These cells are thus
equipped to exert immediate antipathogen effector function. In contrast, adaptive immunity
is based on the specific recognition of a defined antigen. Antigen-specific receptors of B-
and T-cells (BCR and TCR) are generated by random gene-rearrangement and thus are
clonally distributed, i.e. every naive B- and T-lymphocyte carries a unique receptor
(Rajewsky, 1996). A specific response is generated by antigen dependent clonal selection
and expansion (Burnet, 1966). Therefore the adaptive immune response has a necessarily
slow onset, but it provides the important advantage of immunological memory as a
consequence of the persistence of antigen-specific clones. This allows the rapid response of
specific effector cells upon second encounter with a pathogen bearing the relevant antigen
(Zinkernagel et al., 1996).
The receptors and ancient molecular pathways at the core of innate immunity can be traced
even in insects and plants, thus appear to be used in immune defense in most if not all
multicellular organisms. In comparison, adaptive immunity can be found in jawed fish and
‘higher’ vertebrates but not in other closely related fish species. Recent evidence proposed
an explanation for the abrupt emergence of adaptive immunity with the integration of a
retroposon into the genome (Agrawal et al., 1998; Hiom et al., 1998). This event may have
introduced both the RAG genes and the RSS elements – the paradigm of variability due to
DNA recombination - into a gene of the immunoglobulin family.
The harvest of decades of intense research led leading immunologists to conclude that “our
understanding of the basic mechanisms governing the complex adaptive immune responses
is reasonably complete” (Janeway et al., 2001). Yet it becomes clear, that the effector
mechanisms of the adaptive immune system - as an in evolutionary terms recent addition to
host defense - can only function properly within the framework of innate immunity. The
innate and adaptive immune systems together provide a remarkably effective defense
system. It ensures that although we are surrounded by potentially pathogenic micro-
organisms, we become ill only relatively rarely. Many infections are handled successfully
by the innate immune system and cause no disease, others that cannot be resolved by innate
immunity trigger adaptive immunity and are then overcome successfully, followed by
lasting immunological memory.
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1.2 Innate Immunity
1.2.1 Phagocytes are the primary innate effectors
Elie Metchnikoff is considered the founding father of innate immunology. In early 1900 he
discovered that many microorganisms could be engulfed and digested by phagocytic cells,
which he called macrophages (Metchinkoff, 1905). In the mammalian immune system there
are three types of phagocytes neutrophils, macrophages and dendritic cells (DCs). When the
barrier of the epithelia are breached and microbes begin to replicate in the tissues of the
host, macrophages and neutrophils provide a first line of defense and are essential for the
control of common bacterial infections. It is mainly due to phagocytes that many infections
are handled successfully by the innate immune system and cause no disease.
Immune systems of all species have one feature in common: they respond to infection by
switching from a resting to an activated state. Thus, there must be key features of an
infectious process that trigger immune responses. Pathogens reveal their presence to the
cells of the innate immune system via so called pathogen-associated molecular patterns
(PAMPs) that are usually embedded in structures that are essential to their bearers' survival.
As such, PAMPs evolve slowly and tend to be shared by whole classes of bacteria, viruses
or fungi. And, as different classes of microbe carry different PAMPs, a macrophage or
dendritic cell can classify the invader, and respond appropriately.
1.2.2 Pattern Recognition Receptors
Receptors on innate immune cells mediate a number of different functions. Many are
phagocytic receptors (such as the mannose receptor (CD14), DC lectins or the scavenger
receptors) that stimulate ingestion of the pathogens they recognize. Some are chemotactic
receptors (e.g. IL-8R or the CXCRs and the CCRs). A third function is to induce effector
molecules that contribute to the induced responses of innate immunity and molecules that
influence the initiation and nature of any subsequent adaptive immune response. The Toll-
like receptors (TLRs) are the best-studied family of molecules serving this purpose. The
Toll pathway has been discovered for its role in Drosophila development (Anderson et al.,
1985) and only recently it was shown to also participate in defense against infection in
adult flies (Hoffmann and Reichhart, 2002), and a similar pathway is used by plants in their
defense against viruses (Asai et al., 2002). The necessary DNA sequences are found in all
three classes of organisms: invertebrates, vertebrates, and plants. What invertebrates and
plants share in common with the vertebrates are the genes that encode intracellular
signaling pathways leading from the cell surface to the activation of the transcription factor
NF-κB. Each organism has a cassette of genes that encode the proteins of this pathway,
supporting the notion that the activation of NF-κB is the original and central signaling
pathway of activation in innate immunity (Silverman and Maniatis, 2001).
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The central components of the Toll pathway are summarized in Fig. 1.1. The signaling
pathway via MyD88 leads to activation of NF-κB transcription factor and c-Jun NH2
terminal kinase (Jnk) via p38 mitogen-activated protein kinases (MAPKs). In the case of
LPS stimulation also MyD88-independent activation of NF-κB and Jnk is observed (Kawai
et al., 2001).
Fig. 1.1 The IL-1R–TLR signaling pathway. Molecular components involved in IL-1R and TLR4 signaling
are shown. Activated IL-1R1 or TLR4 associates with a cytoplasmic adaptor molecule, MyD88, through the
homophilic interaction between their TIR domains. MyD88 also possess the death domain, which mediates
the association with a serine-threonine kinase (IRAK). Subsequently, another adaptor molecule, TRAF6, is
activated and in turn activates MAPK kinases (MKKs) and the IKK complex. MKK can lead to AP-1
activation through Jnk. The IKK complex induces phosphorylation of IκB, which renders IB competent for
being ubiquitinated and degraded. IB degradation liberates NF-κB and allows it to translocate into the nucleus
where it can induce target gene expression. (From Akira Nat. Immunol. 2001) Note that the activation of both
NF-κb and the MAPK kinase pathway are prerequisites for IFN-β promoter activation (Chapter 1.6).
So far, ten family members (TLR1-TRL10) have been identified, each able to recognize a
specific pathogen component. For most TLRs activating components have been defined,
leaving TLR1, TLR8 and TLR10 without a known ligand (Table 1). Importantly, also
cellular components released from damaged tissue, e.g. fibronectin or heat-shock proteins
(Hsps), have been shown to activate TLRs (Basu et al., 2000; Okamura et al., 2001). These
and other cytosolic molecules may serve as endogenous danger signals (Gallucci and
Matzinger, 2001), leading to the concept that the immune system does not operate
independently of the tissues that it defends.
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TLR Recognized PAMP Example Pathogens Reference
TLR1 ?
TLR2 /
TLR(2/X)
(heterodimer)
Lipoproteins,
Glycophosphatidyl-
inositol
M. tuberculosis, Borrelia
burgdorfei, Treponema
pallidum, Mycoplasma
fermentans
(Means et al., 1999;
Means et al., 1999;
Underhill et al., 1999)
TLR2 /
TLR6
MALP-2
Peptidoglycan (PGN)
Gram-positive bacteria,
mycoplasma
(Takeuchi et al., 2001)
TLR3 Double stranded RNA Most viruses (Alexopoulou et al.,
2001)
TLR4 LPS
Viral Protein
Outer membranes of
Gram-negative bacteria,
Salmonella
respiratory syncytial virus
(Kurt-Jones et al., 2000;
Medzhitov et al., 1997)
TLR5 Flagellin Flagellated bacteria,
Listeria monocytogenes
(Hayashi et al., 2001)
TLR7 (Imidazoquinoline,
Immiquimod)
?, viruses? (Hemmi et al., 2002)
TLR8 ?
TLR9 CpG-DNA most bacteria, DNA-
viruses
(Hemmi et al., 2000)
TLR10 ?
Table 1.1 Toll-like receptors specifically recognize conserved patterns of pathogens
Activation of TLRs leads to the release of several inflammatory mediators, including
chemokines, from resident tissue macrophages and dendritic cells, and modulates the
expression of chemokine receptors on dendritic cells. The most important innate cytokines
that are produced after TLR stimulation include IL-12, TNF-α and the type I IFNs. Data
from knockout mice indicate that MyD88 is a critical component in the signaling pathway
that leads to production of inflammatory cytokines. MyD88-deficient macrophages are
unresponsive to all TLR ligands in terms of cytokine production (Akira et al., 2001; Kawai
et al., 1999). Different TLRs seem to activate similar but distinct signaling pathways. Thus,
pathogens can determine the nature of the immune response through differential activation
of TLRs and the subsequent patterns of cytokine and chemokine expression may be the first
point at which the immune system tailors its response to specific pathogens.
1.2.3 Local amplification at the site of the infection
Three critical processes in both innate and adaptive immune defense are recognition,
amplification, and control. After the initial recognition of pathogen infection, the numerous
signals of the local inflammatory reaction constitute a first amplification process that serves
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to attract, activate and enhance other innate immune mechanisms. Most importantly,
activated macrophages and dendritic cells secrete, and are themselves affected by, early
cytokines (TNF-α, IL-1, IL-6, IL-12 and the type I interferons) and inducible chemokines
(e.g. IL-8, MCP-1). These are for example required for the production of the respiratory
burst of neutrophils that generates reactive oxygen and nitrogen intermediates (Bogdan,
2001), or for the activation of cytotoxicity in NK cells (Biron, 1997). Other important
players in the local immune amplification include inducible cell adhesion molecules, some
opsonins, and the complement system.
Most recently, local immunoregulatory mechanisms have been highlighted by the discovery
of several receptor families, expressed on myeloid cells. So far, three members of the
DAP12 adapter associated TREM family of activating receptors have been described. They
are encoded by an innate immune gene complex on chromosome 17 in the mouse. TREM-1
triggering strongly amplifies LPS mediated inflammation and septic shock (Bouchon et al.,
2001a), while TREM-2 signaling mediates NF-κB independent maturation of DCs
(Bouchon et al., 2001b). Another group of molecules involved in modulating the activity of
macrophages and DCs are the members of the receptor tyrosine kinase Tyro-3 family
(Tyro-3, Axl, and Mer) (Lu and Lemke, 2001). Finally lysophosphatidylcholine that is
released from the membranes of damaged cells is known to promote chemotaxis and later
also regulates T-cell activity via the immunoregulatory receptor G2A (Kabarowski et al.,
2001). Thus the cells of the innate immune system, and especially antigen presenting cells
(APCs), integrate and process a complex set of signals at the site of infection (Lo et al.,
1999), and eventually transport this ‘information’ together with pathogen derived antigen to
the secondary lymphoid organs (Lanzavecchia and Sallusto, 2001).
1.3 Innate links to adaptive Immunity
The primary adaptive immune response takes place in the draining lymph nodes or the
spleen and not in the infected tissue itself. Adaptive immunity is initiated when an innate
immune response fails to eliminate a new infection, and antigen and activated antigen-
presenting cells are delivered to the draining lymphoid tissues. Indeed, the ability to
overcome innate immune defenses is a key feature that distinguishes pathogenic from non-
pathogenic microorganisms. The cells of the innate immune system and the cytokines they
produce, however, play a crucial part as mediators in the initiation and subsequent direction
of adaptive immune responses.
1.3.1 Dendritic cells as mediators
Dendritic cells (DCs) are professional APCs that can activate naïve T cells. They are
widely considered the most important mediators between innate and adaptive immunity,
because they physically travel from the site of local infection to the regions in secondary
lymphoid organs where the initial activation of naïve lymphocytes takes place (Fig. 1.2).
Dendritic cells enter peripheral tissues in an immature state. There, DC maturation can be
induced by inflammatory cytokines and by microbes or - if they are ligands of TLRs - their
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products. DC maturation is characterized by the production of proinflammatory cytokines
(e.g. IL-12 and TNF-α), up-regulation of costimulatory molecules (CD40, CD80 and
CD86) and altered expression of chemokine receptors (CCR2, CCR5 and CCR7). Mature
DCs show increased antigen-presenting capacity and migrate from the peripheral tissues to
draining lymph nodes or the spleen, where they instruct the adaptive immune response by
stimulating T lymphocytes (Cella et al., 1997).
1.3.2 Cytokines and Chemokines as mediators
Early innate cytokines may also influence the nascent adaptive response either directly, or
indirectly via effects on antigen presenting cells. Importantly, the cytokines present during
the initial proliferative phase of T-cell activation shape the functional differentiation of
CD4 T cells (Moser and Murphy, 2000). While IL-12 in combination with autocrine or
NK-cell derived IFN-γ leads to the differentiation of Th-1 cells (Hsieh et al., 1993), IL-6
together with IL-4 promotes the generation of Th-2 cells (Rincon et al., 1997). In addition,
a multitude of chemokines orchestrates the migration and the homing of both innate and
adaptive immune cells and hence enables the encounters required for the generation of an
adaptive response (reviewed in Luster, 2002).
   
Fig. 1.2 Dendritic cells and cytokines link the local innate immune response with the adaptive response
in the lymph node. Immature dendritic cells home to peripheral tissues, where they acquire antigen. Once
activated by a pathogen stimulus they mature and migrate to secondary lymphoid organs. In this graph,
special emphasis is given to the chemokines involved in the orchestrated migration of innate and adaptive
immune cells (Adapted from Luster AD Curr Op Imm 2002).
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1.4 Viruses
Viruses have been known as distinct biological entities for little more than a century. The
fundamental characteristic of this class of pathogens is their absolute dependence on a
living host organism for reproduction. Viruses enter permissive cells, and the infecting
genome contains the information necessary to redirect the cell to the production of all the
components necessary to assemble new virus particles.
The innate immune response is crucial in antiviral defense because it can be activated
quickly and can begin functioning within hours of a viral infection. Such rapid action
contrasts with the activation of the adaptive response, which is orders of magnitude slower
than the replication cycles of some viruses.
Conversely viruses serve as valuable tools for studying the mechanisms of innate and
adaptive immune defense in vivo. In the following, the two model pathogens used in this
study to characterize the type I IFN response of a virus-infected host are briefly described.
1.4.1 Vesicular stomatitis Virus (VSV)
Vesicular stomatitis virus belongs to the family of Rhabdoviridae, whose members are
widely distributed in nature and have a broad host range. In addition to plant rhabdoviruses
more than 70 rhabdoviruses of vertebrates have been identified (Shope and Tesh, 1987).
Rabies virus is the best-known member of this family of viruses and is of importance to
public health as it causes invariably lethal infection in unvaccinated humans. VSV serotype
Indiana (VSV-IND) can infect insects and mammals and caused widespread epizootics in
cattle and swine in Central America and Mexico (Wagner, 1987). VSV in humans may
cause influenza-like disease that is very rarely fatal and almost invariably caused by
laboratory infection or by transmission from infected animal cadavers (Tesh and Johnson,
1975). Since VSV has been commonly used as a model in basic virologic and immunologic
studies, much is known about its molecular biology and immunology making it an ideal
candidate virus for experimental purposes.
Like other rhabdoviruses, VSV particles are bullet shaped (Fig. 1.3 a), approximately 180
nm in length and 65 nm in width. The genome of the VSV-Indiana (VSV-IND) serotype
consists of an unsegmented single strand RNA of 11162 nucleotides (Schubert et al., 1984).
The membrane of one VSV particle is composed of ~50% host cell derived lipid and 50%
protein consisting of 1828 molecules of unglycosylated peripheral matrix protein (M) and
1205 molecules of externally oriented glycoprotein (G) (Thomas et al., 1985). For the
survival of VSV infected mice a functional type I IFN response is critical (Steinhoff et al.,
1995) that is followed by a potent B cell as well as a cytotoxic T cell (CTL) response.
However, only the antibody response is involved in antiviral protection. Interestingly, all
VSV neutralizing antibodies are directed against one major antigenic site of the protein
moiety of the viral glycoprotein (VSV-G) (Kalinke et al., 1996; Roost et al., 1996) and are
detectable in the serum already 2 days after infection (Bachmann et al., 1994).
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1.4.2 Herpes Simplex Virus (HSV)
Herpes simplex virus is a member of the Herpesviridae and belongs to the most intensively
characterized viruses at the clinical, molecular and structural level (Corey, 1998). Other
family members - besides HSV itself - that are of relevance for human pathology include
Epstein-Barr virus (EBV), causing acute infectious Mononucleosis and Varicella Zoster the
causative agent of chickenpox. In nature, herpes simplex viruses infect exclusively humans,
whereas under tissue culture conditions they infect and replicate in most mammalian cell
lines. In fact, herpes simplex virus infections are very common, affecting an estimated 40%
of the population. There are two types of herpes simplex virus, type I and type II. Most
often type I infections involve the mouth and type II the genitalia.
Of interest is that HSV evades the immune system by entering latency in which neither
viral proteins nor particles are detectable (Stevens, 1989). Herpes simplex virus acutely
infects epithelia and spreads to sensory neurons serving the area of infection. After an
effective immune response controls the epithelial infection, the virus persists in the sensory
neurons. Environmental stress and/or alteration of the immune status may reactivate viral
replication and thus leads to recurrent HSV infections.
The HSV virion particle (Fig. 1.3 b) is 150 - 200 nm in diameter composed of about 40
polypeptides, lipids derived from the host-cell nuclear membrane and complex
carbohydrates. The HSV genome is a linear, double-stranded molecule of approximately
150 kb, organized in two segments: Unique Long (UL) and Unique Short (US). The
laboratory strain HSV strain F shows a strongly reduced infectivity for humans. The risk of
laboratory infection may be reduced further as HSV is sensitive to UV inactivation.
Importantly, inactivated HSV (UV-HSV) retains its ability to induce type I IFNs.
Fig. 1.3 Electron micrographs of vesicular stomatitis virus (a) and herpes simplex virus (b).
(a) Vesicular stomatitis virus particles are bullet shaped and ca. 180 nm in length. The exposed surface is,
with the exception of the flat end of the bullet, densely packed with repeated glycoprotein molecules. (b)
Herpesviruses have an envelope surrounding an icosahedral capsid, approximately 100 nm in diameter, which
contains the dsDNA genome. When the envelope breaks and collapses away from the capsid, virions have a
typical "fried-egg" appearance (Micrographs by Dr Frank Fenner and Dr Linda M Stannard).
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1.5 Type I IFNs are the primary antiviral cytokine
IFNs were identified by their ability to protect cells against viral infection (Isaacs and
Lindenmann, 1957). For a broad spectrum of viruses a functional type I IFN response is
critical for the survival of the infected host (Gresser et al., 1976; Muller et al., 1994). Type I
interferons (IFN-α/β) constitute a family of highly homologous cytokines, comprising in
the mouse at least 11 IFN-α isoforms and one IFN-β, which are all located on the same
chromosome (9p in humans and 4q in mice). IFN-γ is the only known type II IFN and
shares no obvious structural homology with type I IFNs. Rather than being induced directly
by virus infection it is synthesized in response to recognition of infected cells by activated
T-lymphocytes and NK cells. However, functional similarities between type I and type II
IFNs exist due to a broad overlap in the types of genes that they induce (reviewed in
Boehm et al., 1997; http://immunol.annualreviews.org/cgi/content/full/15/1/749/DC1).
1.5.1 Type I IFN receptor signaling
The biologic activity of all IFN-α subtypes and of IFN-β is mediated by binding to the
common type I IFN receptor (IFNAR), a heterodimer consisting of the α-chain (IFNAR-1)
and the β-chain (IFNAR-2) (Lutfalla and Uze, 1994; Uze et al., 1990). IFN proteins bind to
the IFNAR with high affinity (equilibrium dissociation constant [Kd] of about 1 · 10-10 M).
IFNAR signaling activates a JAK-STAT signaling pathway (Darnell, 1997; Leonard and
O'Shea, 1998). Activation of the cytoplasmic tyrosine protein kinases Jak1 and Tyk2 leads
to phosphorylation of Stat1 and Stat2 transcription factors that heterodimerize, translocate
to the nucleus and assemble with the DNA-binding protein IRF-9 (also known as p48) to
form the ISGF-3 complex. The ISGF-3 complex binds with high affinity to the IFN-
stimulated response element (ISRE, consensus sequence A/GNGAAANNGAAACT) found
in the promoters of a multitude of IFN stimulated target genes, whose products are
responsible for type I IFN mediated effects and may drastically alter cell homeostasis
(Fig. 1.4).
1.5.2 Type I IFN function
Similar to other early cytokines, type I IFN mediated effects are pleiotropic and can be
classified into 1) direct antiviral, 2) feedback and amplification and 3) immunomodulatory
effects.
Type I IFNs stimulate an ‘antiviral state’ in target cells, able to directly block or impair
virus replication due to the synthesis of enzymes that interfere with cellular or viral
processes. IFNs also slow the growth of target cells and make them more susceptible to
apoptosis (Tanaka et al., 1998). In the case of IFN-sensitive viruses (e.g., picorna-,
orthomyxo-, retro-, pox-, herpes-, adeno-, papilloma-, and hepadnaviruses), both viral and
cellular protein synthesis stops abruptly in IFN treated, infected cells, but not in uninfected
cells. This defense is carried out by at least two cellular proteins, dsRNA-activated protein
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kinase (PKR) and ribonuclease L (RNase L) (reviewed in Sen, 2001). IFN first promotes
the increased expression and accumulation of an inactive protein that subsequently can
become activated when the cell is infected. If the cell is infected, PKR proenzyme can be
activated by viral dsRNA. Activated PKR then phosphorylates the alpha subunit of the eIF2
translation initiation factor (eIF2a), effectively rendering it incapable of contributing to new
protein synthesis in the cell. RNase L is a nuclease capable of degrading most cellular and
viral RNA species. RNase L is activated by unusual poly(A) oligomers, which are produced
by the 2'-5'-oligo(A) synthetase, but only when activated by dsRNA. Further direct antiviral
molecules are Mx proteins of a family of IFN inducible GTPases that are active against
various negative strand RNA viruses by inhibiting the viral polymerase. Yet, recent studies
involving the generation of mice that are triply deficient in RNase L, PKR and Mx1
indicate that there are additional direct anti-viral effects of IFNs (Zhou et al., 1999).
Type I IFNs synergize with other pro-inflammatory stimuli (i.e. PAMPs, cytokines,
chemokines and costimulatory molecules) to attract and activate further innate effectors to
the site of the infection. Importantly, type I IFNs synergize with IL-12 in the activation and
cytotoxicity of NK cells. Together with GM-CSF or TNF-α, type I IFNs support the
activation and maturation of monocytes (Paquette et al., 1998) and resting DCs (Cella et al.,
1999; Luft et al., 1998), respectively. In macrophages autocrine type I IFN is required for
the enhancement of phagocytosis by M-CSF and IL-4 (Sampson et al., 1991) and stimulates
antibody-dependent cytotoxicity. In addition, type I IFNs positively or negatively regulate
the production of various cytokines (e.g. TNF, IL-1, IL-6, IL-8, IL-12 and IL-18) by
macrophages (Taylor and Grossberg, 1998). Recently it has been shown, that type I IFNs
may also regulate their own expression (Harada et al., 1996; Yoneyama et al., 1996). The
molecular basis for this feedback mechanism is described in chapter 1.6.
Finally, type I IFNs are known to enhance antigen presentation by upregulating the
expression of MHC class I molecules and modulate key facets of the adaptive immune
response. An elaborate interplay of positive and negative type I IFN effects influences the
production of IL-12 and IFN-γ that are the prime cytokines in shaping the outcome of
T-helper cell responses (Biron, 2001). IFN-induced IL-15 can stimulate the division of
memory T cells (Zhang et al., 1998), whilst type I IFN may directly promote the survival of
activated T cells (Marrack et al., 1999). Furthermore type I IFNs have been shown to exert
potent adjuvant activity on the differentiation of DCs from monocytes (Santini et al., 2000)
and on the generation of antigen-specific antibody responses (Le Bon et al., 2001). Due to
complex and situation dependent interactions with other regulating stimuli, type I IFNs
immunomodulatory effects are least well understood and offer ample opportunity for future
study.
Besides viruses also certain bacterial or protozoan pathogens induce the production of type
I IFNs in vivo (Diefenbach et al., 1998; Havell, 1993; Nakane and Minagawa, 1982).
Conversely, recombinant IFN-β protected mice against an infection with L. monocytogenes,
Trypanosoma cruzi or T. gondii (Fujiki and Tanaka, 1988; Kierszenbaum and Sonnenfeld,
1984; Orellana et al., 1991). However, compared to viral infections, the role of type I IFNs
for the defense against non-viral pathogens has been considerably less well studied and the
function of endogenously produced IFN-α/β remains to be determined.
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1.6 Feedback regulation of type I IFN production
Viral infection or stimulation with IFN inducers results in the activation of three different
signaling pathways: 1) activation of the NF-κB signaling pathway, via phosphorylation and
degradation of the cytoplasmic I-κB inhibitor mediated by the IKK complex; this activation
allows free NF-κB to translocate to the nucleus and bind to the PRDII element. 2)
activation of the Interferon Regulatory Factors (IRFs), in particular IRF-3 and IRF-7 by
phosphorylation and binding to PRDIII-I. 3) activation of the ATF-2/c-Jun transcription
complex through phosphorylation by MEKK1 kinase, and binding to PRDIV element. Each
of these factors is activated by serine phosphorylation in virus-infected cells, though the
kinases involved in the activation of IRF-3 and IRF-7 have not yet been defined. Signaling
by all three pathways leads to transcriptional activation of the IFN-β gene via the assembly
of an enhanceosome (Thanos and Maniatis, 1995; Wathelet et al., 1998). The high mobility
group proteins HMGI(Y) function as architectural proteins. Their interactions with ATF-
2/c-Jun and NF-κB are required for virus induction of the IFN-β gene, and for cooperative
assembly and stability of the enhanceosome (Yie et al., 1999). The requirements for the
expression of the IFN-α subtype genes are less well studied. It is known however, that IFN-
α promoter regions contain PRD-like elements (PRD-LE) that allow the binding of
members of the IRF family, but most lack the binding site for NF-κB. This suggests a
differential regulation of IFN-β and IFN-α promoter activity.
The molecular mechanisms of type I IFN induction were intensively investigated by
analyzing virus stimulated mouse embryonic fibroblasts (MEFs) derived from gene targeted
mice deficient of factors involved in the type I IFN signaling cascade. MEFs from mice
lacking IFN-β, IFNAR-1, Stat-1, or IRF-9 showed a defective IFN-α response (Erlandsson
et al., 1998; Harada et al., 1996; Marie et al., 1998; Sato et al., 1998). This suggested that
following the production of early IFN-β, and possibly IFN-α4, expression of other IFN-α
genes was dependent on type I IFN receptor feedback signaling.
1.6.1 Interferon regulatory factors (IRFs)
The members of the interferon regulatory factor (IRF) family share a high degree of
homology in the N-terminal DNA binding domain and generally bind the DNA sequence
GAAANNGAAANN; the C-terminal portion of the IRF proteins is unique to each member.
Two members of the IRF family - IRF-3 and IRF-7 - have been shown to play a key role in
the sequential induction of type I IFN genes. Virus mediated serine phosphorylation leads
to IRF-3 activation and translocation to the nucleus (Sato et al., 1998). There, IRF-3 is part
of an enhanceosome complex promoting the expression of IFN-β, and presumably of
IFN-α4. Early type I IFN is secreted and triggers IFNAR signaling in an autocrine fashion.
Among other type I IFN induced genes, IFNAR signaling strongly upregulates IRF-7
expression (Marie et al., 1998; Sato et al., 1998).
Introduction   25
P
I R F - 3
P
p48
P
P
PIRF-7IFN β
many other
IFN induced genes
Jak-1Tyk-2
STAT1
STAT2
P
early or "trigger"
 IFN response
late IFN
response
IRF-7
ISRE
ISGF-3
P
P
Type I IFN
Receptor
Phase I:
Virus induced
Phase II:
Interferon induced
Phase III:
Virus + Interferon induced
IFN β
IFN α and IFNβ
Fig. 1.4 Model for the positive feedback regulation of type I IFN production. In phase I virus-mediated
activation of interferon regulatory factor-3 (IRF-3) leads to the low-level induction of IFN-β. Autocrine
signaling via the type I IFN receptor in phase II activates a large number of IFN stimulated genes. One of
these genes codes for IRF-7, a transcription factor critically required for the induction of IFN-α genes. IRF-7
activation in phase III is again mediated by the viral stimulus. Activated IRF-7 upregulates many IFN-α
subtypes and thereby allows for a pronounced production of “late” type I interferons.
Virus infection leads to IRF-7 activation by phosphorylation that drives the expression of
the majority of IFN-α subtypes, and hence amplifies the type I IFN response (Fig. 1.4). It
appears, that several pathways may lead to IRF-3 and IRF-7 activation. Some viruses, such
as type I herpes simplex virus (HSV), induce an IFN response independent of viral
replication whereas others, e.g. vesicular stomatitis virus (VSV), lose the ability to induce
type I IFN upon inactivation. Furthermore, a variety of non-viral IFN inducers have been
described, including procaryotic DNA motifs (CpG-DNA), synthetic double-stranded RNA
(poly(I:C)), lipopolysaccharide (LPS), and imiquimod derivatives (Bauer et al., 2001;
Megyeri et al., 1995).
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1.7 The major IFN-α producing cell (IPC)
In cell culture virtually any cell type can produce type I IFN in response to appropriate
stimulation. Yet, depending on the expression of pattern recognition receptors distinct cell
types are stimulated by different IFN inducers. For example CpG but not poly(I:C) treated
human CD11c- dendritic cells (DCs) produce type I IFN, whereas a reverse correlation was
found for CD11c+ DCs (Bauer et al., 2001; Kadowaki et al., 2001). Accordingly, CD11c-
DCs express the Toll-like receptor (TLR)-9 and CD11c+ DCs express TLR-3 (Bauer et al.,
2001; Kadowaki et al., 2001), which have been shown to be involved in the recognition of
CpG or poly(I:C), respectively (Alexopoulou et al., 2001; Hemmi et al., 2000). Differential
expression of TLRs on DCs is presumably involved in the fine-tuning of host immune
responses. So far, the major IFN producing cell (IPC) has not been defined in the context of
infection with specific pathogens. Several studies addressed the nature of the human IPC
(Ferbas et al., 1994; Sandberg et al., 1991; Svensson et al., 1996), which eventually was
defined as the subset of CD11c- plasmacytoid DCs (Cella et al., 1999; Siegal et al., 1999).
There are indications, that upon stimulation of mice certain macrophages (Eloranta and
Alm, 1999) or DC subsets can produce type I IFN (Asselin-Paturel et al., 2001; Hochrein et
al., 2001; Nakano et al., 2001).
1.7.1 Plasticty of the myeloid lineage - IPCs and other dendritic cell subsets
The cells of the immune system originate from precursor cells residing in the bone marrow,
where many of them also mature. There is however, a significant degree of plasticity in cell
types that are found in the periphery, both in the blood and solid organs. This feature was
demonstrated most impressively by the analysis of PAX5 deficient cells, which are arrested
at the pro-B cell stage. These can de-differentiate and give rise not only to DCs, NK cells
and T cells but also to myeloid and erythroid cells (Rolink et al., 1999; Schaniel et al.,
2002). Dendritic cells have a remarkable heterogeneity related to both tissue localization
and functional maturation state. Differential expression of DC lineage markers led to the
notion that the mouse and human possess surprisingly divergent DC compartments.
Fortunately, recent progress allowed for most subtypes the definition of similar populations
in both species (for review see Ardavin et al., 2001). Yet, despite extensive research on the
development of dendritic cells, their origin and the differentiation pathways that generate
DCs in vivo remain largely unknown. Monocytes in human blood are attracted to sites of
inflammation where they extravasate and differentiate into dendritic cells under the aegis of
local cytokines such as type I IFNs (Randolph et al., 1999; Santini et al., 2000). Other
examples of stimulation dependent DC plasticity and the discovery of common progenitors
of myeloid and lymphoid DC subsets (Martin et al., 2000; Traver et al., 2000) have led to a
model of instruction on top of lineage heritage for the generation of DC diversity
(Lanzavecchia and Sallusto, 2001; Liu et al., 2001). Similarly, it is not clear whether the
professional interferon producing cells alias plasmacytoid- T-cells, monocytes or DCs,
define a discrete lineage of cells destined to differentiate into dendritic cells or whether they
constitute a multipotent precursor to a set of different immunocytes (Galibert et al., 2001).
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1.8 Aim of the Thesis
The model of type I IFN receptor (IFNAR) feedback for the regulation of IFN-α production
has been established recently from studies of mouse embryonic fibroblasts (MEFs) infected
in cell culture. Yet, in an acutely infected host, fibroblasts presumably do not produce bulk
quantities of type I IFN.
Here we study the requirement of type I IFN receptor signaling and IRF-7 upregulation for
the production of IFN-α during viral infection in vivo. We hypothesize that in vivo the
majority of type I IFN is contributed by a distinct cell type, referred to as professional
interferon producing cell (IPC). The phenotype of IPCs in the mouse and the mechanism by
which high-level IFN-α production is regulated in these cells have not been characterized
previously. In order to identify professional interferon producing cells (IPCs) in the mouse
a two-tier strategy is pursued. One approach aims at genetically marking IPCs in transgenic
mice by the expression of reporter genes under the control of the IFN-α2 or IRF-7
promoter. The second strategy tries to identify the mouse IPC population by cell sorting
using surface markers for dendritic cell subsets. Both approaches can be applied to study
the origin and fate of mouse IPCs. Especially, it will be important to investigate whether
mouse IPCs may function as antigen presenting cells and thus link innate and adaptive
immune responses against viruses and other pathogens.
Materials and Methods   28
2 Materials and Methods
2.1 Mice
2.1.1 General maintenance and breeding
Type I interferon receptor deficient mice (IFNAR-/-) on the SV129 background (Muller et
al., 1994) and IFN-β-/- mice on the Balb/c background (Erlandsson et al., 1998) were bred
under specific pathogen free conditions (SPF). Unmutated SV129 mice (referred to as WT)
were obtained from the SPF-breeding colony of the European Mutant Mouse Archive
(EMMA), Monterotondo, Italy. C57BL/6 mice were purchased at IFFA-Credo (Saint
Germain-sur-l’Abresle, France). Experimental mouse work was done under SPF conditions
in compliance with regulations of the Ministerio della Sanità, Rome, Italy (decreto
ministeriale n˚ 15/2001-b, 3/3.1).
2.1.2 Spleenectomy
Mice were anesthetized via i.p. injection of Avertin (2.5%, ~0.3 ml). Fur was shaved
around the site of the intervention. The skin was washed with Betadine and a horizontal
incision of ~1 cm was made using scissors. The connective tissue under the skin was
loosened with blunt end forceps and a < 1 cm horizontal cut was made in the peritoneal
wall. The spleen was gently pulled onto the exterior surface of the peritoneum. Using a
heated forceps, the artery attached to the hilium of the spleen closest to the stomach and
then the efferent venule on the other side of the spleen were cauterized. Then connective
tissue was cut away and the spleen removed. The peritoneal wall was closed with 2 separate
sutures and the skin was closed with an additional 2 - 3 sutures. The animal was placed in a
fresh pre-warmed cage was observed during the wake up time. The quality of the sutures is
of prime importance as animals scratch and gnaw at the wound and a reopening of the cut is
fatal. Animals were checked twice daily and were used for the experiments 3 - 5 days after
the surgery.
2.1.3 Preparation of single cells suspension from various tissues
Blood was collected by retro orbital bleeding using a Pasteur pipette partially filled with
heparinized PBS (8 mM Na2HPO4-2H2O, 3 mM NaH2PO4-H2O, 150 mM NaCl) 3% FCS.
Peritoneal cavity cells were obtained by flushing 10 ml ice cold PBS 3% FCS through the
peritoneal wall using a syringe with an 18 gauge needle. Bone marrow was flushed from
femurs and tibiae, after the edges of the bones had been clipped off, using PBS 3% FCS
and a syringe with a 26 gauge needle. Livers were rinsed from blood by injection of 10 ml
PBS into the vena cava before explanting. Spleens, peripheral lymph nodes (Inguinal,
axillary and brachial), mesenteric lymph nodes, peyers patches, thymi and kidneys and
lungs were collected into 15 ml Falcon tubes containing 3 - 5 ml PBS 3% FCS and then
passed through a nylon mesh using a steel plunger. Cells were resuspended in 10 ml PBS
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3% FCS. Debris was allowed to settle and the supernatant decanted into a fresh 15 ml
Falcon tube. Suspensions from livers and kidneys contained large quantities of cellular
debris requiring prolonged and repeated settling of debris and decanting followed by
extensive washing of the cells. On pelleted blood and kidney samples red blood cell lysis
was performed on ice for 10 min using ACK lysing buffer (150 mM NH4Cl, 10.0 mM
KHCO3, 0.1 mM Na2EDTA pH 7.4). In all other cases, cells were washed once with PBS
3% FCS and counted using a Neubauer counting chamber (Bender/Hobein, #631A1110).
2.2 Cell culture
2.2.1 Cell Culture of cell lines
All tissue culture reagents used were purchased from Gibco-BRL (www.lifetech.com)
unless otherwise stated. Catalog numbers are: DMEM #41965-039, D-MEM #10938-025,
MEM #31095-029. Fetal calf serum (FCS) was used heat inactivated for 60 min at 56 °C.
Further additives for culture media were 0.1 mM 2β-mercaptoethanol (Fluka, #63690), 2
mM L-glutamine (Gibco, #25030-024). Standard cell culture was performed in antibiotic
free media. For short-term assays under non-sterile conditions 1% penicillin-streptomycin
(Gibco, #15140-130) was added to the media. Cells were usually cultured in T175 flasks
(Falcon BD, #353028).
• BHK cells (BHK-21), baby hamster kidney fibroblast cells were obtained from the
ATCC (#CCL-10) and were cultured in DMEM 5% FCS.
• L929 cells (H-2b), mouse fibroblasts were obtained from the ATCC (#CCL-1) and
were propagated in DMEM 10% FCS.
•  MC 57 G cells (H-2b), methylcholanthren transformed mouse fibrosarkoma cells
were originally provided by Dr. B. B. Knowles (Philadelphia, USA). These cells
were cultured in MEM 5% FCS
•  Vero cells, African green monkey kidney epithelial cells were obtained from the
ATCC (#CCL-81) and were propagated in DMEM 5% FCS.
Confluent cells were split by washing the adherent cell monolayer for 10 min with PBS
(Gibco, #14190-169). Cells were then detached by incubation with Trypsin/EDTA (Gibco,
#25300-054) for 5 min at 37 °C. Single cell suspension was prepared by adding medium
containing 10% FCS and repeated pipe ting followed by the removal of excess cells.
2.2.2 Freezing and thawing of cells
Cells from a confluent flask were trypsinized, washed once and taken up in freezing
medium (DMEM 10% FCS, 10% DMSO). Aliquots were placed in a freezing container
filled with isopropanol and remained for 3 days at –80 °C before storage in the liquid
nitrogen tank. Aliquots were thawed by brief incubation in a water bath at 37 °C, were
washed once in DMEM 10% FCS and then seeded at various dilutions into 6 well plates.
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2.2.3 Generation of mouse embryonic fibroblasts (MEFs)
Wild type and IFNAR-/- MEFs were derived from day 13 embryos (Torres and Kühn,
1997). Embryos were collected in PBS, heads and livers were removed. The remainder was
placed in 4 ml 0.125% trypsin/EDTA and minced into small pieces and incubated for 30
min at 37 °C. The reaction was stopped by adding Dulbecco’s MEM supplemented with
10% FCS and single cell suspension was prepared by vigorous pipeting. After removal of
cell debris, by settling and decanting, cells were seeded in T175 flasks with 25 ml MEM
10% FCS. Cells were grown to confluence and every 2 - 3 days one flask was split into 5
T175 flasks. After 2 - 4 passages MEF cells were frozen for later use (see 2.2.2)
For the IFN production experiments MEFs were seeded in 6 cm petri dishes and after
adhering o.n. the cell monolayers were infected with VSV at a multiplicity of infection
(moi) of 10. After 1 h of incubation at 37 °C the virus suspension was replaced by
Dulbecco’s MEM 10% FCS.
2.3 Viruses
2.3.1 Production and Purification of VSV
Vesicular stomatitis virus Indiana (VSV) (Mudd-Summers isolate) was originally obtained
from D. Kolakofsky (University of Geneva, Geneva, Switzerland) and was grown on BHK
(ATCC CCL-49) cells and plaqued on Vero cells (see 2.3.3). Confluent T175 flasks were
infected with a low multiplicity of infection (moi 0.1, by adding 3 ml of diluted virus/T175
flask), incubated for 1h at RT with occasional shaking. Then 27 ml MEM 2% FCS were
added and incubated at 37˚C, 5% CO2 for 48 h. Supernatants were pooled and cell debris
was removed by centrifugation. Stocks were maintained at –80 °C in MEM containing 2%
FCS.
2.3.2 Production and Purification of HSV
HSV strain F originally obtained by ATCC was grown on Vero cells. HSV was purified
from cell culture supernatant by PEG 40.000 (Serva #33139.01) precipitation. Following
several pelleting steps for 1 h at 43.000 g virus was resuspended in PBS and titrated on
Vero cells. After UV irradiation (1.2 Joule/cm2) complete HSV inactivation was verified by
plaquing on Vero cells.
2.3.3 Plaque Assay for VSV and HSV
One day before the assay Vero cells (diluted to 2 · 105/ml in MEM 5% FCS, 3 ml per well)
were seeded in 6 well cell culture plates. Serial ten-fold dilutions of the virus-containing
sample were prepared in MEM 5% FCS. It is important to mix well in each dilution and to
change tips after every transfer. The medium on the Vero cell monolayer was replaced with
1 ml of virus dilution. The plates were then incubated for 1 h at 37 °C. Each well was
carefully overlaid with 1 ml 1% Methylcellulose/1% DMEM. After overnight incubation at
37 °C, medium was flicked off into 10% bleach and the cell-monolayer was stained for 1h
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with crystal violet solution. Color was flicked off and plates were washed extensively with
tap water and air-dried. Plaques were counted and the pfu determined using the following
formula: pfu virus = ∑plaques of three consecutive wells x (dilution factor of the well with
the lowest dilution counted / 1.11).
2.4 Assay methods
2.4.1 Expression analysis by RT-PCR.
Preparation of total RNA was performed using the TRIZOL reagent (Gibco #15596)
according to the manufacturer's instructions. Tissue samples were snap-frozen and
homogenized in Trizol using a Polytron PT 1200 C (Kinematica, Switzerland). On cultured
cell monolayers and FACS-sorted cells Trizol was applied directly. From samples
containing small cell numbers, directly sorted into Trizol, total RNA was prepared after
adding 200 µg Glycogen (Boehringer Mannheim, #901393) as carrier followed by shearing
of genomic DNA by two passes through a 26 gauge needle. Reusable Plastic materials were
rinsed with RNAase ZAP (Ambion #9780) to reduce the risk of introducing RNase. To
eliminate possible DNA contamination total RNA was incubated for 15 minutes at 37 °C
with 10 units of DNase (Boehringer Mannheim, #776785). cDNA was prepared using
Superscript II (Gibco #18064-014) and oligo dT primer (Gibco, #18418-012) according to
the manufacturer's instructions. To estimate relative amounts of specific mRNAs, PCRs
were performed with serially five-fold diluted cDNA using published primers for IFN-α
(consensus primers annealing with all IFN-α subtypes) and IRF-7 (Marie et al., 1998). The
mRNA content was normalized by RT-PCR analysis with GAPDH-specific primers from
the same publication. The absence of contaminating DNA was verified by PCR analysis of
RNA preparations not treated with reverse transcriptase. Taq Polymerase (#M1668) and
dNTPs (#U1201/1221/1211/1231) were ordered from Promega. PCR reactions were
performed in MicroAmp tubes (Perkin Elmer, #N801-0535/-0580). The PCR-Machine used
was a MJ Research PTC-200, DNA engine, Biozym Diagnostik GmbH, Hess. Oldendorf.
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Gene Primer Name Primer Sequence PCR conditions
#18 IFNa-up ATG GCT AGR CTC TGT GCT TTC CTIFN-α
subtypes #19 IFNa-do AGG GCT CTC CAG AYT TCT GCT CTG
Product length: 524 bp
94 °C-5’, 94 °C-30’’, 53
°C-30’’, 72 °C-1’06’’, 30
cycles, 72 °C-10’
#98 IFNb-up CAT GAA CAA CAG GTG GAT CCT CCA
CGC
IFN-β
#99 IFNb-do TCA GTT TTG GAA GTT TCT GGT AAG
TCT TCG
Product: 560 bp
94 °C-5’, 94 °C-30’’, 60
°C-30’’, 72 °C-60’’, 30
cycles, 72 °C-10’
#34GAPDH-up ACC ACA GTC CAT GCC ATC ACGAPDH
#35GAPDH-do TCC ACC ACC CTG TTG CTG TA
Product length: 452 bp
94 °C-5’, 94 °C-30’’, 60.5
°C-30’’, 72 °C-55’’, 25
cycles, 72 °C-10’
#50 IRF3-up CCA GGT CTT CCA GCA GAC ACTIRF-3
#51 IRF3-do TAG GCT GGC TGT TGG AGA TGT
Product length: 557 bp
94 °C-5’, 94 °C-15’’, 60.0
°C-15’’, 72 °C-1’, 30
cycles, 72 °C-10’
#52 IRF7-up CAG CGA GTG CTG TTT GGA GACIRF-7
#53 IRF7-do AAG TTC GTA CAC CTT ATG CGG
Product length: 360 bp
94 °C-5’, 94 °C-30’’, 61
°C-30’’, 72 °C-43’’, 30
cycles, 72 °C-10’
#180 5'IRF-5a ATT CAG CGG GAA GTC AAG ACG AAGIRF-5
#181 3'IRF-5a GGG CCA CCA CAT TGC TAT ATC AGT
C
Product length: bp
94 °C-5’, 94 °C-15’’, 60.0
°C-15’’, 72 °C-1’, 30
cycles, 72 °C-10’
#136 5VSVGP CCA TGA AGT GCC TTT TGT ACTVSV-GP
#137 3VSVGP ATT GCT GCA TTT TCC GTT GAT
Product length: 495 bp
94 °C-5’, 94 °C-15’’, 60.0
°C-15’’, 72 °C-1’, 30
cycles, 72 °C-10’
Table 2.1 PCR primers used for semiquantitative RT-PCR
2.4.2 Sequencing of subcloned PCR-product and sequence analysis
The 524 bp PCR product of the IFN-α consensus primer PCR on cDNA was purified via
agarose gel electrophoresis and gel-extraction (Qiaex II, Qiagen #20051). Purified fragment
was A:T-ligated into the pGEMT vector (Promega #A3600). 5 ml of the ligation was
transfected by heat-shock into CaCl2 competent bacteria (see 2.5.2) and plated on LB-
Ampicillin plates. Single colonies were picked after o.n. incubation at 37 °C and mini-
preparations by alkaline lysis. Clones with the integration of the correct fragment were
determined by Pvu II digest. Selected clones sequencing reaction was prepared using ABI-
Systems Big-Dye or Dye terminator chemistry. All kits were used according to the
manufacturer's instructions. Sequencing reactions were purified by ethanol precipitation
and were resuspended in formamide (Merck, #1.09684). Sequences were obtained on an
ABI-Systems 310 capillary sequencer or a 373 gel sequencer, respectively and analyzed
using the Sequencher (Gene Codes Corporation) software. Contigs of homologous
fragments were compared to published IFN-α sequences (EMBL accession numbers:
M68944, M13660, K01238, X01973, X01971, X01972, M13710, D00460, M28587,
L38698). Sequence identity to the published IFN-α  subtype was assumed when the
sequence analyzed contained less than 10 mismatches / 300 bp.
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2.4.3 Quantification of type I IFN in blood sera (CPE-assay)
The IFN bioassay was based on the protection of L929 cells from the cytopathic effect of
VSV (CPE inhibition assay). Mouse blood sera were obtained by retro-orbital bleeding
followed by centrifugation at 4300 rpm in Microtainer serum separator tubes (Becton
Dickinson, #365960). To inactivate potential viral contamination, 1:5 pre-diluted serum
samples from VSV infected mice were UV-irradiated with 1.2 Joule/cm2. Duplicates of
serially two-fold diluted sera were transferred to 24 h pre-incubated semiconfluent
monolayers of L929 cells in 96-well plates. After 24 h incubation at 37 °C supernatants
were removed and VSV was added at a MOI of 0.05. After 48 h incubation at 37 °C,
supernatants were taken away and protected cells were stained with 0.5% crystal violet in
5% formaldehyde, 50% ethanol, and 0.8% sodium chloride. Following extensive washing
with water and air drying, the dye was extracted from stained cells with 100 ml/well 0.1 M
sodium citrate in 50% ethanol, pH 4.2 and the crystal violet content was determined on an
ELISA reader at 570 nm. In the CPE inhibition assay an international mouse IFN-α/β
reference standard of 100 IU/ml (Gu02-901-511, NIAID Repository) and recombinant
IFN-αA standards (PBL Biomedical Laboratories, #12100) of 100, 500, 2500, and 10000
IU/ml were included. For IFN quantification the 50% protective serum dilution was
indicative. A log25 titer corresponded to 1000 IU IFN-αA. The contribution of IFN-β or
IFN-α to the total type I IFN activity was determined by pre-incubating sera for 1 h with
excess amounts of neutralizing anti-IFN-α (clone 4E-A1, Yamasa Shoyu) or anti-IFN-β
(clone 7F-D3, Yamasa Shoyu) monoclonal antibodies. Protection from cytopathic effect
due to IFN-γ was formally excluded by an IFN-γ Elisa (Endogen #KM-IFNG) indicating
that the IFN-γ content of all samples tested was below the detection threshold of the assay
(see 2.4.4).
2.4.4 Quantification of IFN-γ in blood sera (ELISA)
For the determination of IFN-γ content in mouse blood sera the Endogen minikit IFN-γ
Elisa (KM-IFNG) was used according to the manufacturer's instructions with the
modifications described here. The required number of wells of a plate were coated o.n. with
anti-IFN-γ antibody and then blocked and washed. IFN-γ standard was diluted and used in
serial twofold dilution starting at 4000 pg/ml. Serum samples were tested in 1:5 and 1:50
dilution. 50 µl of the dilutions were added to the wells and incubated for 1h at 37 °C. After
washing wells were incubated for 1h at RT with biotinylated anti-IFN-γ detection antibody
and then washed again. Incubation with Streptavidin-HRP (Endogen Cat. #N-200) was
carried out at 1:10.000 dilution for 30 min followed by washing. TMB substrate at RT was
then added and incubated in the dark for 30 min and then the reaction was terminated by
adding Stop-Solution. The plate was measured immediately at 450 nm.
2.4.5 Flow cytometric analysis
Freshly prepared single cell suspensions were pre-incubated with Fc-Block reagent (BD
Pharmingen #553142) and stained as indicated with the following mABs in PBS 3% FCS:
FITC conjugated CD5, CD11b, CD19, DX-5, CD40, CD54, CD69, CD80, CD86, Rat
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IgG2a isotype control (BD Pharmingen) or CD62L, CD90, B220, CD8, MHCII, Ly6C
(Southern Biotechnology Associates); PE conjugated CD4, IL-3R, Sca-1, Gr-1, Rat IgG2a
isotype control (BD Pharmingen), Ly6C (Southern Biotechnology Associates) or F4/80
(Serotec); Cychrome conjugated B220 (BD Pharmingen); Biotin conjugated CD11b,
CD11c (BD Pharmingen) mABs were followed by streptavidin-Cychrome (BD
Pharmingen). Stainings were performed either in 6 ml FACS tubes (Falcon, BD) or in 96
well round bottom plates followed by transfer into PPN-96 tubes (Micronic, #M226C2).
Red blood cells and cell debris were excluded by a morphological gate (FSC/SSC), or by
appropriate setting of the FSC threshold, respectively and 300.000 – 1.2 Mio events were
acquired on a Becton Dickinson FACScalibur and analyzed using CellQuest (Becton
Dickinson) software.
2.4.6 Intracellular cytokine staining for IFN-α
Single cell suspensions were prepared from the spleens of C57BL/6 mice, untreated or
VSV infected for 6 h. To accumulate intracellular IFN the cells were incubated for 2h at 37
°C 4% CO2 in DMEM 10% FCS containing 10 µg/µl Brefeldin A (Sigma, #B7651). Cells
were fixed in 2% paraformaldehyde (Sigma, #P6148) for 15 min on ice. A permeabilization
buffer consisting of PBS 0.5% Saponin (Sigma, #S7900) 1% FCS was used for all
following washes and incubation steps. Cells were washed twice and then permeabilized
for 20 min at RT. Monoclonal rat anti-mouse IFN-α antibody (Serotec, #MCA1431) was
used at 10 µg/ml for 30 min at RT. After extensive washing PE-labeled monoclonal goat
anti-rat antibody (Southern Biotechnology Associates) was used at 1:50 dilution and
incubated for 30 min at RT. Cells were washed in PBS 3% FCS (without saponin) and
measured on a FACScalibur cytometer (Becton Dickinson). Controls were performed
omitting the primary antibody or using an isotype control. Moreover, control stainings were
performed on cells from uninduced mice.
2.4.7 Kinetics of IPC turnover in spleen and bone marrow
Mice were injected i.p. with 1 mg bromodeoxyuridine (BrdU, Sigma #B5002) dissolved in
PBS and were fed thereafter with drinking water containing 1 mg/ml BrdU. MACS
enriched CD11c+ cells from spleen or BM were stained intracellularly with FITC
conjugated anti-BrdU mAb and contemporaneously on the cell surface with fluorescent
mABs using the BrdU Flow Kit (BD Pharmingen #559619) according to the manufacturer's
instructions.
2.4.8 Labeling of cells for adoptive transfer cells using CFSE
Single cell suspensions were incubated with a 1/1000 dilution of carboxyfluoroscein
succinimidyl ester (CFSE 0.5 mM (Molecular Probes #C-1157) in DMSO (Fluka #41641)
at 37 °C for 10 min. In order to obtain less intense staining 1/10.000 dilutions were used.
Cells were washed once using ice cold DMEM 10% FCS and injected intravenously in a
volume of 500 µl (Lyons and Parish, 1994).
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2.4.9 Flow cytometric cell sorting of DC subsets (FACS)
Single cell suspension of 3 - 5 spleens was prepared and CD11c+ cells were enriched by
magnetic adsorption cell sorting (MACS, Miltenyi Biotech). Three-color stainings were
made using anti-CD11c-Biotin, anti-CD11b-FITC and anti-GR-1-PE conjugated
monoclonal antibodies followed by Streptavidin-APC (all from Pharmingen, San Diego,
California). 4 - 10 · 104 cells of each subset were sorted from about 107 cells on a MoFlo
cytometer (Cytomation, Fort Collins, Colorado).
2.4.10 Magnetic adsorption cell sorting (MACS)
Cells were enriched from spleen and BM suspensions by magnetic adsorption cell sorting
(Midi MACS, LS+ separation columns, Miltenyi Biotech #424-01) according to the
manufacturer's instructions. The following MACS MicroBeads were used: MHC Class II
(Ia) #524-01, CD45R (B220) #522-01, CD11b (Mac-1) #496-01, and CD11c (N418) #520-
01. To remove cell clumps Pre-Separation Filters (Filcons 30 µm, #414-07) were used. PBS
10% FCS 1 mM EDTA was used as MACS-buffer at all stages.
2.4.11 May-Grünwald Giemsa staining of single cells
May-Grünwald-Giemsa staining consists of a mixture of methylene blue (which dyes acidic
cell components blue), azure (which dyes basic cell components red and violet) and eosin
(which dyes alkaline cell components orange-red). In May Grünwald Giemsa stains
residual RNA, cytoplasm and nucleoli are blue, DNA and primary granula red and violet as
well as hemoglobin and eosinophilic granula are orange-red.
Single cell suspension of FACSorted cells was briefly incubated at 37 °C to ensure natural
morphology of the cells. About 10.000 cells were diluted in 300 µl RPMI-Hepes medium
and were spun onto a microscope slide (Assistant #2406/1) for 10 min at 500 rpm in a
Cytospin centrifuge (Shandon) according to the manufacturer's instructions. Slides were air
dried for 10 min at RT. Slides were fixed for 2.30 min at RT in 100% methanol, dried for
10 min at RT and then incubated for 3 min in concentrated May-Grünwald solution (Fluka,
#63590). The slides were then incubated for 3 min in 50% May-Grünwald solution diluted
in tap water, followed by 10 min incubation in 7% Giemsa solution (Fluka, #48900). The
slides were rinsed with tap water, dried and enclosed with Eukitt before analysis by
brightfield light microscopy.
2.4.12 Immunohistochemistry
Freshly removed organs were immersed in Hank’s balanced salt solution (HBSS 10x,
Gibco #14065-031) and snap frozen in a large volume of liquid nitrogen. Tissue sections of
5 mm thickness were cut in a cryostat, placed on siliconized glass slides, air dried, fixed
with acetone for 10 min, and stored at –80 °C. Interferon was stained using a polyclonal
sheep anti-mouse IFN-α/β antiserum (PBL Biomedical Labs, New Brunswick, NJ, #RDI-
PB32105) or monoclonal rat anti-mouse IFN-α antibody (Serotec #MCA1431). The
primary sheep antibody was detected with affinity purified biotinylated donkey anti-sheep
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Ig antibodies (Jackson ImmunoResearch Labs, West Grove, PA #713-066-147) and
alkaline phosphatase labeled avidin/biotin complexes (ABC/AP Dako, Glostrup, Denmark
#K0391). The primary monoclonal rat antibody was detected with affinity-purified
peroxidase labeled goat anti-rat Ig antibody (Jackson #112-035-102). For signal
amplification by catalyzed reporter deposition, biotinylated thyramine (Bobrow et al.,
1989) and 3% H2O2 was added for 7 min, and covalently bound biotin was revealed by
ABC/AP. For the staining of cell differentiation markers, sections were incubated with rat
monoclonal antibodies against red pulp macrophages (F4/80, Biomedicals, Augst,
Switzerland) marginal zone macrophages (ERTR-9; van Vliet et al., 1985) and against
marginal zone metallophils (MOMA-1, Biomedicals, Augst, Switzerland). Primary rat
antibodies were revealed by sequential incubation with goat antibodies to rat
immunoglobulins (Caltag Labs, San Francisco, CA) and alkaline phosphatase labeled
donkey antibodies to goat immunoglobulins (Jackson). Alkaline phosphatase was
visualized using naphthol AS-BI (6-bromo-2-hydroxy-3-naphtholic acid-2-methoxy
anilide) phosphate and new fuchsin as substrate. Endogenous alkaline phosphatase was
blocked by levamisole. The dilutions of secondary antibodies were made in TBS (50 mM
Tris-HCl (pH 7.4), 150 mM NaCl) containing 5% normal mouse serum. Incubations were
done at RT. for 30 min; TBS was used for all washing steps. Color reactions were
performed at RT for 15 min with reagents from Sigma Chemical Co. (St. Louis, MO).
Sections were counterstained with hemalum and coverslips mounted with glycerol and
gelatin.
2.4.13 In situ hybridization of IRF-7 mRNA
In situ hybridisation was performed according to Neubüser et al. (Neubuser et al., 1995).
Spleens were fixed overnight in freshly prepared 4% paraformaldehyde (PFA) in
phosphate-buffered saline (PBS) and then embedded in paraffin wax. Sections were cut at
5-7 µm and mounted onto Superfrost-Plus slides. The IRF-7 riboprobe was generated by
cloning a 351 bp RT-PCR product into pBluescript followed by Digoxygenin-11-UTP-
labeling using the Boehringer RNA labeling kit. Paraffin sections were dewaxed and
rehydrated, fixed in 4% PFA in PBS for 20 min, digested with 10 µg/ml proteinase K in 20
mM Tris/HCl, pH 7.0, 1 mM EDTA for 10 min, and refixed in 4% PFA in PBS for 20 min.
Hybridization solution contained the digoxygenin-11-UTP-labeled riboprobe (1 ng/µl) in
40% formamide, 5X SSC, 1X Denhardt's solution, 100 µg/ml each of denatured salmon
testis DNA and tRNA. Hybridization occurred over night at 65° C under a siliconized
coverslip. Coverslips were floated off in 5X SSC, followed by a 40 min wash in 0.5X SSC,
20% formamide at 60°C and a 15-min wash in NTE (0.5 M NaCl, 10 mM Tris/HCl, pH
7.0, 5 mM EDTA). The sections were treated with 20 µg/ml RNase A in NTE for 30 min at
37° C and washed in NTE for 15 min, in 0.5X SSC, 20% formamide for 20 min at 60 °C,
and then in 2X SSC for 25 min. Antibody incubation and detection were performed
according to the manufacturer's description (Boehringer Mannheim) Sections were
mounted in Eukitt and photographed under a Zeiss DMRXA microscope.
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2.5 Molecular biology methods and standard cloning
All cloning strategies were designed and first carried out in silico using the Gene
Construction Kit 2 software (www.textco.com/products/gck2.html). This was especially
important for the correct design of long oligo-nucleotide PCR primers used for ET-cloning.
Standard cloning steps of plasmid vectors and the basic molecular biology techniques were
performed according to the protocols from Molecular Cloning (Sambrook et al., 1989). The
bacteria strain XL-1 blue was used for the amplification of plasmid DNA. Isolation of
plasmid DNA was performed using an alkaline lysis method (Birnboim and Doly, 1979).
For cleaner preparations of plasmid Qiagen columns (Qiagen, Hilden) were used. All
enzymes used for restriction digests and cloning purposes were from New England Biolabs
(NEB, Beverly, USA) unless otherwise stated. DNA was recovered from agarose gel slices
with QIAEXII gel extraction kit (Qiagen, Hilden) according to the manufacturer’s
instructions. The restriction enzymes used were from New England Biolabs (NEB).
Agarose Electrophoresis was performed in TAE buffer (0.04 M Trisbase 0.04 M Acetate,
0.002 M EDTA) using SeaKem LE Agarose (Biozym, #50004) containing 4 µl / 100 ml
Ethidium bromide (Sigma #E-8751). 1 kb ladder (Gibco #15615-16) was used as DNA size
marker.
2.5.1 Preparation of CaCl2 competent cells for transfection by heat-shock
A 5 ml starter culture of bacteria (strains HB101, DH5α or XL-1 blue) was grown o.n. at
37 °C. 0.5 ml of the o.n. culture were used to inoculate 20 ml LB medium and grown at 37
°C on a shaker for approximately 4 h until an OD600 of 0.4 was reached. Cells were spun
for 10 min at 4000 rpm and washed once with 10 ml cold 10 mM NaCl and then incubated
for 20 min in 10 ml cold 50 mM CaCl2. After centrifugation the cell pellet was resuspended
in 1 ml CaCl2 15% Glycerol. Aliquots of 200 µl were snap frozen in liquid N2 and stored
until use at - 80 °C.
2.5.2 Transfection by heat-shock
Competent bacteria were thawed on ice and mixed with the plasmid DNA. After incubation
for 30 min on ice cells were heat shocked for 1 min at 42 °C. After another 5 min on ice
cells were either incubated shaking for 1 h at 37 °C in 1 ml LB medium or plated directly.
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2.5.3 Transformation using Flp expressing E. coli
The 294-Flp bacteria used to excise frt-flanked regions in plasmids or BACs were obtained
from Francis Stewart and were originally generated by integrating the 707-Flp plasmid into
E. coli (Buchholz et al., 1998). Competent bacteria were transfected by heat shock or by
electroporation (see chapter 2.6.2) and incubated in LB medium for 1 h at 37 °C. Cells were
then plated on selection plates. Single colonies were picked and used to inoculate 5 ml LB
medium with appropriate antibiotics. Incubation was performed at 30 °C overnight to
reduce Flp expression and increase plasmid yield. Mini preparations were checked for the
loss of frt-flanked regions by restriction digest and loss of Kanamycin resistance.
2.5.4 Southern Blot analysis
For the Southern blot assay 1 µg of BAC DNA were digested with the respective restriction
enzyme and separated o.n. on a 0.7% agarose gel. After capillary blotting on a nylon
membrane (Hybond N+, Amersham #RPN2020B), membranes were pre-incubated in
hybridization-buffer (1% BSA, 1 mM EDTA 0.5M Na-phosphate buffer pH 7.2, 7% SDS)
at 65°C for 30 minutes. DNA probes were labeled by random priming (Gibco Life
Technologies, #18187-013) with 32P α-dGTP (Amersham) Unincorporated nucleotides
were removed by centrifugation on a Sepharose Microspin G-50 column (Pharmacia, #27-
5330-01). Probes were added to hybridization-buffer and allowed to hybridize with the
membrane overnight. Filters were washed four times for 30 min in wash buffer (1 mM
EDTA, 40 mM Na-phosphate, pH 7.2, 1% SDS) at 65 °C and then exposed on a
radiosensitive phosphoimager screen (Molecular Dynamics) or to autoradiographic film
overnight at -80°C.
2.5.5 Colony hybridization
For colony hybridisation a circular nitrocellulose filter was placed on the plate with
transformed cells until the filter was completely wetted. The position of the filter was
marked using needle punches. The filter was removed and then placed sequentially in 10%
SDS for 10 sec, then in 0.5 M KOH, 1 M NaCl for 2 min and in 0.5 M Tris-HCl pH 7.5,
1M NaCl for 5 min. The filter was washed in 4x SSC buffer, the remainders of colonies
were rubbed off and the filter rinsed in fresh 4x SSC. Filters were baked for 1 h at 80 °C.
Hybridisation was performed as described in 2.5.3. Colonies were regrown by incubating
the bacterial plates at 37 °C
2.5.6 Colony PCR
Colony PCR was performed by picking a bacterial colony and suspending it in 200 µl
ddH2O. After an incubation of 10 min, 10 µl of the suspension were used as template in a
standard 50 µl PCR reaction using appropriate screening primers. Colonies were regrown
by incubating the bacterial plates at 37 °C.
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2.6 ET-cloning and BAC handling techniques
A detailed protocol for the preparation of competent cells and for performing ET cloning
experiments can be found at the following web address:
http://www.embl-heidelberg.de/ExternalInfo/stewart/ETprotocols.html.
Here the most relevant steps are summarized. As developed so far, the host for ET-cloning
can be either (i) a strain which endogenously expresses RecE/RecT (see 2.6.1) or (ii) a
strain in which RecE/RecT or Redα/Redβ are expressed from an exogenously introduced
plasmid (see2.6.5).
2.6.1 Generation of PCR fragments for ET-cloning
PCR reactions were performed using the primer pairs listed below. When the amplified
DNA fragment was destined to be part of the construct, PCR was carried out using the
proofreading cloned Pfu-polymerase (Stratagene, #S600159) either alone or in 1:1 mixture
with Taq-polymerase. For ET-subcloning Taq-polymerase (Promega) based PCR was
sufficient. PCR product was purified by gel-extraction or using the Qiaquick PCR
purification kit (Qiagen, #28104). When required, contaminating plasmid used as PCR
template was removed by 1 h DpnI digest followed by Phenol:CH3Cl extraction and
ethanol precipitation. For electroporation PCR products were diluted to 0.3 - 1 µg/µl.
2.6.2 Electroporation of competent cells
Gene Pulser 0.1 cm electroporation cuvettes (Biorad, #165-2089) were precooled on ice for
at least 5 min. Electrocompetent cells were thawed on ice and 50 µl of cells were mixed
with 0.5 - 2 ml of the DNA-containing solution (BAC, plasmid, PCR-product or a fragment
excised from a plasmid). Cells were electroporated at 2.3 kV (2.5 kV for the strain YZ300)
on a Bio-Rad Gene Pulser (25 µF with pulse controller set to 200 Ohms), usually with time
constants between 4.5 and 4.8. 1 ml of LB medium was added and transferred back into the
eppendorf tube. Cells were then incubated at 37 °C for 1 to 1.5 hours under shaking, and
plated on suitable antibiotic selection plates.
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2.6.3 Primer pairs used for ET-recombination
sub-gfp5 139 mer
5’- TCG ACC AGG ATG GGC ACC ACC CCG GTG AAC AGC TCC TCG CCC TTG CTC ACC
ATT GTG GGT CTT GCA GAG GTT GAT GGC TCT CTG GAC TGT GTG TTT GAG TCT TCT
GGC GCG CCT TAC GCC CCG CCC TGC CAC TCA TCG C –3’
sub-gfp3, 160-mer
5'- CCG CCG GGA TCA CTC TCG GCA TGG ACG AGC TGT ACA AGT AAG AAG TTC CTA
TTC TCT AGA AAG TAT AGG AAC TTC AGA TCT GTG TGA GAC AAA GTG TGG AGA GAC
CTC CCC TGG ACT AGA AAC TGC ATC TCA GCG GCC GCA CAA CTT ATA TCG TAT GGG
G -3'
sub-geok5, 75-mer
5'- TCC TCT AGA GTC CAG ATC FTC CGG GTA CCG AGC TCC TGT GCC AGA CTC TGG
TTA CGC CCC GCC CTG CCA CTC ATC -3'
sub-geok3, 115-mer
5'- TCC CGA TTC GCA GCG CAT CGC CTT CTA TCG CCT TCT TGA CGA GTT CTT CTG
AGA AGT TCC TAT TCT CTA GAA AGT ATA GGA ACT TCA GAT CTA CAA CTT ATA TCG
TAT GGG GCT G -3'
PLAP-sub5, 87-mer
5'- TGC TTC CTC TGC TGG CCG GGA CCC TGC TGC TGC TGG AGA CGG CCA CTG CTC
CCT GAG CTA GCA CAA CTT ATA TCG TAT GGG GCT GAC -3'
PLAP-sub3, 84-mer
5'- TGC CCA GGG AGA GCT GTA GCC TCA GGC CCA GCA GCA GCA GCA GCA GCA GCA
TGC TAG CTT ACG CCC CGC CCT GCC ACT CAT CGC -3'
n-ires5, 28-mer
5'- TGA GCG GGT ACC CAG AGT AAT GAC ATG G -3'
n-ires3, 42-mer
5'- TAG TCG GTA CCT TAA TTA AGC TAG CCA AGC GTG GGC TGT ACC -3'
5-NRF2EMCV,74-mer
5'- CCG ATT CGC AGC GCA TCG CCT TCT ATC GCC TTC TTG ACG AGT TCT TCT GAC
CAG AGT CTG GCA CAG GAG CTC GG -3'
3-NRF2EMCV,74-mer
5'- CCC AGG GAG AGC TGT AGC CTC AGG CCC AGC AGC AGC AGC AGC AGC AGC ATG
GTT GTG GCA AGC TTA TCA TCG TG -3'
newlRF7hom5',145-mer
5'- AGA CAG TTT TAC TGT TCG TGA TGA TAT ATT TTT ATC TTG TGC AAT GTA ACA
GAC CCT GCA GGC AGA GCA GCC ACG CTG GGG TTA GGG CTA ATG TAA GGG ACA CAG
GAC CCA ATA CCT CGA GAC AAC TTA TAT CGT ATG GGG CTG -3'
newlRF7hom3', 138-mer
5'- GAG CTT TAT TTT CAT GAT CTG TGT GTT GGT TTT TGT GTG CGG CGC GCC CTG
GGC TGT GGC CCG AGG GAG GTG GCC ACC TAG TGG AGT TAA CCT GCC ACC CCC AGA
GGC TCT AGA TTA CGC CCC GCC CTG CCA CTC ATC -3'
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2.6.4 Preparation of competent bacteria (strain YZ300) for ET-cloning experiments
YZ300 cells (RecA+strain JC8679 that carries the sbcA mutation) from glycerol stock were
streaked out on an LB plate. After o.n. growth at 37 °C a single colony was picked and an
o.n. starter culture (5 ml LB medium) was inoculated. The following day 250 ml LB
medium were inoculated with 1 ml of the starter culture. Bacteria were grown at 37 °C and
harvested at an OD600 of < 0.35. The centrifuge and the rotors SA600 or SS34 (Sorvall)
were pre-cooled by centrifuging for 10 min at -5 °C at 4,000 rpm. The cells were spun in a
first round of centrifugation for 10 min at 7,000 rpm at -5 °C. After pouring away the
supernatant, tubes were put on ice, and the cells resuspended in 5 to 10 ml ice-cold 10%
glycerol using an ice-cold 10 ml pipette. 200 ml of 10% glycerol were added and the cells
were centrifuged. This step was repeated twice. At the end, after pouring away the
supernatant, the tubes were immediately dried with Kleenex tissue taking care not to touch
the pellet. Cells were then resuspended in the residual liquid (the final resuspended volume
usually amounted to 500 µl). 50 µl of cells were transferred into pre-cooled eppendorf
tubes and frozen in liquid N2 or used immediately. For transformation, competent cells
were thawed on ice and mixed with 1 to 2 µl of the recombinogenic linear DNA fragment
(PCR product and/or a fragment excised from a plasmid).
2.6.5 Preparation of competent cells containing BACs for ET-cloning experiments
E. coli cells (strain DH10B) harboring the relevant BAC were transformed with the ET
expression plasmid (pBADabg (Muyrers et al., 1999) or pR6K116/BAD/abg (Zhang et al.,
2000)) by the electroporation procedure (see 2.5.1) and then plated. Single colonies were
picked and grown in 5 ml LB medium overnight. 0.7 ml of culture were then transferred
into 70 ml of LB medium (without glucose) and grown at 37 °C under constant shaking. To
ensure optimal harvesting conditions, bacterial growth curves of the clones under study
have been monitored before the actual culture for competent bacteria was stared. When the
cells reached OD600 = 0.1-0.15, 0.7 ml of a 10% L-arabinose (Sigma) solution were added
to induce ET protein expression. After another 45-60 minutes, the cells usually have
reached an OD600 of 0.3-0.4 and were ready for harvest. For BAC experiments, lower ODs
(around 0.25) have actually yielded better results. The centrifuge and the rotors SA600 or
SS34 (Sorvall) were cooled by centrifuging for 10 min at -5 °C at 4,000 rpm. 35 ml of cells
were spun in a first round of centrifugation for 10 min at 7,000 rpm at -5 °C, while keeping
the other 35 ml on ice. After pouring away the supernatant, the second 35 ml were added
and recentrifuged. 10% glycerol with dH2O was prepared, and cooled on ice for at least 3
hours before use. After pouring away the supernatant, tubes were put on ice, and the cells
resuspended in 5 to 10 ml ice-cold 10% glycerol using an ice-cold 10 ml pipette. 25 more
ml of 10% glycerol were added and the cells were centrifuged. This step was repeated
twice. At the end, after discarding the supernatant, the tubes were immediately dried with
Kleenex tissue taking care not to touch the pellet. Cells were then resuspended in the
remaining liquid (the final resuspended volume usually amounted to l00 µl). 50 µl of cells
were transferred into pre-cooled eppendorf tubes and frozen in liquid N2 or used
immediately. For transformation, competent cells were thawed on ice and mixed with 1 to 2
µl of the recombinogenic linear DNA fragment (PCR product and/or a fragment excised
from a plasmid).
Materials and Methods   42
2.6.6 Preparation of BAC minipreps
Minipreparations of BAC DNA were performed as described by the Research Genetics
BAC fact sheet. Cells from 1.5 ml o.n. culture were pelleted and resuspended in 100 µl
Qiagen solution I. Tubes were placed on ice and 200 µl of Qiagen solution II were added.
Tubes were inverted 7 times and incubated for 2 min on ice. 150 µl of Qiagen solution III
added and the tubes inverted. After brief incubation tubes were spun at maximum speed for
6 min in a microfuge. Supernatant was transferred into a fresh tube and residual debris
removed using a toothpick. After addition of 1 ml 100% ethanol the tube was respun for 6
min at maximum speed. After decanting the supernatant, DNA pellet was rinsed with 70%
ethanol. Residual ethanol was removed by double aspiration and the pellet was air dried at
37 °C. The DNA pellet was resuspended in 20 µl ddH2O. The BAC DNA obtained was
sufficient for two analytic restriction digests.
2.6.7 Preparation of circular BAC for microinjection
Maxipreparations were carried out using the Qiagen large construct kit (Qiagen) according
to the manufacturers instructions. Contamination with genomic bacterial DNA is
minimized by exonuclease treatment. The final resuspension was performed using 200 µl
DNA injection buffer. Usually 5 - 50 µg of BAC DNA was obtained as determined by
spectrophotometry at 260 nm. For microinjection purified BAC was diluted to 1 - 2 ng/µl.
2.6.8 Preparation of linear BAC fragments for microinjection
To obtain linearized BAC fragments that lack the pBeloBAC 11 plasmid backbone, about
10 µg of a BAC maxipreparation were restriction digested for 3 h with Not I. The reaction
was loaded on a 0.8% low melt agarose gel (Biozym, Large DNA Low Melt Agarose)
devoid of ethidium bromide flanked by DNA size markers (left and right). The gel was run
slowly at 50 V o.n.
Two slices on either side of the gel including the edges of the sample and the markers were
cut and stained with ethidium bromide. Plastic wrap was used to avoid contact between the
stained slices and the unstained body of the gel. On the UV-box, gel and slices were aligned
and the insert band on the unstained body was cut at the height of the stained band on the
side slices. The cut band was placed in eppendorf tubes. 30 µl of 5M NaCl solution were
added and the tube was incubated for 30 min at RT. After a quick spin agarose was melted
by full immersion of the tube for 7 min in a water bath heated to 68 °C. Then the tube was
incubated o.n. at 42 °C with 5-10 units beta-agarase (Promega, Agar ACE, cat no M17 4A)
added after the first 10 min of incubation. The tube was spun at full speed for 10 min and
the supernatant was transferred into a fresh tube. For purification the BAC-fragment
containing supernatant was placed into an Ultrafree-MC filter system (Millipore, 30 kD
cut-off, cat no UFC3LTK25) and spun at 6000 rpm in an eppendorf centrifuge. Spinning
was stopped when the volume was around 50 µl. For washing, DNA microinjection buffer
was overlaid and spinning continued. The filter was incubated at 4 °C o.n. to allow the
DNA to come off the membrane, followed by gentle resuspension using a pipet.
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2.6.9 Screening for transgenic founders by PCR on genomic tail DNA
DNA was prepared form mouse tail-biopsies by incubation in Laird-Jaenisch (LJ) lysis
buffer (100 mM Tris-Cl pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl) supplemented
with proteinase K (1 mg/ml). Tissues/cells were incubated overnight at 55 °C and residual
debris was pelleted by centrifugation and then removed. DNA was precipitated by addition
of equal volume of isopropanol, washed with 70% ethanol, airdried and dissolved in TE
(Tris-EDTA, pH 8.0). PCR reactions were performed as described in chapter 2.4.1 using 2
µl of template DNA. C57BL/6 tail DNA served as negative control and the same DNA
spiked with IFN-α2 recombinant BAC was used as positive control. The PCR primer pairs
used for screening are listed in Table 2.2. Note that for both primer pairs specific for the 5’
and 3’ transitions between the WT IFN-α2 sequence and the reporter construct also a PCR
specific for the IFN-α2 WT sequence was performed as a positive control.
Fragment Primer Name Primer Sequence PCR conditions
#20 GFP-5’ CAT CGA GCT GAA GGG CAT CGA CGFP
#21 GFP-3’ GTA CAG CTC GTC CAT GCC GAG AG
Product length: ~ 500 bp
94 °C-5’, 94 °C-15’’, 60.0
°C-15’’, 72 °C-1’, 40
cycles, 72 °C-10’
#107 5IFNa2a AGA GAA CCT AGA GGA GAA GAC5’ Transitn
Promoter /
GFP #108 3IFNa2a
TCG GCC ATG ATA TAG ACG TTG
Product length: 533 bp
94 °C-5’, 94 °C-15’’, 60.0
°C-15’’, 72 °C-1’, 40
cycles, 72 °C-10’
#107 5IFNa2a AGA GAA CCT AGA GGA GAA GAC5’ WT
Promoter /
IFN-a2 #109 3IFNa2b GCT GCT GGT GGA GGT CAT TGC
Product length: 392 bp
94 °C-5’, 94 °C-15’’, 60.0
°C-15’’, 72 °C-1’, 40
cycles, 72 °C-10’
#110 5IFNa2c GAA CAA ATG GGT GCA GAT ACA3’ Transitn
BetaGeoK /
3’ UTR #111 3IFNa2c GCT GAC CGC TTC CTC GTG CTT
Product length: 308 bp
94 °C-5’, 94 °C-15’’, 60.0
°C-15’’, 72 °C-1’, 40
cycles, 72 °C-10’
#112 5IFNa2d TGT GCT GCG AGA TCT TAC TCA3’ WT
IFN-a2 /
3’ UTR #111 3IFNa2c
GCT GAC CGC TTC CTC GTG CTT
Product length: 525 bp
94 °C-5’, 94 °C-15’’, 60.0
°C-15’’, 72 °C-1’, 40
cycles, 72 °C-10’
#113 5IFNa2e ACG TCT ATA TCA TGG CCG ACAECMV-
IRES
#114 3IFNa2e CTT GCA TTC CTT TGG CGA GAG
Product length: 519 bp
94 °C-5’, 94 °C-15’’, 60.0
°C-15’’, 72 °C-1’, 40
cycles, 72 °C-10’
#113 5IFNa2e ACG TCT ATA TCA TGG CCG ACA3’ ∆frtBAC
GFP /
3’ UTR
#111 3IFNa2c GCT GAC CGC TTC CTC GTG CTT
Product length: ~ 500 bp
94 °C-5’, 94 °C-15’’, 60.0
°C-15’’, 72 °C-1’, 40
cycles, 72 °C-10’
Table 2.2 PCR primers used in the screening for transgenic founders
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3 Results
3.1 Type I IFN response to VSV infection in cultured MEFs
Tissue culture experiments have shown previously that the expression of all IFN-α genes,
except IFN-α4, was dependent on type I IFN receptor feedback signaling in Newcastle
disease virus (NDV) stimulated MEFs (Marie et al., 1998; Sato et al., 1998). To validate
this finding under conditions of a productive virus infection, IFNAR competent (WT) and
IFNAR deficient (IFNAR-/-) MEFs were VSV infected and IFN-α mRNA expression was
monitored by RT-PCR analysis. Six hours after VSV infection WT MEFs showed
significant upregulation of both IFN-β  and the IFN-α subtype genes while in MEFs
deficient of type I IFN feedback signaling no upregulation of IFN-α mRNA was detected.
In IFNAR-/- MEFs also the expression IFN-β mRNA was impaired, albeit to a lesser
extend. Similarly mRNA of the transcription factor IRF-7 was upregulated in WT MEFs
but could not be detected in IFNAR-/- MEFs (Fig. 3.1). Upregulation of the transcription
factor IRF-7 has been reported to be dependent on IFNAR feedback and has been shown to
be critically required for IFN-α expression in NDV stimulated MEFs (Marie et al., 1998;
Sato et al., 1998). Thus in VSV infected MEFs the IFN-α production is strictly dependent
on IFNAR feedback signaling.
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Fig. 3.1 Type I IFN receptor feedback is required for IRF-7 upregulation and IFN-α expression in VSV
infected MEFs. MEFs derived from wild type (WT) or IFNAR deficient mice (IFNAR-/-) were infected with
VSV at a multiplicity of infection of 10. Six hours after infection, total RNA of 1 · 106 cultured MEFs was
extracted, and the mRNA content of different samples was normalized by a GAPDH-specific RT-PCR. The
expression of IFN-α mRNA was monitored using consensus primers amplifying all IFN-α subtypes.
Expression of IFN-β and IRF-7 mRNA was determined using specific PCR primers. The analysis was
performed with serially 5 fold diluted cDNA samples starting with undiluted material.
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3.2 Type I IFN response to VSV infection in vivo
To next examine IFN responses in vivo, IFN-α gene expression was analyzed in spleen
from WT and IFNAR-/- mice infected with an intermediate dose of VSV (2 · 106 pfu).
Surprisingly, expression of IFN-α mRNA was detected in the spleens of both WT and
IFNAR-/- mice (Fig. 3.2 a). However, VSV replication is not controlled in IFNAR deficient
mice, leading to highly elevated virus load already at the onset of measurable type IFN
titers, while VSV titers in the sera of WT mice remained below the detection limit (Fig.
3.2c). The consequences of the discrepancy in viral load were apparent also when
measuring type I IFN titers in the sera of VSV infected mice. After a delayed onset, IFN
levels of IFNAR-/- mice rose up to, and eventually exceeded those measured in WT mice
(Fig. 3.2 b).
Thus, to reduce the effect of differential replication of VSV in WT and IFNAR-/- mice, and
to achieve a synchronized stimulation of IFN producing cells in vivo, in the following
experiments mice were injected with an elevated dose of VSV (2 · 108 pfu). Furthermore,
the study was extended to incorporate also non-replicating inducers of type I IFNs.
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Fig. 3.2 IFNAR-/- mice infected with an intermediate dose of VSV show induced IFN-α expression, but
the rapid increase in viral load precludes direct comparison with WT mice. WT mice (filled circles) and
IFNAR-/- mice (open triangles) were i.v. stimulated with 2 · 106 pfu VSV. (a) At the time points indicated,
total RNA from the spleen was prepared and RT-PCR using IFN-α consensus primers was performed as
described in Fig. 3.1. (b) Mice were bled at the indicated time points and serum IFN titers were determined in
a CPE protection assay. A log2 titer of 5 corresponds to 1000 IU of IFN-α. Data points represent mean titers
(± sdev) of the sera of at least three mice. (c) Virus titers in the serum were determined by VSV plaque assay
on serial 10 fold dilutions. The dotted line indicates the detection limit of the assay.
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3.2.1 Requirement of type I IFN feedback signaling in vitro vs. in vivo
In order to directly compare the requirement of type I IFN receptor feedback for the
production of IFN-α, the kinetics of IFN-α mRNA expression was monitored in MEFs
infected with VSV at a moi of 10 (i.e. 10 pfu/cell) and in the spleens of mice acutely
infected with 2 · 108 pfu VSV. WT fibroblasts showed elevated IFN-α mRNA levels
beginning 4 h after VSV infection and peak expression between 9 h and 12 h (Fig. 3.3 a).
Similar to NDV stimulated MEFs (Marie et al., 1998), VSV infected MEFs predominantly
expressed IFN-α4 as determined by subcloning of RT-PCR products and sequence analysis
of random clones (Fig. 3.4 a). In contrast, IFN-α upregulation was not observed in VSV
infected MEFs lacking the type I IFN receptor (Fig. 3.3 a). Surprisingly, IFN-α mRNA was
induced rapidly and to a similar extent in spleen of WT and IFNAR-/- mice. At later time
points, IFN-α expression in spleen of IFNAR-/- mice decreased slightly, whereas spleen
from WT mice showed a further increase in IFN-α expression (Fig. 3.3 b).
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Fig. 3.3 VSV infection stimulates IFNAR independent production of IFN-α in mice, but not in mouse
embryonic fibroblasts (MEFs). (a ) MEFs derived from wild type (WT) or IFNAR deficient mice
(IFNAR-/-) were infected with VSV at a multiplicity of infection of 10 and (b) WT and IFNAR-/- mice were
i.v. injected with 2 · 108 pfu VSV. Total RNA of 106 cultured MEFs or of spleen tissue was extracted, and the
mRNA content of different samples was normalized by a GAPDH-specific RT-PCR. The expression of
IFN-α mRNA was monitored using consensus primers amplifying all IFN-α subtypes. The analysis was
performed with serially 5 fold diluted cDNA samples starting with undiluted material; spleen derived samples
were 5 fold prediluted.
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The IFN-α subtype analysis revealed, that both VSV infected IFNAR competent and
deficient mice showed abundant expression of IFN-α2 and α5, whereas IFN-α4 was found
only rarely (Fig. 3.4 b and c). Thus, different IFN-α patterns found after VSV infection of
MEFs and mice suggested that in vivo the majority of IFN-α is produced by a cell type
different from fibroblasts. Moreover, similar IFN-α patterns found in WT and IFNAR-/-
mice indicated a largely feedback-independent production of early IFN-α in VSV infected
mice.
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Fig. 3.4 Differential IFN-α expression profiles of VSV infected MEFs and mice. PCR products of the
IFN-α expression analysis 6 h after VSV infection of (a) WT MEFs, (b) spleen of WT mice, or (c) spleen of
IFNAR-/- mice were subcloned and DNA sequence of 13, 35, and 25 single clones was analyzed,
respectively. IFN-α sequences were classified according to EMBL database entries. The sequence termed
IFN-α10 corresponds to the IFN-αB sequence available on the EMBL database (accession No. L38698).
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To correlate IFN-α mRNA levels and IFN serum activities, blood serum of VSV infected
mice was taken and analyzed in a cytopathic effect (CPE) inhibition assay. As early as 4 h
after VSV infection IFN activity was found in the serum of both WT and IFNAR-/-
animals. Specific inhibition of IFN-α and/or IFN-β by neutralizing monoclonal antibodies
in the CPE inhibition assay revealed a major contribution of IFN-α to the serum IFN
activity, irrespective of whether IFNAR signaling was functional or not. Serum IFN titers
of WT animals increased more rapidly than those of IFNAR-/- mice, eventually leading to
about 30 fold higher IFN titers in WT animals than in IFNAR-/- mice (Fig. 3.5 a).
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Fig. 3.5 Type I IFN activity in the serum of mice treated with VSV, poly(I:C), or UV-HSV. WT mice
(filled circles) and IFNAR-/- (open triangles) mice were i.v. stimulated with (a) 2 · 108 pfu VSV, (b) 140 µg
poly(I:C), or (c) 2 · 107 pfu UV-HSV. Mice were bled at the indicated time points and serum IFN titers were
determined in a CPE protection assay. A log2 titer of 5 corresponds to 1000 IU of IFN-α. The contribution of
IFN-α or IFN-β to the total IFN activity was determined by specific inhibition with monoclonal antibodies.
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3.3 Type I IFN response induced by HSV in vivo
As mentioned before, virus replication is not controlled in VSV infected IFNAR deficient
mice. The highly elevated virus load and increased cell death could have interfered with
cytokine production in IFNAR-/- mice. Thus, we next analyzed type I IFN responses after
stimulation with non-replicating virus. Since UV inactivated VSV does not induce type I
IFN responses (data not shown), mice were injected with UV inactivated HSV. Two hours
after the treatment, WT and IFNAR-/- mice showed similar peak IFN activity with about
50% and 35% IFN-α contribution, respectively. While the IFN response was short-lived in
IFNAR-/- mice, IFN titers in WT mice were sustained for several hours, and a switch to a
more pronounced IFN-α expression was found (Fig. 3.5 c). To verify the induction of early
IFN-α in the absence of IFNAR-feedback signaling, mice deficient of the type I IFN
receptor or IFN-β were intercrossed and IFNAR-/- IFN-β-/- double-knockout mice and
IFNAR+/- IFN-β-/- littermates were stimulated with UV-HSV. Even in the absence of
IFN-β initial IFN-α titers showed the same magnitude in receptor deficient and competent
mice. At later time points IFN-α production was sustained and further enhanced in IFN
receptor competent mice as compared to IFNAR-/- mice (Fig. 3.6). Thus, upon treatment
with live VSV or UV inactivated HSV early IFNAR-independent IFN-α production is
observed. Yet, at later time points IFNAR-feedback signaling is critical to sustain the
production of IFN-α.
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Fig. 3.6 IFN-α is produced in mice deficient of IFN-β and IFNAR. IFN-β deficient mice (filled diamonds)
and double deficient mice lacking IFN-β and IFNAR (open diamonds)  were i.v. injected with 2·107 pfu UV-
HSV. Sera were taken at indicated time points and analyzed in a CPE protection assay. Mean IFN activity of
3 mice per time point is indicated. Results are shown of one out of two independent experiments. Note that
the indicated IFN serum activities exclusively derived form IFN-α because the analyzed mice were IFN-β
deficient.
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3.4 Role of IRF-3 and IRF-7
The promoter regions of both IFN-β and the IFN-α subtype genes contain elements for the
binding of members of the interferon regulatory factor (IRF) family. Recently the focus has
been centered on IRF-3 and IRF-7 as the main regulators of type I IFN expression. IRF-3
and IRF-7 are considered key components of the type I IFN receptor feedback (Sato et al.,
2000). In MEFS, expression of IRF-3 has been shown to be constitutive (Sato et al., 1998),
thus allowing immediate induction of IFN-β and in some cases of IFN-α4. Also in vivo,
IRF-3 expression was similar in the spleens of WT and IFNAR-/- mice and remained
remarkably stable in the course of VSV infection (Fig. 3.7).
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Fig. 3.7 Expression of IRF-3 mRNA in spleens of WT and IFNAR-/- mice is similar and is not altered
during viral infection. Mice were infected intravenously with 2 · 108 pfu VSV. Total RNA was isolated at
the time points indicated and RT-PCR was performed as described in Fig. 3.1.
In contrast, IRF-7 has been shown to be upregulated upon IFNAR triggering (Marie et al.,
1998; Sato et al., 1998) and was proposed to be critically required for the expression of
IFN-α subtype genes (Sato et al., 1998; Yeow et al., 2000). We therefore asked, whether
early IFNAR-independent IFN-α was produced in the absence of IRF-7 induction. The
RT-PCR analysis of IRF-7 mRNA levels in VSV infected WT and IFNAR-/- mice revealed
a prompt IRF-7 upregulation only in WT mice but not in IFNAR deficient mice (Fig. 3.8).
These experiments indicated that in VSV infected mice early IFN-α was induced in the
absence of detectable IRF-7 upregulation. At later time points IFNAR-independent IRF-7
upregulation was observed (Fig. 3.9) which, however, did not suffice to promote a
sustained production of IFN-α in IFNAR-/- mice.
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Fig. 3.8 VSV infected IFNAR-/- mice show an early induction of IFN-α before the onset of IRF-7
expression. Total RNA from spleen of IFNAR-/- or WT mice was isolated 3 hours after i.v. infection with 2 ·
108 pfu VSV. RT-PCR was performed as described in Fig. 3.1.
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Fig. 3.9 IRF-7 mRNA can be upregulated independent of type I IFN receptor feedback. Total RNA from
spleen of IFNAR-/- or WT mice was isolated after i.v. infection with 2 · 108 pfu VSV at the time points
indicated. RT-PCR was performed as described in Fig. 3.1.
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3.5 Type I IFN response induced by double stranded RNA (poly I:C) in
vivo
To further study the role of feedback signaling with a non-replicating type I IFN inducer,
mice were treated with poly(I:C). Sera of poly(I:C) treated WT and IFNAR-/- mice
displayed early peak IFN activity, followed by a rapid decline in the case of IFNAR-/-
mice. In WT mice IFN activity was sustained at high level for more than 20 hours.
Neutralization of IFN-α and/or IFN-β revealed an abundant contribution of IFN-β to early
type I IFN activity in both WT and IFNAR-/- mice. At later time points, strong IFN-α
production was observed in WT but not in type I IFN receptor deficient mice (Fig. 3.5 b).
Equally, RT-PCR on total RNA of the spleen revealed a strongly impaired IFN-α response
in IFNAR-/- mice (Fig. 3.10).
Preferential production of IFN-β upon poly(I:C) treatment - while mainly IFN-α is
produced after virus stimulation - indicates that different cell types may be involved in the
production of poly(I:C) vs. virus-induced type I IFN. Moreover, these results further
support the hypothesis that the sustained production of IFN-α is IFNAR-dependent.
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Fig. 3.10 Expression of IFN-α is strongly impaired in the spleens of IFNAR-/- mice stimulated with
poly(I:C). Mice were injected intravenously with 140 µg of poly(I:C) at the time points indicated, total RNA
of the spleens was prepared. RT-PCR was performed using IFN-α consensus primers as described in Fig. 3.1
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3.5.1 Requirement of the primary inducing stimulus for type I IFN production
When stimulated with a non-replicating IFN inducer (UV-HSV or poly(I:C)), type I IFN
titers in the sera of IFNAR deficient mice declined rapidly after initial peak expression. To
determine whether short lived IFN response observed in IFNAR-/- mice was due to short
half life of the inducing stimulus or whether in the absence of receptor feedback the IFN
producing cells became generally unable to produce type I IFN, poly(I:C) stimulated mice
were restimulated after 24h by a second injection of poly(I:C). The type I IFN serum titers
revealed, that also after a second stimulus, peak expression of both WT and IFNAR-/- mice
was similar (Fig. 3.11), ruling out a general loss of cells able to produce type I IFNs.
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Fig. 3.11 The poly(I:C) induced IFN response may be restimulated and reaches similar peak levels in
WT (filled circles) and IFNAR-/- (open triangles) mice. Mice were injected twice at a 24 h interval with 70
µg of poly(I:C). Serum IFN titers were monitored in a CPE protection assay. Data points represent mean IFN
titers (±sdev) of the sera of three mice.
Results – Feedback regulation of type I IFN production in vivo   54
Moreover, type I IFN production of IFNAR-/- mice could be sustained by continuous
poly(I:C) stimulation, and showed kinetics similar to WT mice after a single injection of
poly(I:C) (Fig. 3.12). Interestingly, continued poly(I:C) stimulation had only a minor effect
on type I IFN titers in the sera of WT mice.
How long poly(I:C) or UV-HSV remained active in vivo cannot be readily determined.
However, the kinetics observed in these experiments indicated, that poly(I:C) activity in
vivo is likely to be short lived and that in the absence of receptor feedback, type I IFN
production was strictly dependent on the availability of the primary inducing stimulus.
Conversely it can be concluded, that type I IFN receptor feedback in vivo constitutes a
mechanism to sustain IFN production, even if the inducing stimulus is active only for a
short time.
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Fig. 3.12 IFN serum titers may be sustained by continued stimulation with poly(I:C). WT (circles) and
IFNAR-/- (triangles) mice were injected with 140 µg poly(I:C). Two mice of each group received additional
injections of 140 µg poly(I:C) (filled symbols) at 5, 10 and 24 h after the first injection. Type I IFN serum
titers were determined by a CPE protection assay. Graph shows the pooled results of two independent
experiments.
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3.6 Site of type I IFN production in vivo
To localize IFN producing cells, mice were infected with VSV and at several time points
after infection spleen sections were analyzed immunohistochemically with polyclonal
antibody directed against type I IFN. Specific staining became detectable 6 h after infection
and decorated a structure surrounding follicles, i.e. the marginal zone. In VSV infected
spleens of both WT and IFNAR-/- mice the intensity of type I IFN staining peaked 9h after
infection (Fig. 3.13). The observed staining pattern correlates well with maximal IFN titers
in the serum of VSV infected mice (Fig. 3.5).
WT
IFNAR-/-
time after infection
Fig. 3.13 Type IFN production is detected in the marginal zone of the spleens of WT and IFNAR-/- mice
and peaks 9 h after VSV infection. WT and IFNAR-/- mice were infected with 2 · 108 pfu VSV. Spleens
were snap frozen at the time points indicated and sections were analyzed cryo-histochemically with a
polyclonal serum against type I IFN (red). Sections were counterstained with hemalum (blue) to visualize
lymph follicles.
In the following experiments WT and IFNAR-/- mice were infected with VSV and 9 h
later, consecutive sections were stained with polyclonal antibody directed against type I
IFN or with an IFN-α specific monoclonal antibody. While staining with the polyclonal
serum appeared more sensitive, stainings with monoclonal antibody revealed distinct type I
IFN producing cells scattered in groups within the marginal zone (Fig. 2.14 a and b). After
treatment with VSV or UV-HSV, spleens of WT and IFNAR-/- mice showed similar
marginal zone stainings with polyclonal antibody, albeit staining of spleens from IFNAR
deficient mice was somewhat weaker (Fig. 2.14 c).
In situ hybridization of spleen sections of untreated mice with an IRF-7 probe did not
reveal evidence for constitutive IRF-7 expression, neither in few marginal zone cells nor
anywhere else in the spleen (data not shown). After VSV infection of WT mice a strong
IRF-7 induction was observed all over the spleen. In contrast, no IRF-7 induction was
detected in spleens of VSV infected IFNAR-/- mice (Fig. 2.14 d). Together with the above
RT-PCR data these observations indicate that virus-induced early IFN-α can be produced
independent of IFNAR signaling and IRF-7 upregulation.
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Despite substantial IFN levels in the serum, no specific type I IFN staining was detected in
the marginal zone of poly(I:C) treated mice (Fig. 2.14 c). Thus, after injection of virus
particles, irrespective of whether they were replication competent or not, type I IFN
production is located in the marginal zone. The soluble inducer poly(I:C) did not induce
high enough type I IFN production in the spleen to be detected by immunohistology.
Probably under these conditions type I IFN is produced at low level by numerous cell types
and in various tissues.
To test this hypothesis WT mice were stimulated for 6 h with 140 µg poly(I:C), and total
RNA prepared from several tissues was tested for IFN-α expression by RT-PCR.
Significant levels of IFN-α mRNA were observed in all tissues tested, including the liver,
heart, kidneys and lymph nodes of poly(I:C) stimulated mice. In contrast, VSV infected
mice showed no or very low IFN-α expression in the heart, kidneys and lungs. However,
IFN-α expression in was not exclusively confined to the spleen but was also detected in the
liver of VSV infected mice (data not shown). This indicated that IFN produced in organs
other than the spleen do contribute to the type I IFN titers measured in the serum after
intravenous injection of VSV.
In an attempt to evaluate the contribution of spleen derived IFN vs. IFN produced in other
tissues, C57BL/6 mice were spleenectomized and after recovery infected intravenously
with VSV. Surprisingly, Serum IFN titers of spleenectomized mice did not diverge
significantly from the titers observed in unoperated control animals (Fig. 3.15). This result,
together with the observation that after viral infection type I IFN is produced by a defined,
rare cell type, makes it important to characterize the interferon producing cell population
(IPC) in the mouse, and to determine whether it is present also in organs other than the
spleen.
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Fig. 3.15 Spleenectomy does not significantly alter the type I IFN response to VSV. C57BL/6 mice were
spleenectomized (open symbols) or left untreated (filled symbols). Three days later, mice were infected
intravenously with 2 · 108 (circles) or 2 · 106 (diamonds) pfu VSV. Sera were taken at the time points
indicated and analyzed in a CPE protection assay. Data points represent mean IFN activity of 2 - 3 sera.
In the following chapters two independent strategies are described to identify type I IFN
producing cells and to characterize their tissue distribution and properties in the course of
viral infection. The first strategy attempts to visualize IPCs by the transgenic expression of
a reporter gene, whereas the second approach aims at the identification of IPCs in WT mice
by the means of intracellular and/or surface markers.
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3.7 Genetic marking of type I IFN producing cells (IPCs)
In cell culture most any cell type may produce type I IFN in response to a suitable stimulus.
It has been known for a long time, however, that after in vivo stimulation the majority of
type I IFN is produced by few cells producing IFN-α at high level. Mainly due to their
rarity and lack of lineage markers, the phenotype of these so-called major IFN producing
cells (IPCs) remained elusive. This section describes two strategies to generate transgenic
mice expressing a reporter gene in order to identify type I IFN producing cell types. The
project aims at genetically marking IPCs exploiting two of their prominent characteristics:
High-level expression of IFN-α genes, and - as a more speculative approach -
induced/constitutive expression of the transcription factor IRF-7 (Fig. 3.16). As determined
by the analysis of IFN-α expression patterns in virus infected spleens (see Fig. 3.4), IFN-
α2 is one of the most abundantly expressed IFN-α subtypes in vivo and therefore was
chosen as target gene.
IFN-α2
promoter pAeGFP
frt
ECMV-IRES β-Gal NEO
frt
IFN-α2
promoter pAeGFP
frt
IRF-7
Ex3 Ex9IRF-7promoter Ex1 β-Gal NEO NRF-IRES PLAP pA
Ex3 Ex9IRF-7promoter Ex1 β-Gal NEO PLAP pAECMV-IRES
IRF-7
promoter Ex1 β-Gal NEO Ex3 Ex9pA
IRF-7
IRF-7
PLAP
PLAP
PLAP
PLAP
Ex3 Ex9IRF-7promoter Ex1 β-Gal NEO NRF-IRES PLAP pA
IFN-α2
promoter pAeGFP
frt
ECMV-IRES β-Gal NEO
frt
a
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c
d
e
Fig. 3.16 Transgene constructs for the expression of reporter genes under the control of the IRF-7 (a-c)
or the IFN-α2 (d,e) promoter. Mouse IFN producing cells (IPCs) may be visualized after introduction of a
reporter transgene. (a) This construct contains a β-Gal reporter in the beta-Geo/b cassette followed by the
EMCV-internal ribosomal entry site (IRES) and a PLAP reporter. β-Galactosidase activity may be visualized
by X-Gal staining in histological sections, or in flow cytometry by intracellular staining with the FDG
reagent. PLAP may be visualized by surface antibody staining in histology and cytometry. (b) This construct
is analogous to (a) with the NRF-IRES replacing the EMCV-IRES. (c) This construct uses β-Gal as a single
reporter gene. (d) This construct contains eGFP reporter followed by the EMCV-IRES driving expression of
the β-Gal reporter in the beta-GeoK cassette. GFP is a fluorescent protein and can be readily detected by flow
cytometry. (e) This construct may be derived from (d) after Flp-mediated recombination. It contains eGFP as
a single reporter gene. Note that the Kanamycin resistance contained in the beta-GeoK and the beta-Geo/b
cassettes functions as a selectable marker in the ET-cloning process (see 3.7.2).
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3.7.1 Rationale for the choice of approach
The choice of reporter genes. In general, reporter genes are nucleic acid sequences
encoding easily assayed proteins. They are used to replace other coding regions whose
protein products are difficult to detect. In the transgene constructs three widely applied
reporters in mammals were used. The idea was to utilize different markers for the two
constructs that may eventually allow double stainings in doubly transgenic mice.
GFP (green fluorescent protein) is derived from the bioluminescent jellyfish Aequorea
victoria. GFP is highly fluorescent. GFP shows low toxicity, no interference with normal
cellular activities, and is easy to assay. These properties made GFP, especially the ER-
targeted variant eGFP, the most commonly used reporter gene. However, because GFP
fluorescence is not the result of an enzymatic reaction, the signal is not amplified, as it is
the case with β-Gal and PLAP, which may result in lower sensitivity. eGFP was used in the
IFN-α2 reporter construct, as it can be readily detected by flow cytometry and requires no
further treatment of the cells before the assay.
LacZ as reporter gene, which encodes for β-galactosidase in E. coli, is widely used in the
analysis of histological sections. Reporter gene expression is usually visualized by x-Gal
staining. The recent introduction of the fluorescein di-β-D-galactopyranoside (FDG)
reagent and derivatives allowed the use of the β-Gal reporter also for viable cells in flow
cytometry (Nolan et al., 1988; Zhang et al., 1991). Besides β-galactosidase, the beta-Geo/b
and beta-GeoK cassettes encode Kanamycin resistance and are used here as selectable
marker in the ET-cloning approach (see 3.7.2).
Human placental alkaline phosphatase (PLAP) has been used successfully for the
identification of transgenic cells within complex in vivo systems such as mice (Jacob and
Baltimore, 1999). Over-expression of PLAP shows no adverse effects on mouse
development or viability (Skynner et al., 1999). PLAP is expressed on the cell surface and
alkaline phosphatase activity can readily be assayed in histological sections. Because of
endogenous phosphatase activity in some tissues, recognition of PLAP using a monoclonal
antibody (Zymed) is favorable and allows for the use of PLAP staining in flow cytometry.
The choice of internal ribosomal entry sites (IRES). IRESs are cis-acting elements that
recruit the small ribosomal subunits to an internal initiator codon in the mRNA with the
help of cellular trans-acting factors (Martinez-Salas, 1999). In recent years IRES elements
have found ample use in molecular biology as they allow bicistronic expression in
eucaryotes. Due to stable expression characteristics in many tissues, the EMCV-IRES from
encephalomyocarditis virus is the most commonly used element. A recent report
established the NF-κB repressing factor (NRF)-IRES as highly efficient ribosomal entry
site (Oumard et al., 2000). However, it had not been tested, whether the NRF-IRES would
be actively expressed in all tissues. Alongside the EMCV-IRES, the NRF-IRES was chosen
in order to allow the first in vivo comparison of the expression efficiency of these elements.
The choice of the integration site into the IFN-α2 and IRF-7 genes. All type I IFN genes
lack introns. The integration site of the IFN-α2 reporter construct was therefore chosen to
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entirely replace the IFN-α2 ORF and leave the 5' and 3' flanking regions untouched.
Thereby the reporter construct may use the endogenous IFN-α2 polyadenylation signal
(Fig. 3.16d). The reporter construct is however bigger than the IFN-α2 ORF (5.5 kb vs. 920
bp). Flp mediated excision of the EMCV-IRES and the beta-GeoK cassette reduces the
integrated reporter to the 800 bp GFP-ORF. This configuration is most likely to faithfully
reproduce the expression characteristics of the IFN-α2 gene. The IRF-7 gene is composed
of 9 exons. A regulatory sequence important for IRF-7 expression has been reported to
reside in the first intron (Sato, Taniguchi 1998). Therefore, integration of a transgene
should leave the first intron intact and possibly maintain the spacing of this intron to the
IRF-7 promoter. Moreover, the first Exon of IRF-7 only codes for the 5' UTR and 4 2/3
amino acids. The integration was therefore targeted to entirely replace the second exon of
IRF-7 with exception of the first G. As a consequence, transgene protein synthesis should
start at the endogenous ATG, contain the first 5 amino acids of IRF-7 and would then
continue with β-galactosidase starting with its second amino acid. In all variants of the IRF-
7 construct (Fig. 3.16 a,b,c), the inserted reporter ends with a synthetic polyadenylation
site.
The use of BACs. When this project was conceived, the cloned genes for neither IRF-7 nor
for any IFN-α subtype were present in the laboratory. Furthermore, sequence information
of both the murine genomic IFN locus and the genomic organization of the IRF-7 gene
were unavailable in the public domain. We therefore opted for the use of bacterial artificial
chromosomes (BACs) that contain our gene of interest. These BACs may be obtained
through PCR-based screens on a BAC library of the mouse genome (strain Sv129).
Compared to the classical, smaller transgenes, the use of BAC constructs for the generation
of transgenic mice has additional advantages. While small transgene constructs may be
integrated into the genome of a transgene founder up to 50 times, BACs as transgenes
integrate at a low copy number, i.e. usually only once. This allows for a better control of
the gene dose and facilitates the breeding of stable lines of transgene expressing mice.
Because of the size of BAC constructs it is likely that all regulatory sequences required for
controlled expression of the transgene are co-introduced. In addition, erroneous transgene
expression, known as position effect due to foreign regulatory elements in the
neighborhood of the integrated transgene, is reduced. For the generation of the transgene
constructs and their homologous integration into bacterial artificial chromosomes (BACs) a
novel method for DNA engineering, called ET cloning, was applied. ET-cloning constitutes
a convenient way to introduce modifications in large DNA constructs such as BACs
(Muyrers et al., 1999), where the use of enzymatic restriction is precluded.
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3.7.2 ET-cloning, DNA engineering based on homologous recombination
ET-cloning was developed by Youming Zhang and Joep Muyrers in the group of Francis
Stewart at the European Molecular Biology Laboratory in Heidelberg, Germany (Zhang et
al., 1998). It is based on DNA exchange by recombination through short regions of
homology that is mediated by the RecE and RecT proteins. Recombination occurs in vivo
between a linear DNA molecule which contains homology arms of 42 nt or more on each of
its ends, and a circular DNA target containing the chosen homology arm sequences.
Homology arms may be introduced via PCR using long synthetic oligo-nucleotides. In the
final recombinant product, the sequence between the homology regions on the circular
target DNA is replaced by the sequence present between the homology arms on the linear
DNA fragment. Correct recombinants are selected using antibiotic resistance genes
introduced by the ET-recombination process (Muyrers et al., 2000). ET recombination has
been successfully applied to regular plasmids, large cloning vectors (e.g. cosmids, BACs)
and the E. coli chromosome. A remarkable development of this methodology was its recent
application to direct cloning and subcloning (Zhang et al., 2000). The basic ET cloning
variations - as used in this thesis - are schematized in figure Fig. 3.17. The sequence of
PCR primers used for the ET-recombination can be found in chapter 2.6.3.
Fig. 3.17 Schematic illustration of the main variations of the ET recombination technology applied to
the generation of the targeting constructs described in this thesis. (a) ET-cloning: A linear DNA fragment
(e.g. a PCR product) is precisely integrated into a target molecule at the location defined by the short
homology regions. (b) ET-subcloning: A fragment of interest from a donor plasmid (or a BAC) can be
subcloned into a more convenient acceptor vector. The acceptor vector is amplified by PCR including the
appropriate homology arms in the PCR primers. Note that the target molecule not necessarily needs to be a
circular plasmid or BAC but may also be a linear DNA fragment (Original scheme by Giuseppe Testa).
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3.7.3 Generation of the IRF-7 reporter constructs
Schematic drawings of the assembly of all plasmids described in the following can be
found in Fig. 3.18.
Generation of the pACYC/PLAP plasmid. This plasmid was assembled by ET-subcloning to
add a NheI restriction site at both ends of the PLAP ORF (Fig. 3.18 a, right panel). The
PCR primers used on pACYC184 template were Plap-sub5 and Plap-sub3. The PCR
reaction was performed and then digested with DpnI to destroy residual pACYC184
template. The 2 kb PCR product was purified by gel extraction. The MSCV puro PLAP
plasmid (a kind gift of J. Jacob, Atlanta; www.emory.edu/Microbio/jacob; Jacob and
Baltimore, 1999) was digested with EcoRI. The ~1.6 kb fragment containing the PLAP-
ORF was purified by gel extraction and coelectroporated with the PCR modified
pACYC184 fragment into YZ300 cells. Bacteria expressing the recombined plasmid were
selected on LB-Cm plates. 8 of 18 minipreps showed the expected fragments after NheI
digest. Two selected clones were then tested further with analytic PvuII and SacII digests.
The band pattern observed confirmed the expected results.
The NRF-IRES PCR. This proof-reading (cloned Pfu) PCR reaction was performed on
pBSRlucNluc plasmid (a kind gift of H. Hauser, GBF, Germany; (Oumard et al., 2000) to
endow the NRF-IRES with restriction sites for NheI and PacI at the 3' end and KpnI on
both ends (Fig. 3.18 a, left panel). For the PCR reaction the n-ires5 and n-ires3 primer pair
was used. The PCR product was purified, KpnI digested and then re-purified (Qiagen).
Generation of the pGK-beta-Geo/b-NRFIRES plasmid. The purified fragment of the NRF-
IRES PCR was used as insert for conventional ligation into the KpnI linearized and CIP
treated pGK-beta-Geo/b plasmid (a kind gift of Youming Zhang). The beta-Geo/b ORF
contains an integrated prokaryotic promoter for the expression of a β-Gal-Neomycin fusion
protein. This protein also confers resistance to Kanamycin. Selection was performed on
LB-Kan plates. Of 22 minipreps, 13 contained the insert and 7 clones contained the NRF-
IRES in the correct orientation as evidenced by analytic DraI digests.
Generation of the pGK-beta-Geo/b-NRFIRES-PLAP(NheI) plasmid. Nhe I digest of the
pACYC/PLAP plasmid yielded a 1.6 kb fragment, which was purified by gel extraction.
The pGK-beta-Geo/b-NRFIRES plasmid was linearized using the unique NheI site, and
then CIP treated. Both fragments were annealed in standard ligation. Selection of
transformed bacteria was performed on LB-Kan plates. Of 18 minipreps 13 contained the
PLAP insert, and 5 of these in the correct orientation as judged by analytic BamHI and
BstEII digests.
Generation of the pGK-beta-Geo/b-NRFIRES-PLAP(PacI) plasmid. This plasmid
constitutes a minor modification of the construct described before. Instead of NheI sites,
PacI sites were used for the sub-cloning. The insert containing the PLAP ORF was obtained
directly from the MSCV puro PLAP plasmid after PacI digest and purification. Of 18
minipreps 9 contained the insert and four contained the PLAP ORF in the correct
orientation as determined by BamHI, XbaI and DraI digest.
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To verify that the NRF-IRES in the constructs was free of PCR errors, four clones of the
pGK-beta-Geo/b-NRFIRES-PLAP(NheI) and one correct clone of the pGK-beta-Geo/b-
NRFIRES-PLAP(PacI) were sequenced. In all cases the sequence for the NRF-IRES was
error free. The sequencing also evidenced the expected difference in the spacing between
the NRFIRES and the start codon of the PLAP ORF in the two constructs. Due to the
difference in restriction site used for ligation, the pGK-beta-Geo/b-NRFIRES-PLAP(PacI)
plasmid contained an additional 6 bp (i.e. the NheI site).
3.7.4 Introduction of IRF-7 homology arms into 4 variants of the reporter construct
by ET-subcloning.
I) Generation of the pACYC-beta-Geo/b-NRFIRES-PLAP(NheI) plasmid. This plasmid was
generated to endow the IRF-7 reporter construct with the homology arms required for ET-
recombination into exon 2 of the IRF-7 gene (Fig. 3.18 c). The PCR primers used on
pACYC184 template were newIRF-7 5'hom and newIRF-7 3'hom. The PCR reaction was
performed and then digested with DpnI to destroy residual pACYC184 template. The 2 kb
PCR product was purified by gel extraction. The pGK-beta-Geo/b-NRFIRES-PLAP(NheI)
plasmid was linearized by XbaI digest. The fragment was desalted by ethanol precipitation
and then coelectroporated with the PCR modified pACYC184 fragment into YZ300 cells.
Bacteria expressing the recombined plasmid were selected on LB-CmKan plates. 8 out of
14 minipreps showed the correct recombination as revealed by analytic EcoRI and DraI
digests. For one positive clone the homology arms to the IRF-7 gene introduced by ET-
subcloning were sequenced and confirmed correct.
II) Generation of the pACYC-beta-Geo/b-NRFIRES-PLAP(PacI) plasmid. This plasmid
was generated analogous to the (NheI) variant described above. Two out of 6 minipreps
showed the desired recombination.
III) Generation of the pACYC-beta-Geo/b-EMCVIRES-PLAP plasmid: This plasmid was
generated by ET-cloning, exchanging the NRF-IRES of the pACYC-beta-Geo/b-
NRFIRES-PLAP(NheI) plasmid with the EMCV-IRES. The pACYC-beta-Geo/b-
NRFIRES-PLAP(NheI) plasmid contains a unique HindIII site inside the NRF-IRES. Hind
III linearization 'destroys' the NRF-IRES leaving the beta-Geo/b cassette and the PLAP
ORF close to the ends of the linear 8.4 kb fragment. The fragment was purified by gel
extraction.
Proof reading PCR (cloned Pfu/Taq 1:1) was performed on the EMCV-IRES contained in
the pGK/IRES-beta-GeoK plasmid (obtained from Youming Zhang) using the 5-
NRF2EMCV and 3-NRF2EMCVprimers. The PCR reaction was then digested with DpnI
to destroy residual plasmid template. The 0.8 kb PCR product containing the EMCV-IRES
was purified by gel extraction. The 5' primer contains a homology stretch to the 3' end of
the beta-Geo/b cassette and the 3' primer is in part homologous to the 5' end of the PLAP
ORF. Therefore ET-recombined plasmid could be generated by coelectroporation of the
two purified fragments into competent YZ300 bacteria. The selection was done on LB-Kan
plates. Of 9 minipreps 4 showed the correct exchange to the EMCV-IRES and 3 still
contained the NRF-IRES as evidenced by analytic XbaI, PstI and Eco RI digests.
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IV) Generation of the pACYC-beta-Geo/b plasmid. This plasmid constitutes the most
straightforward reporter construct. It contains the β-Gal ORF in the pGK-beta-Geo/b
cassette and was generated in a single ET-subcloning step starting from the XbaI linearized
pGK-beta-Geo/b plasmid (obtained from Youming Zhang). The fragment was purified by
gel extraction and was co-electroporated with the PCR modified pACYC fragment
(described in the (Nhe) variant) into competent YZ300 cells. Bacteria expressing the
recombined plasmid were selected on LB-CmKan plates. All 8 minipreps yielded the
correct recombination as evidenced by analytic PstI and EcoRI digests.
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Fig. 3.18 Cloning strategy for the generation of an IRF-7 reporter transgene. (a) Proof reading PCR on
the NRF-IRES and generation of the pACYC/PLAP plasmid by ET subcloning. (b) Two consecutive steps of
conventional subcloning led to the generation of the pGK-betaGeo/b-NRFIRES-PLAP plasmid. i) Unique
KpnI sites (K) contained in the PCR primers allow the assembly of pGK-betaGeo/b-NRFIRES. ii) This
plasmid may be then linearized by NheI digest for the ligation of the ~1.6 kb NheI-PLAP fragment. (c) The
linearized construct is ET-subcloned into pACYC plasmid backbone, which adds the homology arms required
for (d) the integration into exon 2 of the IRF-7 BAC. Here the strategy for the generation of one variant of the
construct (see Fig. 3.16b) is described. The other variants were generated following a similar strategy. Details
on the modifications are described in the text.
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3.7.5 Characterization of a BAC clone containing the IRF-7 gene
PCR on genomic DNA with the IRF-7 specific primers used in the RT-PCR experiments
(#52 IRF7-up and #53 IRF7-do) yielded a 437 bp product. Subcloning and sequencing of
the PCR product revealed two stretches identical with the published IRF-7 cDNA sequence
separated by one small intron (87 bp). These primers were then used in a PCR-based screen
of a Mouse BAC Library, performed by Research Genetics (Huntsville, Alabama). This
screen yielded four positive BAC clones (396G1, 396H1, 443A15, 443B15). Glycerol
stocks of the bacteria (strain DH10B) were mailed to our lab. PCR screening and Southern
blot using the IRF-7 specific PCR product as probe was performed on several colonies of
these clones. These screens revealed that only clone 396G1 contained the IRF-7 gene, all
others were negative. Moreover, later it was noted that the original glycerol stock was
contaminated with as second, unrelated BAC that did not contain the IRF-7 gene. A fresh
glycerol stock containing only clone 396G1 was prepared and was used for further
characterization.
Restriction digests of BAC DNA separated by agarose gel electrophoresis yielded a discrete
band pattern. In combination with a Southern blot of the same gel, the bands containing
parts of the gene of interest can be identified. For the Southern blot shown in Fig. 3.19 the
IRF-7 specific PCR product was used as probe. Digestion of the IRF-7 containing BAC
with various enzymes also allowed a rough estimate of the size of the BAC, about 110 kb,
by summing up the sizes of the DNA bands. A ~3 kb fragment of the EcoRI digest and a
5.5 kb fragment of the HindIII digest were positive in the Southern blot and were isolated
and subcloned into the pBluescript (Stratagene) vector. Of 19 minipreps 5 contained the
HindIII insert and of 12 minipreps 7 contained the EcoRI insert as de as determined by
IRF-7 specific PCR. The plasmids were called pBSIRF-7/HindIII and pBSIRF-7/EcoRI,
respectively.
3.7.6 Homologous integration of the IRF-7 reporter constructs into the IRF-7
containing BAC
Several attempt were made to achieve the integration of any of the four versions of the
construct into the IRF-7 BAC. However, despite intensive screening, positive recombinants
were not obtained. Further attempts to obtain integration were postponed, in favor of the
development of the IFN-α2 constructs described in the following, until an improved ET
cloning plasmid (developed by Youming Zhang) would be available. The improved
plasmid yields highly improved integration frequencies and has been filed for a patent.
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Fig. 3.19 Restriction digest of the IRF-7 BAC. The IRF-7 BAC was digested with the restriction enzymes
indicated and bands were separated on a 0.7% agarose gel. The Southern blot (IRF-7 probe) of the same gel is
superimposed. For better visibility, the bands of the blot light up in false color (green). Identifying positive
bands allows a coarse mapping of the IRF-7 locus. The positive bands of the EcoRI and the HindIII digests
(red circles) were isolated from a preparative gel and subcloned in pBluescript for further analysis.
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3.7.7 Generation of the IFN-α reporter constructs
Schematic drawings of the assembly of all plasmids described in the following can be
found in Fig. 3.20.
Generation of the pYZC/GFP plasmid. This plasmid was generated by ET-subcloning to
endow the ORF of eGFP with homology arms required for the integration into the IFN-α2
BAC (Fig. 3.20 a, left panel). The PCR primers used on pACYC184 template were
subGFP5 and subGFP3. Besides the homology arms, an additional frt-site followed by a
unique BglII site was included in subGFP3. The PCR reaction was performed and then
digested with DpnI to destroy residual pACYC184 template. The ~2 kb PCR product was
purified by gel extraction. The pEGFP-N1 plasmid (Clontech) was digested with NotI and
PstI. The ~800 bp fragment containing the eGFP-ORF was purified by gel extraction and
coelectroporated with the PCR modified pACYC184 fragment into YZ300 cells. Bacteria
expressing the recombined plasmid were selected on LB-Cm plates. 6 of 8 minipreps
showed the expected fragments after Eco RI and XbaI digest.
Generation of the pYZC/IRES-beta-GeoK plasmid. This plasmid was generated by ET-
subcloning to add frt site on the 3' end and BglII restriction sites at both ends of the IRES-
beta-GeoK cassette (Fig. 3.20 a, right panel). The GeoK cassette contains an ORF that
confers Kan-resistance. The PCR primers used on pACYC184 template were subGeoK5
and subGeoK3. The PCR reaction was performed and then digested with DpnI to destroy
residual pACYC184 template. The ~2 kb PCR product was purified by gel extraction. The
pGK/IRES-beta-GeoK plasmid (obtained from Youming Zhang) was BamHI digested. The
~4.8 kb IRES-beta-GeoK containing fragment was isolated by gel extraction and
coelectroporated with the PCR modified pACYC184 fragment into YZ300 cells. Bacteria
expressing the recombined plasmid were selected on LB-CmKan plates. Two of 12
minipreps showed the expected fragments after BglII digest.
Generation of the pYZC/GFP-IRES-beta-GeoK plasmid. This plasmid was assembled by
standard cloning by ligating the BglII fragment of the pYZC/IRES-beta-GeoK plasmid into
the BglII linearized and CIP treated pYZC/GFP plasmid (Fig. 3.20 b). Selection was done
on LB-CmKan plates. 7 out of 14 minipreps showed ligation in the correct orientation as
evidenced by Eco RI digest. Test digests using AscI and NotI yielded the expected ~5.5 kb
fragment of the IFN-α2 reporter construct and a ~2 kb fragment of the pACYC plasmid
backbone.
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c) ET-recombination into the IFN-α2 BAC
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Fig. 3.20 Cloning strategy for the generation of an IFN-α2 reporter transgene. (a) Generation of the
plasmids pYZC/GFP and pYZC/IRES-beta-GeoK by ET subcloning. Unique BglII sites (B) contained in the
PCR primers allow the assembly of the pYZC/GFP-IRES-beta-GeoK plasmid by standard subcloning (b).
The 5.5 kb fragment containing the reporter construct can be purified after digests with the rare cutting
restriction enzymes AscI and NotI (A,N). (c) Site specific integration of the reporter construct by ET-
recombination, replacing the IFN-α2 ORF in the BAC, can be verified by Southern blot using a 3' flanking
probe on a HindIII (H) digest of the BAC.
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3.7.8 Characterization of a BAC clone containing the IFN-α2 gene
Sequence alignment of published IFN-α cDNAs revealed that the IFN-α2 cDNA sequence
contained unique stretches allowing for the generation of specific RT-PCR primers. Using
the primer pair #26 IFNa2up (CTG TGC TTT CCT CGT GAT G) and #27 IFNa2do (CAG
ATA CAG GCA TGG ATG TAC) a 729 bp PCR product could be amplified from mouse
genomic DNA. Subcloning and sequencing of this PCR product confirmed the identity with
the published IFN-α2 sequence. These primers were then used in a PCR-based screen of
the BAC Mouse ES-129/SvJ (Rel. I) genomic library, performed by Genome Systems (now
Incyte Genomics, St. Louis, Missouri). This screen yielded one positive BAC clone. An
LB-agar stab of the bacteria containing this BAC clone (strain DH10B) was mailed to our
lab. Confirmation that the BAC clone contained the IFN-α2 gene was obtained by IFN-α2
specific PCR followed by subcloning and sequencing of the PCR product.
For further characterization, DNA of the IFN-α2 BAC was digested with various restriction
enzymes. The fragments were separated by agarose gel electrophoresis. Digestion of the
IFN-α2 containing BAC with various enzymes allowed a rough estimate of the size of the
BAC, about 80 kb, by summing up the sizes of the DNA bands.
Fig. 3.21 shows selected digests with the corresponding Southern blot probed with the
IFN-α2 specific PCR product. In most digests 5 fragments were recognized by the probe
indicating that up to five regions with high homology to IFN-α2 were contained in the
BAC. To determine whether other functional IFN-α subtype genes were contained in the
BAC, a PCR using the IFN-α consensus primers (see Fig. 3.4) was performed. The PCR
product was subcloned and 24 clones were sequenced. Besides clones containing the IFN-
α2 sequence, others containing four different IFN pseudogene sequences were observed.
However, no clone of a further functional IFN-α subtype ORF was found.
The DNA bands that tested positive for IFN-α homology in the Southern blot were cut
from a preparative gel and purified by gel extraction. IFN-α2 specific PCR on these
fragments revealed that in the Eco RI digest a ~6 kb fragment and in the Hind III digest a 3
kb band contained the IFN-α2 ORF. The 3 kb fragment was subcloned in pBluescript
(generating pBSIFNa2HindIII) and entirely sequenced by primer walking. The sequence
revealed that the complete IFN-α2 ORF (920 bp) was contained in this fragment, preceded
by 1.2 kb and followed by 1.4 kb regions. The 3' region contained an EcoRI restriction site.
Together with the EcoRI site in the MCS of pBluescript, a 720 bp fragment could be
excised and was used as probe in Southern blots. In contrast to the probes covering parts of
the IFN-α2 ORF, this probe was specific and thus allowed the identification of fragments
containing the IFN-α2 gene. This probe was used in the screens for the homologous
integration of the reporter transgene.
Moreover, the subcloned Hind III fragment allowed testing of the IFN-α2 cloning strategy.
Functionality of the homology arms of the 5.5 kb IFN-α2 reporter construct was verified by
ET-recombination into the pBSIFNa2HindIII plasmid (pBSIFNa2HindIII+construct). To
test the functionality of the frt sites, the plasmid containing the whole IFN-α2 reporter
construct was transfected into FRT expressing bacteria. In all clones tested the 4.5 kb beta-
GeoK cassette was excised as evidenced by analytic restriction digests and the loss of
Kanamycin resistance.
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Fig. 3.21 The IFN-α2 BAC contains 5 regions highly homologous to IFN-α2. Southern hybridization of
IFN-α2 BAC restriction fragments. A PCR product covering the IFN-α2 ORF was used as a probe. High
homology between the IFN-α subtype genes apparently leads to cross hybridization. In most digests 5
fragments showed positive signals, indicating the presence of several genes homologous to IFN-α2 in the
BAC. By PCR on gel extracted bands it was shown that the fragments producing the most intense
hybridization signal (i.e. a 6 kb Eco RI and a 3 kb Hind III band, red circles) contained the IFN-α2 ORF.
3.7.9 Homologous integration of the IFN-α reporter construct into the IFN-α2
containing BAC
In order to obtain the recombinant IFN-α2 BAC, a ~5.5 kb fragment containing the reporter
construct was purified after AscI/NotI double digest of the pYZC/GFP-IRES-beta-GeoK
plasmid. This fragment was electroporated in ET-competent DH10B bacteria harboring
both the IFN-α2 BAC and the pR6K/BAD/abg/Tet ET-recombination plasmid. Selection
was performed on LB-CmKan plates. 43 minipreps were HindIII digested and analyzed on
a 0.7% agarose gel. Positive clones were expected to show the characteristic 3 kb band
shifted to 5.6 kb (see Fig. 3.22 and Fig. 3.20). 5 clones contained a 5.6 kb band, however, a
band at 3 kb was still visible. To test, whether these clones contained the correct integration
and whether the residual 3 kb band was an unrelated DNA fragment previously hidden as a
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double band, a Southern blot from the same gel was hybridized using the EcoRI fragment 3'
of the IFN-α2 gene as a probe. All 5 clones showed the expected band shift in the Southern
blot. In the following, all five clones were partially sequenced to verify the integrity of the
regions where the ET-recombination had taken place. As BAC DNA can't be readily
sequenced, PCRs were performed on the BACs in the regions of interest. PCR products
were then directly sequenced. All clones showed the correct DNA sequence.
       
Fig. 3.22 Screening for ET-recombinant IFN-α2 BAC clones. BAC DNA was HindIII digested and
fragments were separated on an agarose gel (left panel). Southern blot of the same gel was performed using
the EcoRI probe specific for the IFN-α2 3' flanking region (right panel). As expected, recombinant fragments
showed a characteristic shift from 3 kb to 5.6 kb (see also Fig. 3.20). In the agarose gel the WT 3 kb and the
recombinant 1.8 kb fragments are visible as double bands (db).
To further validate that 5 correct integrations have been obtained and that the recombinant
BACs are free of further alterations, a series of restriction digests were performed on these
clones and on WT BAC to identify band shifts on agarose gels and in Southern blots. DraI,
EcoRI, BamHI and Hind III digests were analyzed and blots were hybridized with the
IFN-α2 screening PCR probe. The shifted bands and a correct distribution of the other
bands were observed in both the agarose gels and the Southern blots.
DNA of one recombinant IFN-α BAC was then electroporated into Flp expressing bacteria
in order to delete the frt-flanked IRES-beta-GeoK cassette. Of 18 minipreparations 3
showed the correct deletion as determined by HindIII digest followed by separation of the
fragments on an agarose gel. As expected, these 3 clones also showed a loss of Kanamycin
resistance.
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Ultrapure maxipreparations of two recombinant IFN-α2 BAC clones and of all three
recombinant∆frt IFN-α2 BAC clones were prepared and reanalyzed after BglI restriction
digest on agarose gels and by Southern blot. The EcoRI 3' UTR fragment (Fig. 3.23) and a
GFP probe (Table 2.2) were used for hybridisation. All clones showed the correct band
pattern. Recombinant BAC clone #42 and clone #12 of the Flp deleted BACs, the two
clones yielding the highest DNA content in the maxipreparations, were selected for DNA
microinjection into oocytes. These injections were performed using circular BAC DNA.
Several attempts for microinjections were made by the Monterotondo transgene facility
between February and July 2001, yielding 44 live born offspring. In the screening for
transgenic founders at least 3 different transgene specific PCR reactions and appropriate
controls were performed on each sample of genomic tail DNA (for details see chapter
2.6.9). However, none of the mice tested so far carried the transgene.
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Fig. 3.23 Band shift confirms the integration of the reporter construct and ∆frt deletion of the IRES-
beta-GeoK cassette. BAC DNA of WT, recombinant (Rec) and Rec∆frt clones was BglI digested and
fragments were separated on an agarose gel (left panel). Southern blot was performed on the same gel and
hybridized using the EcoRI probe specific for the IFN-α2 3' flanking region (right panel). Recombination
replaced a BglI site in the IFN-α2 ORF, introducing a new BglI site in the betaGeoK cassette. Flp mediated
deletion eliminated this BglI site leading to the band shifts observed. Shifted bands are labeled with a red dot.
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In order to increase the chances of obtaining transgene positive founders it was decided to
prepare NotI linearized BAC fragment (Fig. 3.24). The prepared BAC fragment was micro-
injected by the Laboratory of George Kolias, Greece.
NotI
BamHI
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Digest: Not I
BamHI
a b c d
DNA: rBAC fragment BACBAC fragment
BamHI
BAC
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e gf
Fig. 3.24 Preparation and verification of recombinant IFN-α2 BAC fragment. (a) Preparative Not I
digest of the recombinant IFN-α2 BAC (rBAC) clone #42. The lower band (red arrow) comprises the
pBeloBAC11 backbone (~7 kb). The upper band contains the IFN-α2 reporter construct (> 70 kb) and was gel
purified from an unstained part of the gel. (b) Analytic electrophoresis of the purified fragment. (c,d) Analytic
digests of the 'wild type' IFN-α2 BAC (BAC) to verify that Not I cuts only twice and leaves the fragment
containing the IFN-α2 ORF untouched (green arrow). (e) Analytic digest of the purified recombinant
fragment. Note that the band containing the integration of the reporter construct is slightly shifted (blue
arrow). The shift is also evident in a Southern blot comparing Bam HI digests of WT (f) and recombinant (g)
IFN-α2 BAC. The EcoRI probe specific for the IFN-α2 3' flanking region was used for hybridisation.
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3.8 Identification of the type I IFN producing cell (IPC) in the mouse
3.8.1 Colocalization of type I IFN with surface markers in histological sections
The phenotype of the major IFN producing cell in VSV pathophysiology is not known.
Since the marginal zone is a complex tissue containing specialized macrophages, DCs,
endothelial cells and non-recirculating B cells, and probably other cell types, colocalization
studies with markers for marginal zone cells could not further resolve the nature of mouse
IPCs (Fig. 3.25).
IFN-α/β
F4/80
MOMA-1
ERTR-9
WT IFNAR-/-
untreated VSV VSV
Fig. 3.25 Localization type I IFN production and of Macrophage populations in sections of untreated
and VSV infected spleen. WT and IFNAR-/- mice were either left untreated or were infected for 12 h with 2
· 108 pfu VSV. Spleens were snap frozen and sections were analyzed cryo-histochemically with polyclonal
serum against type I IFN or monoclonal antibodies against F4/80 (red pulp macrophages), MOMA-1
(metallophilic macrophages), and ERTR-9 (marginal zone macrophages). All specific stainings were
visualized by the APAAP reaction (red). Sections were counterstained with hemalum (blue) to visualize
lymph follicles. Note the dramatic changes of macrophage localization in the course of VSV infection.
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3.8.2 By intracellular cytokine staining
In an attempt to directly identify the cells producing IFN-α by flow cytometry, spleens of
untreated and VSV infected C57BL/6 mice were stained intracellularly with a monoclonal
rat anti-mouse IFN-α antibody. In several experiments a minor population of IFN-α
producing cells was identified. The intensity of the IFN staining in these cells was about 5
fold above background. IFN-α positive cells were observed at a frequency of 1/1000 -
1/700 in the spleens of 6h VSV infected mice, but not in spleens of untreated mice. The
light scatter characteristics of this cell population showed a forward scatter significantly
higher than lymphocytes and a low side scatter (data not shown). A similar FSC/SSC
profile has been observed for human IPCs (Svensson et al., 1996).
However, probably due the complex staining protocol requiring an in vitro incubation step,
the staining intensity was variable. Moreover, due to the fixation of the cells and the harsh
washing conditions involving saponin, the staining of several surface markers was strongly
reduced and for some surface antibody binding of the epitope was even lost totally.
3.8.3 FACSorting of dendritic cell subsets in the spleen
In a third approach we aimed at identifying the phenotype of the mouse IPC in VSV
pathophysiology by FACSorting of cell subtypes classified by differential expression
pattern of surface markers. In analogy to the DC origin of human and mouse IPCs (Asselin-
Paturel et al., 2001; Cella et al., 1999; Nakano et al., 2001; Siegal et al., 1999) we focused
on the analysis of mouse DC subsets. Mice were VSV infected and 9 h later several
CD11c+ DC subsets were MACS enriched, FACS-sorted and then analyzed for the IFN-α
mRNA content (Fig. 3.26).
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Fig. 3.26 FACSorting scheme of DC fractions. MACS enriched CD11c+ cells were stained with anti-
CD11c-Biot./Str.-APC, anti-CD11b-FITC, and anti-GR-1-PE and DC subsets were FACSorted using the
indicated gates A-F. Cells from gate C/D were further subdivided by separating GR-1- (fraction C) and GR-1+
cells (fraction D). DC subsets from the spleen were sorted and total RNA was prepared and analyze by RT-
PCR. The RT-PCR results are shown in the following figures.
Surprisingly, only CD11cintCD11b-GR-I+ DCs (fraction D) were strongly positive for IFN-
α mRNA, whereas neither lymphoid DCs (CD11c+CD11b-, fraction A), myeloid DCs
(CD11c+CD11b+, fraction B), CD11cintCD11b+ DCs (fraction E), nor granulocytes
(CD11c+GR-1+, fraction F) showed high IFN-α expression (Fig. 3.27). CD11cintCD11b-
DCs (fraction C) showed slightly enhanced IFN-α mRNA levels (which were at least 125
fold lower than those of fraction D), that might be due to contaminating cells of fraction D.
A similar result was obtained from sorted fractions of UV-HSV infected mice. While all
other sorted fractions remained negative, and fraction C showed a minor signal, the cells in
fraction D strongly expressed IFN-α mRNA (data not shown).
We next asked, whether CD11cintCD11b-GR-I+ cells are producers of IFN-α independent of
IFNAR feedback signaling. For this purpose DC subsets were isolated from VSV infected
IFNAR-/- mice. Again only CD11cintCD11b-GR-I+ cells showed high-level IFN-α mRNA
(Fig. 3.28). These results indicate that although other DC subsets are able to produce IFN-α
upon in vitro stimulation (Hochrein et al., 2001), they do not play a major role in IFN-α
production after VSV infection in vivo.
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Fig. 3.27 In VSV infected mice CD11cintCD11b-GR-1+ DCs express high-level IFN-α. C57BL/6 mice
were either left untreated or i.v. infected for 9h with 2 · 108 pfu VSV. Splenic CD11c+ cells were enriched by
magnetic cell adsorption and fractions A-F were FACSorted as described in Fig. 3.26. Total RNA of about 4-
10·104 sorted cells was prepared and analyzed by RT-PCR as described in Fig. 2.1.
WT
IFNAR-/-
A
B
C
D
A
B
C
D
1:
5
1:
5
1:
25
1:
12
5
1:
62
5
1:
31
25
1:
5
1:
5
1:
25
1:
12
5
1:
62
5
1:
31
25
1:
5
1:
5
1:
25
1:
12
5
1:
62
5
1:
31
25
- + + + + + - + + + + +- + + + + +RT:
αIFN-         IRF-7       GAPDH
Fig. 3.28 IFN-α production by CD11cintCD11b-GR-1+ DCs is independent of IFNAR feedback, Sv129
(WT) and IFNAR-/- mice were i.v. infected for 9h with 2 · 108 pfu VSV. Splenic CD11c+ cells were enriched
by magnetic cell adsorption and fractions A-D were FACSorted as described in Fig. 3.26. Total RNA of about
4 - 10 · 104 sorted cells was prepared and analyzed by RT-PCR as described in Fig. 2.1.
Results – Characterization of mouse IPCs   80
To determine the pattern of IFN-α subtypes expressed by VSV stimulated WT and
IFNAR-/- IPCs, the IFN-α PCR product of CD11cintCD11b-GR-1+ DCs (Fraction D) was
subcloned and the DNA sequence of several clones was determined. This analysis revealed
that the IPCs of both WT and IFNAR-/- mice expressed a broad spectrum of IFN-α
subtypes and that they showed abundant expression of IFN-α2 and IFN-α5. However,
compared to WT controls, the expression of several IFN-α subtypes were slightly
underrepresented in IPCs isolated from mice incapable of type I IFN receptor feedback.
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Fig. 3.29 IPCs isolated from VSV infected mice express a broad spectrum of IFN-α subtypes. PCR
products of the IFN-α expression analysis 9 h after VSV infection of IPCs sorted from the spleens of WT or
IFNAR-/- mice were subcloned. DNA sequence of 36 and 32 single clones was analyzed, respectively. IFN-α
sequences were classified according to EMBL database entries. The sequence termed IFN-α10 corresponds to
the IFN-αB sequence available on the EMBL database (accession No. L38698).
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3.9 Phenotype of the murine IPC
Sorted mouse IPCs rapidly died in cell culture. Less than 20% of the cells survived o.n.
culture at 37 °C. Survival could not significantly be enhanced by the addition of cytokines
or inducers of maturation such as IL-3, IFN-α, VSV, UV-HSV or poly(I:C) (data not
shown). In cytospins, freshly sorted IPCs from the spleens of C57BL/6 mice showed a
homogenous morphology, characterized by round shape, smooth surface and eccentric
nucleus (Fig. 3.30). These cells were highly similar to human plasmacytoid dendritic cells
except that uninduced mouse IPCs only rarely showed dendritic outgrowths. Most recently
it has been reported, however that mouse IPCs rapidly develop dendrites after stimulation
with CpG DNA (Nakano et al., 2001).
        
Fig. 3.30 Morphology of sorted mouse IPCs (CD11cintCD11b-GR-1+ DCs). CD11cintCD11b-GR-1+ cells
were FACSorted from spleens of C57BL/6 mice as described in Fig. 3.26. Cells were May-Grünwald Giemsa
stained and photographed at 40x. Measure indicates 10 µm.
To analyze the surface markers expressed, the IPC population within CD11c+ enriched cells
could be identified by staining with any two of the fluorescent markers CD11b, CD11c,
Ly6C/Gr-1, B220. The gated population, combined with a morphological gate (FSC/SSC),
was 75% - 97% pure as assessed by staining with another of the above markers as a third
fluorochrome. Best data homogeneity was obtained by screening the CD11c+ Ly6C+ or the
CD11b- Gr-1+ population for expression of B220 as the third fluorochrome (data not
shown). The data shown in the following figures were obtained with both marker
combinations mentioned above.
To differentiate surface marker expression of the splenic CD11c+Ly6c+ IPC and the
CD11c+Ly6c- DC population, MACS purified CD11c+ cells were stained with a selection
of monoclonal antibodies (Fig. 1). Mouse IPCs lacked the expression of lineage markers of
B cells (CD19), T cells (CD5), myeloid cells (CD11b) and NK cells (DX5). In contrast to
splenic DCs, IPCs stained strongly positive for B220, and > 80% were positive for CD90
and Sca-1. IPCs of the mouse were negative for the expression of IL-3R, F4/80 and
CD62L, and showed a characteristic bimodal distribution for CD4 expression. Interestingly,
Gr-1 on IPCs could not be costained with Ly6C. Taking the known cross-reactivity of the
Gr-1 mAb with the Ly6C antigen into consideration, this suggests that on IPCs both
antibodies compete for the same epitope, and that the Ly6C mAb showed the higher
binding affinity.
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Fig. 3.31 Comparison of surface marker expression on splenic CD11c+ Ly6C+ IPCs and CD11c+ Ly6C-
DCs. CD11c+ spleen cells of Sv129 mice were obtained by MACS sorting and stained with anti CD11c, Ly6C
and the mAbs indicated. Numbered squares in (a) indicate the gates used in combination with a
morphological gate (FSC/SSC) for the subsequent analysis of the IPC (1/bold line) and DC (2/hairline)
fraction. Panel (b) shows the FSC/SSC distribution of IPC cells from gate 1. Profiles in (c) show stainings
with FITC-conjugated mAbs (Ly6C-PE) in the left and middle column while the histograms on the right
where obtained using PE-conjugated mAbs (Ly6C-FITC). Grey lines represent staining with IgG2a isotype
controls. All panels are representative of at least 3 independent analyses.
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3.10 Properties of the murine IPC
As described above, sorted IPCs showed poor survival in cell culture in vitro. To estimate
the IPC half-life in vivo, i.e. how quickly the IPC population is renewed in the spleen and
the bone marrow, naive Sv129 mice were continuously treated with BrdU. At different time
points BrdU incorporation was monitored by FACS analysis of CD11c+ enriched cells and
the percentage of BrdU positive cells was determined (Fig. 2). In the spleen more than 75%
of CD11c+ Ly6C+ IPC were BrdU positive after 15 days of continuous labeling. In the bone
marrow the plateau level of > 75% BrdU positive cells was reached significantly earlier, i.e.
already after 6 days. Moreover, BrdU incorporation had a rapid onset in bone marrow IPC,
while the splenic IPC population showed a 3 - 5 day lag period before BrdU positive cells
accumulated. This suggests an influx of approximately 6 - 7% bone marrow derived IPCs
into the spleen per day.
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Fig. 3.32 IPC renewal in the bone marrow occurs at a higher rate than in the spleen. For in vivo BrdU
labeling, Sv129 mice were injected with 1 mg BrdU and subsequently fed with drinking water containing 1
mg/ml BrdU. At the time points indicated MACS sorted CD11c+ spleen or BM cells were fixed and stained
with anti-BrdU mAb. IPCs from the spleen (circles) or BM (squares) were identified by CD11c/Ly6C and
independently by CD11b/Gr-1 staining. For d3 and d15 the proportion of BrdU positive splenic DCs are
shown (in brackets). Each data point represents the mean of 2 analyses and of samples derived from 2-3 mice.
To analyze the properties of IPCs and CD11c+ DCs of the spleen in response to viral
infection, we analyzed the expression activation markers and costimulatory molecules
involved in APC function 9h after infection with VSV. Expression of the early activation
marker CD69 was strongly induced in activated IPCs. Equally, MHC class II and CD 86,
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the activation induced costimulatory molecule, were upregulated in both IPCs and DCs.
Interestingly, and in contrast to DCs, upregulation of these molecules on IPCs was found to
be highly dependent on type I IFN receptor signaling. This hints at differential use of
signaling pathways that govern receptor upregulation in DCs and IPCs. After the short term
in vivo stimulation analyzed here, only minor changes were monitored in stainings for
CD40 and CD80 in both IPCs and DCs (data not shown).
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Fig. 3.33 In contrast to classical DCs, upregulation of activation markers on IPCs is IFNAR dependent.
WT and IFNAR-/- mice were left untreated (hairline) or injected with 2 · 108 pfu VSV (bold line). Nine hours
later, CD11c+ spleen cells were isolated by MACS sorting and the expression of CD69, CD86 and MHCII
was analyzed on IPCs or classical DCs. IPCs and DCs were discriminated by anti CD11c/Ly6C(PE) staining,
as described in Fig. 3.31. Staining with B220 is used as a control for the purity of the cell fraction analyzed.
Results are representative of three independent experiments.
Within the CD11c+ enriched spleen cells, prepared from Sv129 mice at various time points
after infection, we observed a highly variable percentage of IPCs ranging from 16% to less
than 2% towards later time points after infection (data not shown). To further analyze and
quantify the reduced IPC abundance after VSV infection, we developed a protocol to
directly determine IPC counts for various tissues of Sv129 mice using two-color
immunofluorescence flow cytometry. Freshly prepared single cell suspensions were stained
with a mixture of FITC-conjugated antibodies to lineage markers (CD5, CD11b, CD19,
DX5) and Ly6C-PE (Fig. 3.34 a). The purity of the gated lineage negative, Ly6C positive
IPC population was monitored using CD11c or B220 as a third fluorochrome. Purity was
> 80% for most tissues tested (Fig. 3.34 c).
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Fig. 3.34 The number of IPCs is drastically reduced in the spleens of acutely VSV infected mice. Sv129
mice were left untreated or infected with 2 · 106 pfu VSV. 18 hours later spleen cell suspensions were
prepared and were stained with Ly6C, B220, and FITC-conjugated CD5, CD11b, CD19 and DX-5 mABs
(lineage). Panels in (a) show 106 ungated cells. Thresholds were set to exclude RBCs and cell debris. Gated
events (grey circle) are shown in (b) as FSC/SSC distribution. The proportion of IPCs indicated in (c) as % of
total cells was determined by gating on lineage nevative Ly6C+B220+ cells that showed a FSC/SSC
distribution characteristic for IPCs.
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Relative IPC counts for selected tissues are shown in Fig. 3.35 were determined by gating
on lineage negative, Ly6C+B220+ cells in combination with a morphological gate (FSC/
SSC, Fig. 3.34 b). In uninfected Sv129 mice high IPC counts were found in the liver and
bone marrow as well as in the lungs and spleen (0.8% – 0.4% of total cells, respectively).
Peripheral LN and similarly mesenteric LN, Peyers patches and kidneys showed IPC
frequencies of about 0.2%. IPC counts < 0.1% were monitored in the thymus, PBLs and
peritoneal cavity cells (Fig. 3.35 and data not shown). Within 18h after injection of 2 · 106
pfu VSV we observed an up to 10 fold decrease in IPC counts in secondary lymphoid
organs, especially in the spleen and peripheral LNs. In other peripheral organs, i.e. the liver
and lungs of infected animals, rather a slight increase in IPC counts was observed. IPCs
counts in the spleen and LN were similarly reduced in infected IFNAR deficient mice. Of
note, however, are the drastically opposite trends of IPC counts in the bone marrow of VSV
infected IFNAR-/- mice as compared to Sv129 WT mice. A tentative explanation for the
observed phenomenon could be IPC efflux from the bone marrow, as well as from
secondary lymphoid tissue, is triggered by an IFNAR independent signal, while IPC
differentiation from a bone marrow precursor is induced by IFNAR signaling.
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Fig. 3.35 Tissue distribution of IPCs before and after VSV infection. Sv129 and IFNAR-/- mice were left
untreated or were infected with 2 · 106 pfu VSV 18 h previously. Cell suspension from the organs indicated
was prepared and IPC counts were determined cytometrically as described in Fig. 3.34. Data are means
(± sdev) of samples from 3–6 mice.
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In order to analyze IPC homeostasis in untreated mice and to study IPC disappearance early
after virus infection and the conditions of IPC repopulation at later time points, we
monitored the accumulation of BrdU positive IPCs in naïve and VSV infected mice.
Compared to untreated mice, the IPC renewal in the bone marrow of VSV infected mice
was significantly enhanced (Fig. 3.36), eventually leading to increased IPC counts that
were maintained for several days of VSV infection (Fig. 3.35 and data not shown).
Following the IPC loss observed in the spleen early after infection, the spleen was
gradually repopulated. The IPC population found in the spleen tree days after infection
already contained a more than 6 fold increased number of BrdU positive cells as compared
to uninfected control mice, suggesting that spleens are repopulated with IPCs from the bone
marrow during the recovery phase from acute viral infection.
0
25
50
75
1 3 1 3
Spleen BM
Time of BrdU labeling [d]
B
rd
U 
 IP
C 
ce
lls
 [%
]
+
Fig. 3.36 IPC turnover is enhanced in the spleens of mice recovering from acute VSV infection. Sv129
mice were injected i.p. and thereafter fed in the drinking water with BrdU. At the same time the mice were
infected with 2 · 106 pfu VSV (filled symbols) or were left uninfected (open symbols). The proportion of
BrdU positive IPCs was determined cytometrically as described in Fig. 3.32.
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4 Discussion
4.1 Virus induced IFN-α production in the absence of feedback signaling
in vivo
Despite extensive in vitro studies, the role of type I IFN receptor (IFNAR) feedback
signaling in viral pathogenesis in vivo has not been assessed previously. We show that after
viral infection of mice not only IFN-β but also IFN-α is produced immediately and largely
independent of IFNAR feedback signaling. This is in contrast to the current model of
IFNAR feedback-dependent expression of IFN-α , that was established based on
experiments with cultured cells in vitro. To reconcile the previous in vitro data with our in
vivo observations, we hypothesized that after viral infection of mice a cell type different
from fibroblasts, i.e. the murine IPC, produced the majority of type I IFN, and that in these
cells IFN-α expression was regulated differently than in fibroblasts. Indeed, we found that
after in vivo infection the subset of CD11cintGR-1+ dendritic cells produced IFN-α at high
level, and that early IFN-α production by this cell type was largely independent of IFNAR
feedback.
The positive feedback regulation of IFN-α genes was first observed in NDV infected MEFs
that lack IFN-α expression in the absence of a functional IFN signaling cascade (Harada et
al., 1996; Sato et al., 1998). One study showed IFNAR independent IFN-α4 expression in
NDV infected MEFs (Marie et al., 1998). Interestingly, IFN-α4 was previously found to
dominate IFN-α responses of NDV stimulated L929 fibroblasts (Hoss-Homfeld et al.,
1989). However, MEFs infected with VSV (Fig. 3.1, 3.3), or vaccinia virus (Deonarain et
al., 2000) showed a strictly IFNAR dependent expression of all IFN-αs. Equally, Sendai
virus infected MEFs from IFN-β deficient mice were found unable to produce any IFN-α,
unless stimulated by the addition of exogenous IFN-β (Erlandsson et al., 1998).
In contrast to these in vitro data, we found that VSV infected mice mount an early IFNAR-
independent IFN-α response. Furthermore, IFN-β deficient and IFN-β/IFNAR double-
deficient mice treated with UV-HSV still expressed substantial IFN-α levels (Fig. 3.6).
While IFN-α production in IFN-β-/- mice could have been promoted by priming with
natural type I IFN, produced pathogen-independently (Taniguchi and Takaoka, 2001),
IFN-α production in IFN-β/IFNAR double-deficient mice indicated, that IFNAR triggering
was not a prerequisite for early IFN-α production. IFN-α levels reached in IFN-β-/- were
sufficient to control intravenous VSV infection (data not shown). In contrast, IFN-β
deficient mice infected peripherally with vaccinia virus showed a markedly increased
susceptibility to lethal disease (Deonarain et al., 2000): following intranasal infection,
IFN-β-/- mice showed up to 105 fold increased virus titers in the lung as compared to WT
mice, and eventually succumbed to the infection. Interestingly, in these experiments virus
titers in spleen of WT and IFN-β-/- mice were comparably low, indicating that upon local
infection vaccinia virus replication was better controlled in the spleen than in the
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peripherally infected organ. Thus, it appears that depending on the route of infection virus
may activate IPCs or other susceptible cell types that differ in their requirement of IFNAR
feedback for the IFN-α induction.
Apart from the route of infection also the nature of the stimulus may determine the cell
type(s) involved in type I IFN production (Levy, 2002). Our histology data show that
poly(I:C) does not induce marginal zone IPCs to produce high-level type I IFN, suggesting
that the observed IFN titers were contributed mainly by non-IPCs. It is possible that in
analogy to the human plasmacytoid DC, mouse IPCs express TLR-9 but not TLR-3 that is
involved in poly(I:C) recognition (Alexopoulou et al., 2001; Kadowaki et al., 2001), and
thus mouse IPCs are not triggered by poly(I:C). IFN titers in poly(I:C) treated mice showed
an early peak of IFN-β expression that only in animals with a functional receptor-feedback
was followed by sustained IFN-α expression. This indicated that similar to in vitro VSV
infected MEFs, IFN-α expression by non-IPCs in vivo required IFNAR feedback signaling.
In the current model of positive feedback regulation, IFNAR dependent upregulation of the
transcription factor IRF-7 plays a central role. Virus treated mutant MEFs that failed to
induce IRF-7 also lacked expression of IFN-α. The IFN-α response could be restored by
ectopic expression of IRF-7 (Sato et al., 1998). In IFNAR deficient mice, we observed early
IFN-α responses in the absence of detectable IRF-7 upregulation. One possibility is that
under these conditions low constitutive IRF-7 levels suffice to drive early IFN-α
expression. In this context it is worth noting that in all RT-PCR experiments, unlike other
DC subsets, CD11cintCD11b-GR-1+ DCs (fraction D) showed some background IRF-7
expression already in uninfected wild type mice (Fig. 3.27). Alternatively, IPCs might be
able to utilize an IRF-7 independent pathway for IFN-α expression, as suggested by the
recent finding, that ectopic expression of IRF-5 can substitute for IRF-7 to allow expression
of certain IFN-α genes (Barnes et al., 2001). Ultimately, only the generation and analysis of
IRF-7 deficient mice can define the role of IRF-7 in the expression of virus-induced IFN-α
in vivo.
Our immune histological analysis of VSV infected mice revealed that IPCs are
predominantly located in the marginal zone. Similarly, we and others have found the same
IPC distribution in UV-HSV treated mice (Fig. 3.14, Eloranta and Alm, 1999; Eloranta et
al., 1996). The importance of the marginal zone for pathogen surveillance was
demonstrated by the scavenger function of marginal zone cells, which can retain
microscopically small particles, including pathogens, from the blood (Matsuno et al.,
1986). Mice that were experimentally depleted of macrophages in the marginal zone (Seiler
et al., 1997), and osteopetrotic (op) mutant mice that are M-CSF deficient and lack the
same macrophage populations, showed an increased sensitivity to pathogen infection
(Guleria and Pollard, 2001). Thus, in order to be stimulated early in the course of an
infection it appears “reasonable” that IPCs are located in the marginal zone. From
histological colocalization studies it had been concluded that MOMA-1+ metallophilic and
ERTR-9+ marginal zone macrophages might be involved in type I IFN production (Eloranta
and Alm, 1999). Since we could not observe a strict correlation of MOMA-1 and ERTR-9
vs. IFN-α/β stainings, and following recent evidence that the human and mouse IPC are
plasmacytoid DCs (Asselin-Paturel et al., 2001; Cella et al., 1999; Nakano et al., 2001;
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Siegal et al., 1999), we FACS-sorted several DC subsets form spleen of VSV infected and
from UV-HSV stimulated mice and analyzed them for IFN-α mRNA expression. These
experiments indicated, that the subset of CD11cintCD11b-GR-1+ DCs showed high IFN-α
mRNA levels. Interestingly, we did not find increased levels of IFN-α message in myeloid
or lymphoid DCs (fractions A and B, respectively) isolated from VSV or UV-HSV treated
mice, as could have been expected form recent in vitro data (Hochrein et al., 2001).
In conclusion, we suggest to extend the current model of IFNAR feedback dependent
expression of IFN-α as follows: i) In vivo, local infections may stimulate the production of
mainly IFN-β by non-IPCs to protect surrounding tissues in a paracrine fashion. These cells
produce IFN-α IFNAR dependently, i.e. only if sufficient autocrine type I IFN stimulation
is provided. ii) Systemic infection and acute viremia, that require a generalized anti-viral
state, may stimulate IPCs to produce IFN-α early and at high level independent of IFNAR
feedback signaling. However, IFNAR feedback defines the magnitude and the duration of
sustained IFN-α production, even when the primary inducing stimulus itself is short lived.
To our knowledge, we present the first set of ex vivo data defining IPCs in viral
pathogenesis. Our results support the concept that highly specialized DCs, located in the
marginal zone, produce type I IFN upon pathogen contact. The observation that early
IFN-α production of mouse IPCs is largely independent of IFNAR signaling indicates a
less stringently regulated IFN-α expression in IPCs as compared to other cell types. Further
experiments will reveal, whether - depending on the tissue tropism and the stimulation
mechanism - different pathogens may activate discrete cell populations to produce type I
IFN, and whether mouse IPCs do play a role in antigen-processing and -presentation.
4.2 Phenotypic and functional characterization of the mouse IPC subset
Originally, we have analyzed rapid upregulation of IFN-α expression after VSV infection
for IPC classification, thus identifying a population of CD11b-CD11cintGR-1+ cells. Later it
became obvious that the Gr-1 specific antibody cross-reacted at low affinity with the Ly6C
antigen. Consequently, binding of anti-Gr-1 antibody was diminished by the competition of
high affinity anti-Ly6C antibody. CD11c enriched cells from the spleen could therefore be
divided into a CD11c+Ly6C- dendritic cell population and CD11c+Ly6C+ IPCs. The latter
expressed CD90, Sca-1, and CD54 but not F4/80 or CD62L (Fig. 3.31). The IPC population
showed a characteristic low orthogonal light scatter, expressed B-220 in addition to Ly6C,
but lacked expression of T-, B-, myeloid and NK- lineage-specific markers (CD5, CD19,
CD11b and DX5). These properties allowed the identification of IPCs within unsorted cell
suspensions from various organs providing the basis for direct quantitation of IPCs in the
absence or presence of acute VSV infection (Fig. 3.34). Most recently, the mouse IPC was
identified also by other groups, contributing valuable insight to the initially defined
characteristics. The CD11c+Ly6C+ IPC subset in the mouse shares many similarities with
the human plasmacytoid dendritic cells, including morphology, IPC function, and the
expression of sets of TLR (Bruno et al., 2001) and other surface markers. Yet, unlike
human plasmacytoid dendritic cells, mouse IPCs do not express the IL-3 receptor, pointing
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at possible differences in the requirement for survival stimuli. This is evidenced by the
difficulty to culture unstimulated mouse IPCs in vitro (Asselin-Paturel et al., 2001).
4.3 Origin of IPCs
Dendritic cells can be derived from proliferating pluripontent precursors in the mouse bone
marrow by appropriate cell culture conditions in vitro (Metcalf, 1997; Traver et al., 2000).
However, the differentiation pathways that generate DCs in vivo remain largely unknown
(Ardavin et al., 2001)*. In particular, a direct non-proliferating DC precursor has not been
defined for myeloid or lymphoid DCs. Like other immune cells, including DCs, mouse
IPCs probably derive from a precursor population in the bone marrow. Interestingly, the
mouse bone marrow contained a cell type very similar to splenic IPCs. The expression of
all surface markers tested was virtually identical on splenic and bone marrow derived IPCs
(data not shown). The lack of a bone marrow counterpart of other DC subsets makes the
relative abundance of bone marrow cells with IPC phenotype surprising. To analyze the
renewal rate of IPCs purified from bone marrow and spleen, BrdU labeling experiments
have been performed. The turnover kinetics and the accumulation of BrdU positive IPCs
were faster in the bone marrow than in the spleen. These observations suggested that IPCs
do reside in the bone marrow and that they can directly populate secondary lymphoid
organs.
Yet, direct homing to secondary lymphoid tissues is untypical for immature DC subsets.
Classically, immature dendritic cells home to peripheral organs. There they acquire antigen
and once activated by a pathogen stimulus they undergo maturation and then migrate to the
draining lymph nodes and/or spleen (Cella et al., 1997; Sallusto et al., 1998). Thus, DCs in
lymphoid organs have been widely considered to be mature, antigen-presenting cells
capable of activating naïve T-cells. However, unlike myeloid and lymphoid dendritic cells
found in secondary lymphoid organs, mouse IPCs display immature morphology, lacking
the cell protrusions typically found on dendritic cells. In contrast to splenic DCs, IPCs enter
lymphoid tissues apparently independent of maturation inducing stimuli. Accordingly,
freshly isolated IPCs, in contrast to splenic DCs, were found unable to stimulate
proliferation of allogeneic T-cells. IPCs activated and matured by in vitro stimulation with
CpG-DNA induced weak but evident T-cell proliferation (Asselin-Paturel et al., 2001;
Nakano et al., 2001). So far, poor survival in cell culture limited the detailed analysis of the
T-cell stimulatory capacity of mouse IPCs. Thus it is still open, whether IPCs may serve as
antigen presenting cells capable of initiating an adaptive immune response in vivo.
*Note added in proof: A CD11c+ MHCII- proliferating precursor able to differentiate in vivo into all known
DC subsets, but not into other myeloid or lymphoid cells, has now been identified in mouse peripheral blood
(del Hoyo et al., 2002).
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4.4 IPCs in viral pathophysiology
Upon VSV infection of mice, activated IPCs showed upregulation of cell surface
molecules, including MHC class II and CD86 costimulatory molecules. Interestingly,
upregulation of activation markers by IPCs - but not by other splenic DCs - was dependent
on type I IFN receptor signaling. This suggested the use of discrete signaling pathways in
DCs and IPCs involved in the induction of cell maturation. Nevertheless, with respect to
the evident high-level expression of early inflammatory cytokines, i.e. type I IFNs and
IL-12 (Dalod et al., 2002), and the induction of the MHC class II antigen presentation
machinery, activated IPCs share many properties with classical DC subsets (Cella et al.,
1997).
However, activated IPCs rapidly disappeared from the secondary lymphoid organs of VSV
infected animals. One possibility is that the activation stimulus caused a rapid change of
IPC morphology as well as surface marker expression. In spleen-cell suspensions from
uninfected mice, we could uniquely identify mouse IPCs by the combination of any two of
the following surface markers, CD11c, B220, Ly6C and absence of lineage-specific
markers (i.e. CD5, CD19, CD11b and DX5), or by combining one of the above criteria with
the typical FSC/SSC characteristics. Abrupt and simultaneously altered expression of all 4
surface markers plus a dramatic change in the cell morphology are, however, unlikely to
occur, and thus cannot explain the disappearance of activated IPC from spleen. In addition,
monitoring activated IPCs over time, we did not observe shifts in cell size or modulation of
cell surface marker expression, or ‘tailing’ in the FACS profiles that would be indicative of
altered marker expression and cell shape changes. As a second possibility, stimulated IPCs
might be rapidly driven into apoptosis, either due to (over)stimulation or due to the
cytopathic effect of VSV. Yet, 2 · 105 viral particles administered intravenously initiate the
disappearance of more than a 10 times greater number of IPCs in the spleen alone. The
observation that even low viral doses lead to a generalized reduction of IPC counts in
lymph nodes and spleen makes a hypothesis involving cell death less likely. IPC loss in
secondary lymphoid organs is paralleled by an increase of IPC counts in peripheral organs
such as the lung. We therefore favor the possibility that activated IPCs physically leave
secondary lymphoid organs and relocate to different organs.
A number of recent studies evidence that the IPC population indeed shows dynamic
responses to different kinds of stimuli. Human blood IPC counts are sharply depressed after
the administration of corticosteroids and return to normal levels within days after steroid
cessation (Shodell and Siegal, 2001). In HIV infected patients long-term survivors showed
increased IPC numbers while disease progression was accompanied by markedly reduced
IPC levels (Feldman et al., 2001). IPC counts correlated with the viral load found in the
corresponding patients (Soumelis et al., 2001). A similar depression in IPC counts has been
observed in patients suffering from systemic lupus erythematosus (SLE) (Cederblad et al.,
1998). Moreover, in the case of SLE a significant relocation of IPCs to the skin could be
demonstrated (Blomberg et al., 2001; Farkas et al., 2001). Migration of IPCs to the site of
local inflammation has also been observed in bacterial neuroinfections and in allergic
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rhinitis (Pashenkov et al., 2002; Jahnsen et al., 2000). Furthermore, chronically inflamed
lymph nodes harbor enlarged quantities of IPCs (Cella et al., 1999).
These observations raise the question of the biological significance of IPC relocation. As
discussed earlier, stimulation of high-level IFN-α production by IPCs might be a hallmark
of acute viremia that can be better controlled by a generalized antiviral state. It is
conceivable, that besides IFN molecules distributed by the blood stream, also IPCs (the
cells producing it) may contribute to the amplification of innate immune reactions in
peripheral organs. Recently an intriguing connection between type I IFNs, DCs and NK
cells has been observed. On its own, IFN-α  was almost incapable of inducing DC
maturation. In contrast, IFN-α maturation of DCs was potentiated in the presence of NK
cells. Similarly, type I IFN mediated activation of NK cells is enhanced in the presence of
DCs, suggesting an IFN-α dependent amplification loop that augments the activation of
directly interacting DCs and NK cells (Gerosa et al., 2002). In a similar fashion, activated
IPCs might function as sentinels that require further stimulation for maturation and possibly
differentiation.
In response to an acute inflammatory stimulus (Bruno et al., 2001) or by injection of Flt-3
ligand (Bjorck, 2001) IPC counts in mouse bone marrow, and shortly afterwards in the
blood and peripheral organs, were dramatically increased. Also in humans Flt-3 ligand and
G-CSF administration have been shown to rapidly elevate IPC numbers in the blood
(Arpinati et al., 2000; Pulendran et al., 2000). Thus, the bone marrow may function as a
reservoir for IPC homeostasis, allowing prompt IPC recruitment to peripheral tissues upon
stimulation. Accordingly IPC numbers in the bone marrow of WT mice were augmented
after VSV infection. Yet, VSV infected IFNAR-/- showed sharply decreased IPC counts.
The hypothesis of an IPC reservoir in the bone marrow offers a tentative explanation for the
observed contrary trends in IFNAR-/- as compared to WT mice: while type I IFNs might
directly or indirectly induce the generation of IPCs from a precursor and thus raise IPC
levels in the bone marrow, an IFN independent stimulus may trigger the release of IPCs
into the periphery.
A non-proliferating CD11c+Ly6C+CD31+ cell type from the bone marrow, very similar to
the mouse IPCs, has recently been shown to be able to mature in vitro into macrophages,
lymphoid or myeloid dendritic cells. This reopens the question that has already been
formulated for human plasmacytoid dendritic cells (Galibert et al., 2001), i.e. whether IPCs
are destined to become a specific dendritic cell type or might serve as a precursor for
different maturation routes depending on the stimulus they receive in peripheral tissues.
4.5 Outlook: What is the fate of the IPC in vivo?
Several open questions may be addressed by the analysis of the BAC-transgenic IFN-α2 or
IRF-7 reporter mice. Firstly, it is not clear whether mouse IPCs constitute the only cell
population capable of high-level type I IFN production. Human IPC, as probably their
counterpart in the mouse, express a distinct set of TLR (Jarrossay et al., 2001; Kadowaki et
al., 2001) making it conceivable that different viral IFN inducers may stimulate bulk IFN
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production in different cell subsets. Sendai and lymphocytic choriomeningitis virus
(LCMV) for example fail to stimulate high-level IFN production by IPCs (Dalod et al.,
2002; Feldman et al., 1994). We obtained similar results for poly(I:C), though it is not clear
whether poly(I:C) predominantly stimulates another specific cell type or a broad spectrum
of non-IPC cells. A recent example for cellular complementarity in cytokine production has
been provided for IL-12, another early cytokine (Dalod et al., 2002). Secondly, also the
route of infection might influence the source of type I IFN in vivo. Many natural viral
infections are acquired through respiratory or mucosal routes. It is therefore intriguing that
besides the bone marrow, the lungs of naive mice showed the highest IPC counts (Fig.
3.35) and it will be important to determine whether IPCs of the lung are activated during
local pulmonary infections. Thirdly, expression of the reporter gene may help to follow the
fate of activated IPCs in vivo. The destination of IPC relocation and the cell types that
possibly differentiate from activated IPCs could be identified. This may help to resolve the
controversial question whether IPCs represent a distinct hematological entity or whether
they are a conglomerate of immature cells with distinct differentiation fates.
In summary, the observation that activated IPCs leave secondary lymphoid tissues, and thus
behave opposite from maturing dendritic cells, make it unlikely that IPCs play a dominant
role in the antigen presentation initiating an adaptive response. The fate of the disappearing
IPC cells is, however, not known. It is conceivable that IPCs acquire antigen, mature and
differentiate outside secondary lymphoid organs and eventually relocate to the spleen and
lymph nodes as antigen presenting cells during later stages of acute viral infections.
Rapid IPC relocation in response to inflammation/infection together with the dynamic
increase in IPC output by the bone marrow supports the idea that IPCs might constitute an
immature pluripotent precursor, able to differentiate according to stimuli and maturation
environment, rather than a distinct lineage of committed cells. Testing this hypothesis will
help to determine whether and in what way patients suffering from chronic viral infections
such as HIV or Hepatitis C benefit from boosted IPC counts. The therapeutic value of an
increased IPC population surely includes but might go well beyond the mere increase in
local and generalized IFN-α output. Also non-viral human diseases, such as multiple
sclerosis, Behcet's disease and certain cancers have been successfully treated with type I
IFNs (Karp et al., 2000; Pitha, 2000; Steis et al., 1987; Walther and Hohlfeld, 1999;
Zouboulis and Orfanos, 1998). However, systemic administration of type I IFNs often
causes severe side effects that preclude its general use in many cases (ibid.). It is
conceivable, that a therapy aimed at activating the patients’ endogenous interferon
production, i.e. by boosting and/or specifically activating IPCs may be efficient and at the
same time may alleviate undesired side effects.
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6 Abbreviations
Ab(s) antibody(ies); mAb monoclonal antibody, pAb polyclonal serum
Ag antigen
APC antigen presenting cell
BAC bacterial artificial chromosome
BCR B cell receptor
BM bone marrow
bp base pair
BSA bovine serum albumin
β-Gal beta galactosidase
CD cluster of differentiation
cDNA complementary DNA
CPE cytopathic effect
CpG prokaryotic DNA motif
CTL cytotoxic T lymphocyte
DC dendritic cell
DMEM Dulbecco’s Modified Eagle’s Medium
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
DNAse deoxyribonuclease
dNTP 2’ deoxyribonucleosidetriphosphate
DTT dithiothreitol
EDTA ethylene-diaminetetraacetic acid
ELISA enzyme-linked immunosorbent assay
EMCV encephalomyocarditis virus
ES cells embryonic stem cells
ET-Cloning homologous recombination in bacteria expressing RecE and RecT
FACS fluorescence activated cell sorting
FCS fetal calf serum
FDG fluorescein di-β-D-galactopyranoside
FITC fluorescein isothiocyanate
FSC forward scatter
GFP green fluorescent protein
GM-CSF granulocytes macrophage colony stimulating factor
HIV human immunodeficiency virus
HSV type I herpes simplex virus
i.p. intraperitoneal
i.v. intravenous
IFN interferon
IFNAR type I IFN receptor
Ig immunoglobulin
IL interleukin
IPC professional IFN producing cell
IRES internal ribosomal entry site
IRF interferon regulatory factor
kb kilobase pairs
LB Luria Bertrami medium
LCMV lymphocytic choriomeningitis virus
LN lymph node
Abbreviations   108
LPS lipopolysaccharide
MACS magnetic adsorption cell sorting
MEF mouse embryonic fibroblast
MHC major histocompatibility complex
moi multiplicity of infection
mRNA messenger RNA
MZ marginal zone
NDV Newcastle disease virus
NEO neomycin resistance
NK natural killer cell
NRF NF-kB repressing factor
OD optical density
PAMP pathogen associated molecular pattern
PBS phosphate buffered saline
PC peritoneal cavity
PCR polymerase chain reaction
PE phycoerythrin
pfu plaque forming units
PKR double stranded RNA-dependent protein kinase R
PLAP human placental alkaline phosphatase
poly(I:C) synthetic double stranded RNA
PRR pattern recognition receptor
RAG recombination activating gene
RNA ribonucleic acid
rpm revolutions per minute
RPMI Rosewell-Park-Memorial-Institute cell culture medium
RSS recombination signal sequences
RT room temperature
RT-PCR reverse transcription PCR
SA streptavidin
SDS sodium dodecyl sulfate
SPF specific pathogen free
SSC side scatter
TCR T cell receptor
tg transgene
TLR Toll-like receptor
Tris Tris(hydroxymethyl)aminoethane
UV ultraviolet
UV-HSV UV-inactivated herpes simplex virus
VSV Vesicular stomatitis virus
WT wild type
YZ300 ET-recombination competent strain of RecA+ bacteria
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8 Zusammenfassung
Bei verschiedenen Virusinfektionen ist die Induktion einer wirkungsvollen Typ I
Interferonantwort (IFN-α/β) entscheidend wichtig für das Überleben des Wirtsorganismus.
In vivo wird der größte Teil des Typ I Interferons von einem seltenen Zelltyp produziert,
der als professionelle Interferon-produzierende Zelle (IPC) bezeichnet wird. Der Phänotyp
von IPCs in der viralen Pathogenese in der Maus und die molekularen Mechanismen der
Typ I Interferon Produktion durch IPCs sind bisher nicht untersucht worden.
Durch Experimente an mit Newcastle disease Virus (NDV) infizierten Fibroblasten (MEFs)
in der Zellkultur, wurde das Modell der autokrinen Rückkopplungsregulation der Typ I
Interferonproduktion etabliert. Gemäß diesem Modell ist die Transkription der IFN-α Gene
– mit der Ausnahme von IFN-α4 – sowohl von der Aktivierung des Typ I IFN Rezeptors
(IFNAR), als auch von der Aktivierung der Transkription von Interferon Regulations
Faktor (IRF)-7 abhängig. In einem akut infizierten Wirtsorganismus wird jedoch der größte
Teil Typ I Interferon wahrscheinlich nicht von Fibroblasten produziert. Deshalb haben wir
die Rolle der Rückkopplungsregulation für die Typ I Interferonproduktion in der viralen
Pathogenese in vivo untersucht. Überraschenderweise waren mit vesikulärem Stomatitis
Virus (VSV) oder mit UV-inaktiviertem Herpes Simplex Virus (UV-HSV) behandelte
Mäuse in der Lage umgehend IFN-α herzustellen, und dies weit gehend unabhängig von
IFNAR Aktivierung und der Transkription von IRF-7. Typ I Interferon wurde in großer
Menge von wenigen Zellen produziert, die sich in der Marginalzone (MZ) der Milz
befanden. Im Gegensatz dazu konnte in mit synthetischer Doppelstrang-RNA (poly(I:C))
behandelten Mäusen keine Interferonproduktion durch Zellen in der MZ festgestellt
werden. Darüber hinaus war die Produktion von IFN-α in poly(I:C) behandelten Mäusen
IFNAR abhängig. Diese Ergebnisse werden im Rahmen eines erweiterten Modells der
IFN-α Produktion diskutiert, in dem Unterschiede der Regulation der Typ I Interferon-
produktion in unterschiedlichen Zelltypen berücksichtigt wurden.
Um die professionelle IFN produzierende Zelle in der Maus zu ermitteln, wurden
Reportergene unter die Kontrolle der Promotoren der Gene für IFN-α2 oder IRF-7 gestellt.
Diese Transgenkonstukte wurden durch homologe Rekombination (ET-cloning) in
künstlichen bakteriellen Chromosomen (BACs) integriert. Derzeit werden transgene Mäuse
generiert, die diese BAC Reporterkonstrukte exprimieren. Die Analyse dieser Mäuse kann
es ermöglichen, die Reifung und Differenzierung von IPCs in vivo zu verfolgen, und
Erkenntnisse darüber zu gewinnen, ob aktivierte IPCs als Antigen präsentierende Zellen
fungieren können.
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In einem zweiten Ansatz zur Identifizierung von IPCs der Maus, wurden zahlreiche
Zellpopulationen von CD11c positiven dendritischen Zellen (DC) aus VSV infizierten
Mäusen isoliert und auf die Transkription von IFN-α mRNA untersucht. Im Gegensatz zu
allen anderen untersuchten Populationen, produzierten CD11cintCD11b-GR-1+ dendritische
Zellen große Mengen IFN-α. Dieser Zelltyp wies eine den plasmazytoiden dendritischen
Zellen des Menschen ähnliche Morphologie auf. Interessanterweise produzierten IPCs der
Maus IFN-α unabhängig davon, ob sie aus VSV infizierten Mäusen mit funktionellem oder
defektem IFNAR isoliert worden waren. Demnach aktiviert VSV vorrangig einen darauf
spezialisierten DC Zelltyp – die IPC der Maus – welcher in der Folge große Mengen von
IFN-α weitgehend unabhängig von IFNAR Rückkopplungsregulation produziert. Die
Infektion mit VSV führte auf IPCs der Maus umgehend zur Aufregulation von MHC
Klasse II und CD86 Molekülen, ein Charaktermerkmal von dendritischen Zellen. Im
Gegensatz zu DCs verschwanden IPCs jedoch rasch aus sekundär lymphatischem Gewebe
akut infizierter Mäuse. Gleichzeitig nahm die Zahl der IPCs im Knochenmark stark zu und
ein leichter Anstieg der Zellzahl wurde auch in einigen der peripheren Organe beobachtet.
Eine Wiederbesiedlung der Milz mit IPC Zellen fand während des Abklingens der akuten
Virusinfektion statt.
Somit ist der hier beschriebene IPC Zelltyp in der Lage sofort nach viraler Aktivierung
IFN-α zu produzieren und weist einige Eigenschaften von dendritischen Zellen auf. Da
aktivierte IPCs jedoch die sekundären lymphatischen Organen verlassen, ist es un-
wahrscheinlich, dass Ihnen eine bedeutende Rolle während der Antigenpräsentation in der
Anfangsphase einer adaptiven Immunantwort zukommt.
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9 Kurzzusammenfassung
Eine wirkungsvolle Typ I Interferonantwort (IFN-α/β) ist entscheidend wichtig für die
Kontrolle von viralen Infekten. In dieser Studie zeigen wir, dass die Produktion von IFN-α
in Fibroblasten (MEFs) die mit vesikulärem Stomatitis Virus (VSV) infiziert sind, abhängig
von der Aktivierung des Typ I IFN Rezeptors (IFNAR) ist. Im Gegensatz dazu ist in
infizierten Mäusen eine frühe IFN-α Antwort IFNAR unabhängig. In VSV infizierten
Mäusen wurde Typ I IFN von wenigen Zellen produziert, die sich in der Marginalzone
(MZ) der Milz befanden. Im Gegensatz zu anderen dendritischen Zelltypen (DCs),
produzieren CD11cintCD11b-GR-1+ DCs große Mengen IFN-α, unabhängig davon, ob sie
aus VSV infizierten Mäusen mit funktionellem oder defektem IFNAR isoliert wurden.
Dieser dendritische Zelltyp wies eine den menschlichen professionellen Interferon-
produzierenden Zellen (IPC) ähnliche Morphologie auf. Die VSV Infektion führte auf IPCs
der Maus umgehend zur Aufregulation von MHC Klasse II und CD86 Molekülen, ein
Charaktermerkmal von dendritischen Zellen. Im Gegensatz zu DCs verschwanden IPCs
jedoch rasch aus sekundär lymphatischem Gewebe akut infizierter Mäuse. Demnach
aktiviert VSV vorrangig IPCs zur Produktion von großen Mengen IFN-α und dies weit
gehend unabhängig von der IFNAR Rückkopplungsregulation. Da aktivierte IPCs jedoch
die sekundären lymphatischen Organen verlassen, ist es unwahrscheinlich, dass Ihnen eine
bedeutende Rolle während der Antigenpräsentation in der Anfangsphase einer adaptiven
Immunantwort zukommt.
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10 Abstract
An effective type I interferon (IFN-α/β) response is critical for the control of many viral
infections. Here we show that in vesicular stomatitis virus (VSV) infected mouse
embryonic fibroblasts (MEFs) the production of IFN-α is dependent on type I IFN receptor
(IFNAR) triggering, whereas in infected mice early IFN-α production is IFNAR-
independent. In VSV infected mice type I IFN is produced by few cells located in the
marginal zone of the spleen. Unlike other dendritic cell subsets (DCs), FACS-sorted
CD11cintCD11b-GR-1+ DCs show high IFN-α expression, irrespective of whether they were
isolated from VSV infected IFNAR competent or deficient mice. This DC subset showed a
morphology reminding plasmacytoid dendritic cells and similar to the human professional
IFN producing cell (IPC) and was therefore termed mouse IPC. On mouse IPCs, VSV
infection leads to a prompt upregulation of MHC class II and CD86 molecules, a hallmark
of DC maturation. However, in contrast to DCs, IPCs rapidly disappeared from secondary
lymphoid tissues of acutely virus-infected mice. Thus, VSV preferentially activates mouse
IPCs to produce high-level IFN-α largely independent of IFNAR feedback signaling.
Because activated IPCs apparently leave secondary lymphoid tissues, they are unlikely to
constitute a major antigen presenting cell during the initial activation of the adaptive
immune response.
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Abstract
 
An effective type I interferon (IFN-
 

 
/
 

 
) response is critical for the control of many viral infec-
tions. Here we show that in vesicular stomatitis virus (VSV)-infected mouse embryonic fibro-
blasts (MEFs) the production of IFN-
 

 
 is dependent on type I IFN receptor (IFNAR) triggering,
whereas in infected mice early IFN-
 

 
 production is IFNAR independent. In VSV-infected
mice type I IFN is produced by few cells located in the marginal zone of the spleen. Unlike
other dendritic cell (DC) subsets, FACS
 
®
 
-sorted CD11c
 
int
 
CD11b
 

 
GR-1
 

 
 DCs show high
IFN-
 

 
 expression, irrespective of whether they were isolated from VSV-infected IFNAR-
competent or -deficient mice. Thus, VSV preferentially activates a specialized DC subset pre-
sumably located in the marginal zone to produce high-level IFN-
 

 
 largely independent of
IFNAR feedback signaling.
Key words: IFN type I • virus infection • dendritic cell subsets • IFN regulatory factor 7 • 
type I IFN receptor
 
Introduction
 
Type I IFNs (IFN-
 

 
/
 

 
) constitute a family of cytokines
comprising in the mouse at least 11 IFN-
 

 
 isoforms and
one IFN-
 

 
, which were identified by their ability to pro-
tect cells against viral infection (1). For a broad spectrum of
viruses a functional type I IFN response is critical for the
survival of the infected host (2, 3). Beyond the direct an-
tipathogenic activity, type I IFNs synergize with other
proinflammatory stimuli to activate innate effectors such as
NK cells, macrophages, and dendritic cells (DCs)
 
*
 
 (4)
and may modulate antigen presentation and the adaptive
immune response (5).
The biologic activity of all IFN-
 

 
 subtypes and of IFN-
 

 
 is
mediated by binding to the common type I IFN recep-
tor (IFNAR), a heterodimer consisting of the 
 

 
-chain
(IFNAR-1) and the 
 

 
-chain (IFNAR-2, references 6 and
7). IFNAR signaling activates a multitude of IFN-inducible
genes whose products may drastically alter cell homeostasis;
in order to impede viral replication, cell proliferation is
halted and both transcription and translation are strongly
reduced. High-level expression of type I IFN, that can be
detrimental to the host (8, 9), is tightly regulated (10) and
usually restricted to the state of acute viremia.
The molecular mechanism of type I IFN induction
was intensively investigated by analyzing virus-stimulated
mouse embryonic fibroblasts (MEFs) derived from gene-
targeted mice deficient of factors involved in the type I
IFN signaling cascade. MEFs from mice lacking IFN-
 

 
,
IFNAR-1, signal transducer and activator of transcription
1, or IFN regulatory factor (IRF)-9 showed a defective
IFN-
 

 
 response (11–14). This suggested that after the pro-
duction of early IFN-
 

 
, and possibly IFN-
 

 
4, expression
of other IFN-
 

 
 genes was dependent on IFNAR feedback
signaling. Two members of the IRF family, IRF-3 and
IRF-7, have been shown to play a key role in the sequen-
tial induction of type I IFN genes. Virus-mediated serine
phosphorylation leads to IRF-3 activation and translocation
to the nucleus (15). There, IRF-3 is part of an enhanceo-
some complex promoting the expression of IFN-
 

 
, and
presumably of IFN-
 

 
4. Early type I IFN is secreted and
triggers IFNAR signaling in an autocrine fashion. Among
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other type I IFN–induced genes, IFNAR signaling strongly
upregulates IRF-7 expression (12, 13). Virus infection leads
to IRF-7 activation by phosphorylation that drives the ex-
pression of the majority of IFN-
 

 
 subtypes, and hence am-
plifies the type I IFN response. It is not known, however,
which serine kinase(s) is/are responsible for the activation
of IRF-3 and IRF-7. It appears that several pathways may
lead to IRF-3 and IRF-7 activation. Some viruses, such as
type I herpes simplex virus (HSV), induce an IFN response
independent of viral replication whereas others, e.g., vesic-
ular stomatitis virus (VSV), lose the ability to induce type I
IFN upon inactivation. Furthermore, a variety of nonviral
IFN inducers has been described, including prokaryotic
DNA motifs (CpG-DNA), synthetic double-stranded RNA
(poly[I:C]), lipopolysaccharide, and imiquimod derivatives
(16, 17).
In cell culture, virtually any cell type can produce type I
IFN in response to appropriate stimulation, yet, depending
on the expression of pattern recognition receptors distinct
cell types are stimulated by different IFN inducers. For
example CpG-DNA but not poly(I:C)–treated human
CD11c
 

 
 DCs produce type I IFN, whereas a reverse cor-
relation was found for CD11c
 

 
 DCs (17, 18). Accord-
ingly, CD11c
 

 
 DCs express the Toll-like receptor (TLR)-9
and CD11c
 

 
 DCs express TLR-3 (17, 19), which have
been shown to be involved in the recognition of CpG or
poly(I:C), respectively (20, 21). So far, the major IFN-
producing cell (IPC) has not been defined in the context
of infection with specific pathogens. Several studies ad-
dressed the nature of the human IPC (22–24), which
eventually was defined as the subset of CD11c
 

 
 plasmacy-
toid DCs (25, 26). There are indications that upon stimu-
lation of mice certain macrophages (27) or DC subsets can
produce type I IFN (28–30).
Considering the above information, in an acutely in-
fected host fibroblasts presumably do not produce the ma-
jority of type I IFN. Therefore, we investigated whether
the positive feedback regulation of type I IFN induction, as
identified in MEFs, also plays a role in viral pathogenesis
in vivo. Surprisingly, VSV- and UV-HSV–treated mice
mount early IFN-
 

 
 responses largely independent of
IFNAR feedback signaling. We provide evidence that un-
like fibroblasts, mouse IPCs can produce early IFN-
 

 
 inde-
pendent of IFNAR signaling. These data are discussed in
the context of an extended model of IFN-
 

 
 induction
based on the cell type involved in the production of IFN-
 

 
.
 
Materials and Methods
 
Mice and Viruses.
 
IFNAR-deficient mice (IFNAR
 

 
/
 

 
) on the
SV129 background (3) and IFN-
 

 

 
/
 

 
 
 
mice on the Balb/c back-
ground (14) were bred under specific pathogen free (SPF) condi-
tions. Unmutated SV129 mice (referred to as wild-type [WT])
were obtained from the SPF-breeding colony of the European
Mutant Mouse Archive (EMMA), Monterotondo, Italy. C57BL/6
mice were purchased at IFFA-Credo. Experimental mouse
work was done under SPF conditions in compliance with regula-
tions of the Ministerio della Sanità, Rome, Italy (decreto ministe-
riale n
 

 
 15/2001-b, 3/3.1). VSV-IND (Mudd-Summers isolate)
was originally obtained from D. Kolakofsky, University of
Geneva, Geneva, Switzerland. VSV was grown on BHK-21 cells
(31) and plaqued on Vero cells. Stocks were maintained in MEM
containing 2% heat-inactivated FCS. HSV strain F originally ob-
tained by American Type Culture Collection was grown on Vero
cells. HSV was purified from cell culture supernatant by PEG
40.000 (Serva) precipitation. After several pelleting steps for 1 h at
43,000 
 
g
 
 virus was resuspended in PBS and titrated on Vero cells.
After UV irradiation (1.2 Joule/cm
 
2
 
) HSV inactivation was veri-
fied by plaquing on Vero cells.
 
Cell Culture.
 
WT and IFNAR
 

 
/
 

 
 MEFs were derived from
day 13 embryos (32) and maintained in DMEM supplemented
with 10% FCS. Cell monolayers were infected with VSV at a
multiplicity of infection (MOI) of 10. After 1 h of incubation at
37
 

 
C the virus suspension was replaced by DMEM 10% FCS.
 
Expression Analysis.
 
Preparation of total RNA was performed
using the TRIZOL reagent (GIBCO BRL) according to the
manufacturer’s instructions. Tissue samples were snap-frozen and
homogenized in Trizol using a Polytron (Kinematica). On cul-
tured cell monolayers and FACS
 
®
 
-sorted cells Trizol was applied
directly. To eliminate possible DNA contamination total RNA
was incubated for 15 min at 37
 

 
C with 10 U of DNase (Boeh-
ringer Mannheim). cDNA was prepared using Superscript II
(GIBCO BRL) according to the manufacturer’s instructions. To
estimate relative amounts of specific mRNAs, PCRs were per-
formed with serially fivefold diluted cDNA using published
primers for IFN-
 

 
 (consensus primers annealing with all IFN-
 

 
subtypes) and IRF-7 (13). The mRNA content was normalized
by RT-PCR analysis with GAPDH-specific primers from the
same publication. The absence of contaminating DNA was veri-
fied by PCR analysis of RNA preparations not treated with re-
verse transcriptase.
 
Quantification of IFN Activity.
 
The IFN bioassay was based on
the protection of L929 cells from the cytopathic effect (CPE) of
VSV (CPE inhibition assay). To inactivate potential viral con-
tamination, 1:5 prediluted serum samples from VSV-infected
mice were UV-irradiated with 1.2 Joule/cm
 
2
 
. Duplicates of seri-
ally twofold diluted sera were transferred to 24 h preincubated
semiconfluent monolayers of L929 cells in 96-well plates. After
24 h incubation at 37
 

 
C supernatants were removed and VSV
was added at a MOI of 0.05. After 48 h incubation at 37
 

 
C, su-
pernatants were taken away and protected cells were stained with
0.5% crystal violet in 5% formaldehyde, 50% ethanol, and 0.8%
sodium chloride. After extensive washing with water and air dry-
ing, the dye was extracted from stained cells with 100 
 

 
l/well 0.1 M
sodium citrate in 50% ethanol, pH 4.2, and the crystal violet
content was determined on an ELISA reader at 570 nm. In the
CPE inhibition assay an international mouse IFN-
 

 
/
 

 
 reference
standard of 100 IU/ml (Gu02–901–511; NIAID Repository) and
recombinant IFN-
 

 
A standards (PBL Biomedical Laboratories) of
100, 500, 2,500, and 10,000 IU/ml were included. For IFN
quantification the 50% protective serum dilution was indicative.
A log
 
2
 
5 titer corresponded to 1,000 IU IFN-
 

 
A. The contribu-
tion of IFN-
 

 
 or IFN-
 

 
 to the total type I IFN activity was de-
termined by preincubating sera for 1 h with excess amounts of
neutralizing anti–IFN-
 

 
 (clone 4E-A1; Yamasa Shoyu) or anti-
IFN-
 

 
 (clone 7F-D3; Yamasa Shoyu) mAbs. Protection from
CPE due to IFN-
 

 
 was formally excluded by an IFN-
 

 
 Elisa
(Promega) indicating that the IFN-
 

 
 content of all samples tested
was below the detection threshold of the assay.
 
Immunohistochemistry.
 
Freshly removed organs were im-
mersed in HBSS and snapped frozen in liquid nitrogen. Tissue
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sections of 5-
 

 
m thickness were cut in a cryostat, placed on sili-
conized glass slides, air dried, fixed with acetone for 10 min, and
stored at –70
 

 
C. IFN was stained using a polyclonal sheep anti–
mouse IFN-
 

 
/
 

 
 antiserum (PBL Biomedical Labs) or mono-
clonal rat anti–mouse IFN-
 

 
 antibody (Serotec). The primary
sheep antibody was detected with affinity purified biotinylated
donkey anti–sheep Ig antibodies (Jackson ImmunoResearch Lab-
oratories) and alkaline phosphatase labeled avidin/biotin com-
plexes (ABC/AP Dako). The primary rat mAb was detected with
affinity purified peroxidase labeled goat anti–rat Ig antibody. For
signal amplification by catalyzed reporter deposition, biotinylated
thyramine (33) and 3% H
 
2
 
O
 
2
 
 was added for 7 min, and covalently
bound biotin was revealed by ABC/AP. Alkaline phosphatase
was visualized using naphthol AS-BI (6-bromo-2-hydroxy-3-
naphtholic acid-2-methoxy anilide) phosphate and new fuchsin as
substrate. Endogenous alkaline phosphatase was blocked by le-
vamisole. The dilutions of secondary antibodies were made in
TBS containing 5% normal mouse serum. Incubations were done
at room temperature for 30 min; TBS was used for all washing
steps. Color reactions were performed at room temperature for
15 min with reagents from Sigma-Aldrich. Sections were coun-
terstained with hemalum and coverslips mounted with glycerol
and gelatin.
 
In Situ Hybridization of IRF-7 mRNA.
 
Spleens were fixed
overnight in 4% paraformaldehyde in PBS and then embedded in
paraffin wax. Sections were cut at 5–7-
 

 
m and mounted onto
Superfrost-Plus slides (BDH). The IRF-7 riboprobe was gener-
ated by cloning a 351 bp RT-PCR product into pBluescript fol-
lowed by Digoxygenin-11-UTP-labeling using the Boehringer
RNA labeling kit. In situ hybridization was performed as de-
scribed previously (34).
 
DC Subset Isolation by FACS
 
®
 
 Sorting.
 
Single cell suspension
of 3–5 spleens was prepared and CD11c
 

 
 cells were enriched by
magnetic adsorption cell sorting (MACS
 
®
 
; Miltenyi Biotec).
Three-color stainings were made using anti-CD11c–biotin–,
anti-CD11b–FITC–, and anti-GR-1–PE–conjugated mAbs fol-
lowed by streptavidin-APC (all from BD PharMingen). 4–10
 
 	
 
10
 
4
 
 cells of each subset were sorted from 
 

 
10
 
7
 
 cells on a MoFlo
cytometer (Cytomation).
Results
 
Feedback Signaling Is Required for the Expression of IFN-
 

 
mRNA in VSV-infected MEFs but not in VSV-infected
Mice.
 
Tissue culture experiments have shown previously
that the expression of all IFN-
 

 
 genes, except IFN-
 

 
4, was
dependent on IFNAR feedback signaling in Newcastle dis-
ease virus (NDV)-stimulated MEFs (12, 13). To validate
this finding under conditions of a productive virus infec-
tion, IFNAR competent (WT) and IFNAR-deficient
(IFNAR
 

 
/
 

 
) MEFs were VSV-infected and IFN-
 

 
 mRNA
expression was monitored by RT-PCR analysis. WT fi-
broblasts showed elevated IFN-
 

 
 mRNA levels beginning
4 h after VSV infection and peak expression between 9 h
and 12 h (Fig. 1 a). Similar to NDV-stimulated MEFs,
VSV-infected MEFs predominantly expressed IFN-
 

 
4 as
determined by subcloning of RT-PCR products and se-
quence analysis of random clones (Fig. 2 a). In contrast,
IFN-
 

 
 upregulation was not observed in VSV-infected
MEFs lacking the IFNAR (Fig. 1 a). Thus, in VSV-
infected MEFs the IFN-
 
 
 
production is strictly dependent
on IFNAR feedback signaling.
To next examine IFN responses in vivo, IFN-
 

 
 gene
expression was analyzed in spleen from WT and IFNAR
 

 
/
 

 
mice infected with VSV. Surprisingly, IFN-
 

 
 mRNA was
induced rapidly and to a similar extent in spleen of WT and
IFNAR
 

 
/
 

 
 
 
mice. At later time points, IFN-
 

 
 expression in
spleen of IFNAR
 

 
/
 

 
 
 
mice decreased slightly, whereas
spleen from WT mice showed a further increase in IFN-
 

 
expression (Fig. 1 b). The IFN-
 

 
 subtype analysis revealed
that both VSV-infected IFNAR-competent and -deficient
Figure 1. VSV infection stim-
ulates IFNAR-independent pro-
duction of IFN- in mice, but
not in MEFs. (a) MEFs derived
from WT or IFNAR-deficient
mice (IFNAR/) were in-
fected with VSV at a MOI of 10
and (b) WT and IFNAR/
mice were intravenously injected
with 2 	 108 PFU VSV. Total
RNA of 106 cultured MEFs or
of spleen tissue was extracted, and
the mRNA content of different
samples was normalized by a
GAPDH-specific RT-PCR.
The expression of IFN-
mRNA was monitored using
consensus primers amplifying all
IFN- subtypes. The analysis
was performed with serially five-
fold diluted cDNA samples start-
ing with undiluted material;
spleen derived samples were
fivefold prediluted.
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mice showed abundant expression of IFN-
 

 
2 and 5, whereas
IFN-
 

 
4 was found only rarely (Fig. 2 b and c). Thus, dif-
ferent IFN-
 

 
 patterns found after VSV infection of MEFs
and mice suggested that in vivo the majority of IFN-
 

 
 is
produced by a cell type different from fibroblasts. More-
over, similar IFN-
 

 
 patterns found in WT and IFNAR
 

 
/
 

 
mice indicated a largely feedback-independent production
of early IFN-
 

 
 in VSV-infected mice.
 
Early IFNAR-independent and Late IFNAR-dependent
IFN-
 

 
 Expression in VSV- and UV-HSV–treated Mice.
 
To
correlate IFN-
 

 
 mRNA levels and IFN serum activities,
blood serum of VSV-infected mice was taken and analyzed
in a CPE inhibition assay. As early as 4 h after VSV infec-
tion IFN activity was found in the serum of both WT and
IFNAR
 

 
/
 

 
 animals. Specific inhibition of IFN-
 

 
 and/or
IFN-
 

 
 by neutralizing mAbs in the CPE inhibition assay
revealed a major contribution of IFN-
 

 
 to the serum IFN
activity, irrespective of whether IFNAR signaling was
functional or not. Serum IFN titers of WT animals in-
creased more rapidly than IFNAR
 

 
/
 

 
 mice eventually
leading to 
 

 
30-fold higher IFN titers in WT animals than
in IFNAR
 

 
/
 

 
 mice (Fig. 3 a).
Since VSV replication is not controlled in IFNAR-defi-
cient mice, a highly elevated virus load and increased cell
death could have interfered with cytokine production in
IFNAR
 

 
/
 

 
 mice. Thus, we next analyzed type I IFN re-
sponses after stimulation with nonreplicating virus. Since
UV-inactivated VSV does not induce type I IFN responses
(data not shown), mice were injected with UV-inactivated
HSV. 2 h after the treatment, WT and IFNAR
 

 
/
 

 
 mice
showed similar peak IFN activity with 
 

 
50 and 35% IFN-
 

 
contribution, respectively. While the IFN response was
short-lived in IFNAR
 

 
/
 

 
 mice, IFN titers in WT mice
were sustained for several hours, and a switch to a more
pronounced IFN-
 

 
 expression was found (Fig. 3 c). To
verify the induction of early IFN-
 

 
 in the absence of
IFNAR-feedback signaling, mice deficient of the IFNAR
or IFN-
 

 
 were intercrossed and IFNAR
 

 
/
 

 
 IFN-
 

 

 
/
 

 
double-knockout mice and IFNAR
 

 
/
 

 
 IFN-
 

 

 
/
 

 
 litter-
mates were stimulated with UV-HSV. Even in the absence
of IFN-
 

 
 initial IFN-
 

 
 titers showed the same magnitude
in receptor deficient and competent mice. At later time
points IFN-
 

 
 production was sustained and further en-
hanced in IFN receptor competent mice as compared with
IFNAR
 

 
/
 

 
 mice (Fig. 4). Thus, upon treatment with live
VSV- or UV-inactivated HSV early IFNAR-independent
IFN-
 

 
 production is observed. Yet, at later time points
IFNAR-feedback signaling is critical to sustain the produc-
tion of IFN-
 

 
.
 
Early IFN-
 

 
 Production in the Absence of IRF-7 Induc-
tion.
 
The transcription factor IRF-7 has been shown to
be upregulated upon IFNAR triggering (12, 13) and was
proposed to be critically required for the expression of
IFN-
 

 
 subtype genes (12, 35). Therefore, we asked
whether early IFNAR-independent IFN- was produced
in the absence of IRF-7 induction. The RT-PCR analy-
sis of IRF-7 mRNA levels in VSV-infected WT and
IFNAR/ mice revealed a prompt IRF-7 upregulation
only in WT mice but not in IFNAR-deficient mice (Fig.
5). These experiments indicated that in VSV-infected mice
early IFN- was induced in the absence of detectable IRF-7
upregulation. At later time points IFNAR-independent
IRF-7 upregulation was observed (data not shown) which,
however, did not suffice to promote a sustained production
of IFN- in IFNAR/ mice.
Poly(I:C) Treatment of Mice Induces Late IFN- Produc-
tion. To further study the role of feedback signaling with
a nonreplicating type I IFN inducer, mice were treated
with poly(I:C). Sera of poly(I:C)–treated WT and IFN-
AR/ mice displayed early peak IFN activity, followed by
a rapid decline in the case of IFNAR/ mice. In WT
mice IFN activity was sustained at a high level for 
20 h.
Neutralization of IFN- and/or IFN- revealed an abun-
dant contribution of IFN- to early type I IFN activity in
both WT and IFNAR/ mice. At later time points, strong
IFN- production was observed in WT but not in IFNAR-
deficient mice (Fig. 3 b).
Preferential production of IFN- after poly(I:C) treat-
ment, while mainly IFN- is produced after virus stimula-
tion, indicates that different cell types may be involved in the
Figure 2. Differential IFN- expression profiles of VSV infected MEFs
and mice. PCR products of the IFN- expression analysis 6 h after VSV
infection of (a) WT MEFs, (b) spleen of WT mice, or (c) spleen of
IFNAR/ mice were subcloned and DNA sequence of 13, 35, and 25
single clones was analyzed, respectively. IFN- sequences were classified
according to EMBL database entries. The sequence termed IFN-10
corresponds to the IFN- sequence available on the EMBL database
(GenBank/EMBL/DDBJ accession no. L38698).
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production of poly(I:C)– versus virus-induced type I IFN.
Moreover, these results further support the hypothesis that
the sustained production of IFN- is IFNAR dependent.
VSV Infection but not Poly(I:C) Treatment Stimulates High-
Level Type I IFN Production in Cells Located in the Marginal
Zone of the Spleen. To localize IPCs, mice were infected
with VSV and 9 h later, spleens were analyzed immunohis-
tochemically with type I IFN-specific antibodies. Consecu-
tive sections were stained with polyclonal antibody di-
rected against type I IFN or with an IFN-–specific mAb.
While staining with the polyclonal serum appeared more
sensitive and decorated a structure surrounding follicles,
i.e., the marginal zone, stainings with mAb revealed dis-
tinct type I IPCs scattered in groups within the marginal
zone (Fig. 6 a and b). After treatment with VSV or UV-
HSV, spleens of WT and IFNAR/ mice showed similar
marginal zone stainings with polyclonal antibody, albeit
staining of spleens from IFNAR-deficient mice was some-
what weaker (Fig. 6 c). Despite comparable IFN levels in
the serum, no specific type I IFN staining was detected in
the marginal zone of poly(I:C)–treated mice (Fig. 6 c).
Thus, after injection of virus particles, irrespective of
whether they are replicative or not, type I IFN production
is localized to the marginal zone. The soluble inducer
poly(I:C) did not induce high enough type I IFN produc-
Figure 3. Type I IFN activity in the serum of
mice treated with VSV, poly(I:C), or UV-HSV.
WT mice (black circles) and IFNAR/ (white tri-
angles) mice were intravenously stimulated with
(a) 2 	 108 PFU VSV, (b) 100 g poly(I:C), or (c)
2 	 107 PFU UV-HSV. Mice were bled at the in-
dicated time points and serum IFN titers were de-
termined in a CPE protection assay. A log2 of 5
corresponds to 1,000 IU of IFN-. The contribu-
tion of IFN- or IFN- to the total IFN activity
was determined by specific inhibition with mAbs.
Figure 4. IFN- is produced in mice deficient of IFN- and IFNAR.
IFN-–deficient mice (black diamonds) and double-deficient mice lack-
ing IFN- and IFNAR (white diamonds) were intravenously injected
with 2 	 107 PFU UV-HSV. Sera were taken at indicated time points
and analyzed in a CPE protection assay. Mean IFN activity of three mice
per time point is indicated. Results are shown of one out of two indepen-
dent experiments. Note that the indicated IFN serum activities exclusively
derived form IFN- because the analyzed mice were IFN- deficient.
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tion in the spleen to be detected by immunohistology.
Probably under these conditions type I IFN is produced at
a low level by numerous cell types and in various tissues.
In situ hybridization of spleen sections of untreated mice,
with an IRF-7 probe, did not reveal evidence for constitu-
tive IRF-7 expression, neither in few marginal zone cells
nor anywhere else in the spleen (data not shown). After
VSV infection of WT mice a strong IRF-7 induction was
observed all over the spleen. In contrast, no IRF-7 induc-
tion was detected in spleens of VSV-infected IFNAR/
mice (Fig. 6 d). Together with the above RT-PCR data
these observations indicate that virus-induced early IFN-
can be produced independent of IFNAR signaling and
IRF-7 upregulation.
Identification of the Major IPC. The phenotype of the
major IPC in VSV pathophysiology is not known. Since
the marginal zone is a complex tissue containing specialized
macrophages, DCs, endothelial cells, and nonrecirculating
B cells, colocalization studies with markers for marginal
zone cells could not further resolve the nature of mouse
IPCs (data not shown). In analogy to the DC origin of hu-
man and mouse IPCs (25, 26, 29, 30) we aimed for the
analysis of mouse DC subsets. Mice were VSV-infected
and, 9 h later, several CD11c DC subsets were FACS®-
sorted and analyzed for the IFN- mRNA content (Fig. 7
a). Surprisingly, only CD11cintCD11bGR-I DCs (frac-
tion D) were strongly positive for IFN- mRNA, whereas
neither lymphoid DCs (CD11cCD11b, fraction A),
myeloid DCs (CD11cCD11b, fraction B), CD11cint
CD11b DCs (fraction E), nor granulocytes (CD11cGR-1,
fraction F) showed high IFN- expression (Fig. 7 b). CD11cint
Figure 5. VSV infected IFNAR/ mice show an early induction of
IFN- before the onset of IRF-7 expression. Total RNA from spleen of
IFNAR/ or WT mice was isolated 3 h after intravenous infection with
2 	 108 PFU VSV. RT-PCR was performed as described in Fig. 1.
Figure 6. VSV and UV-HSV injection, but not poly(I:C) stimulation, leads to high-level production of type I IFN by cells located in the marginal
zone of the spleen. (a) WT mice were VSV infected and after 9 h spleens were analyzed immunohistochemically with a polyclonal serum against type I
IFN (pAb, top two panels) or with an IFN-–specific mAb (mAb, bottom two panels). (b) A higher magnification of the marginal zone area of the bottom
right panel in (a) stained with mAb is shown. (c) WT and IFNAR/ mice were VSV, poly (I:C), or UV-HSV injected. After 9 h and 6 h after UV-HSV
stimulation, spleens were analyzed immunohistochemically with a polyclonal serum against type I IFN. Sections in (a–c) were counterstained with he-
malum (blue) to visualize lymph follicles. (d) In situ hybridization of IRF-7 mRNA (blue) was performed on paraffin sections of spleen from WT and
IFNAR/ mice prepared 9 h after VSV infection.
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CD11b DCs (fraction C) showed slightly enhanced IFN-
mRNA levels (which were at least 125-fold lower than
fraction D), that might be due to contaminating cells of
fraction D. We next asked whether CD11cintCD11bGR-I
cells are producers of IFN- independent of IFNAR feed-
back signaling. For this purpose DC subsets were isolated
from VSV-infected IFNAR/ mice. Again only CD11cint
CD11bGR-I cells showed high-level IFN- mRNA
(Fig. 7 c). These results indicate that although other DC
subsets are able to produce IFN- upon in vitro stimula-
tion (28), they do not play a major role in IFN- produc-
tion after VSV infection in vivo.
Discussion
Here we show that after viral infection of mice not only
IFN- but also IFN- is produced immediately and largely
independent of IFNAR feedback signaling. This is in con-
trast to the current model of IFNAR feedback-dependent
expression of IFN-, that was established based on in vitro
data. To reconcile the previous in vitro data with our in
vivo observations, we hypothesized that after viral infection
of mice a cell type different from fibroblasts, i.e., the mu-
rine IPC, produced the majority of type I IFN, and that in
these cells IFN- expression was regulated differently than
in fibroblasts. Indeed, we found that after in vivo infection
the subset of CD11cint.GR-1 DCs produced IFN- at
high level, and that early IFN- production by this cell
type was largely independent of IFNAR feedback.
The positive feedback regulation of IFN- genes was
first observed in NDV-infected MEFs that lack IFN- ex-
pression in the absence of a functional IFN signaling cas-
cade (11, 12). One study showed IFNAR-independent
IFN-4 expression in NDV-infected MEFs (13). Interest-
ingly, IFN-4 was previously found to dominate IFN-
responses of NDV-stimulated L929 fibroblasts (36). How-
ever, MEFs infected with VSV (Fig. 1), or vaccinia virus
(37) showed a strictly IFNAR-dependent expression of all
IFN-s. Equally, Sendai virus-infected MEFs from IFN-–
deficient mice were found unable to produce any IFN-,
unless stimulated by the addition of exogenous IFN- (14).
In contrast to these in vitro data, we found that VSV-
infected mice mount an early IFNAR-independent IFN-
response. Furthermore, IFN-–deficient and IFN-/
IFNAR double-deficient mice treated with UV-HSV still
expressed substantial IFN- levels (Fig. 4). While IFN-
production in IFN-/ mice could have been promoted
by priming with natural type I IFN, produced pathogen in-
dependently (38), IFN- production in IFN-/IFNAR
double-deficient mice indicated that IFNAR triggering
was not a prerequisite for early IFN- production. IFN-
levels reached in IFN-/ were sufficient to control intra-
venous VSV infection (data not shown). In contrast, IFN-
–deficient mice infected peripherally with vaccinia virus
showed a markedly increased susceptibility to lethal disease
(37): after intranasal infection, IFN-/ mice showed up
to 105-fold increased virus titers in the lung as compared
Figure 7. In VSV-infected mice CD11cintCD11bGR-1 DCs ex-
press high-level IFN-. (a) Mice were intravenously infected with 2 	
108 PFU VSV and 9 h later spleens were removed to prepare single cell
suspensions. MACS®-enriched CD11c cells were stained with anti-
CD11c-Biot./Str.-APC, anti-CD11b-FITC, and anti-GR-1-PE, and
DC subsets were FACS®-sorted using the indicated gates A–F. Cells
from gate C/D were further subdivided by separating GR-1 (fraction
C) and GR-1 cells (fraction D). Sorted fractions were derived from
spleen of (b) VSV infected or untreated C57BL/6 mice, and of (c) VSV-
infected Sv129 (WT) and IFNAR/ mice. Total RNA of 4–10 	 104
sorted cells was prepared and analyzed by RT-PCR as described in
Fig. 1.
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with WT mice, and eventually succumbed to the infection.
Interestingly, in these experiments virus titers in spleen of
WT and IFN-/ mice were comparably low, indicating
that upon local infection vaccinia virus replication was bet-
ter controlled in the spleen than in the peripherally infected
organ. Thus, it appears that depending on the route of in-
fection virus may activate IPCs or other susceptible cell
types that differ in their requirement of IFNAR feedback
for the IFN- induction.
Apart from the route of infection also the nature of the
stimulus may determine the cell type(s) involved in type I
IFN production. Our histology data show that poly(I:C)
does not induce marginal zone IPCs to produce high-level
type I IFN, suggesting that the observed IFN titers were
contributed mainly by nonIPCs. It is possible that in anal-
ogy to the human plasmacytoid DCs, mouse IPCs express
TLR-9 but not TLR-3 that is involved in poly(I:C) recog-
nition (19, 21), and thus mouse IPCs are not triggered by
poly(I:C). IFN titers in poly(I:C)–treated mice showed an
early peak of IFN- expression that only in animals with a
functional receptor feedback was followed by sustained
IFN- expression. This indicated that similar to in vitro
VSV-infected MEFs, IFN- expression by nonIPCs in
vivo required IFNAR feedback signaling.
In the current model of positive feedback regulation,
IFNAR-dependent upregulation of the transcription factor
IRF-7 plays a central role. Virus-treated mutant MEFs that
failed to induce IRF-7 also lacked expression of IFN-.
The IFN- response could be restored by ectopic expres-
sion of IRF-7 (12). In IFNAR-deficient mice, we ob-
served early IFN- responses in the absence of detectable
IRF-7 upregulation. One possibility is that under these
conditions low constitutive IRF-7 levels suffice to drive
early IFN- expression. In this context it is worth noting
that in all RT-PCR experiments, unlike other DC subsets,
CD11cintCD11bGR-1 DCs (fraction D) showed some
background IRF-7 expression already in uninfected WT
mice (Fig. 7 b). Alternatively, IPCs might be able to utilize
an IRF-7–independent pathway for IFN- expression, as
suggested by the recent finding, that ectopic expression of
IRF-5 can substitute for IRF-7 to allow expression of cer-
tain IFN- genes (39). Ultimately, only the generation and
analysis of IRF-7–deficient mice can define the role of
IRF-7 in the expression of virus-induced IFN- in vivo.
Our immune histological analysis of VSV-infected mice
revealed that IPCs are predominantly located in the mar-
ginal zone. Similarly, we and others have found the same
IPC distribution in UV-HSV–treated mice (27, 40). The
importance of the marginal zone for pathogen surveillance
was demonstrated by the scavenger function of marginal
zone cells, which can retain microscopically small particles,
including pathogens, from the blood (41). Mice that were
experimentally depleted of macrophages in the marginal
zone (42), and osteopetrotic (op) mutant mice that are
M-CSF deficient and lack the same macrophage popula-
tions, showed an increased sensitivity to pathogen infection
(43). Thus, in order to be stimulated early in the course of
an infection it appears “reasonable” that IPCs are located in
the marginal zone. From histological colocalization studies
it had been concluded that MOMA-1 metallophilic and
ERTR-9 marginal zone macrophages might be involved
in type I IFN production (27). Since we could not observe
a strict correlation of MOMA-1 and ERTR-9 versus IFN-
/ stainings, and after recent evidence that the human
and mouse IPC are plasmacytoid DCs (25, 26, 29, 30), we
FACS®-sorted several DC subsets from spleen of VSV-
infected mice and analyzed them for IFN- mRNA ex-
pression. These experiments indicated that the subset of
CD11cintCD11bGR-1 DCs showed high IFN-
mRNA levels. Interestingly, we did not find increased lev-
els of IFN- message in myeloid or lymphoid DCs (frac-
tions A and B, respectively) isolated from VSV-infected
mice, as could have been expected form recent in vitro
data (28).
In conclusion, we suggest to extend the current model
of IFNAR feedback dependent expression of IFN- as fol-
lows. (i) In vivo, local infections may stimulate the produc-
tion of mainly IFN- by nonIPCs to protect surrounding
tissues in a paracrine fashion. These cells produce IFN-
IFNAR dependently, i.e., only if sufficient autocrine type I
IFN stimulation is provided. (ii) Systemic infection and
acute viremia that require a generalized antiviral state may
stimulate IPCs to produce IFN- early and at high-level
independent of IFNAR feedback signaling; however,
IFNAR feedback defines the magnitude and duration of
sustained IFN- production.
To our knowledge, we present the first set of ex vivo
data defining IPCs in viral pathogenesis. Our results sup-
port the concept that highly specialized DCs, located in the
marginal zone, produce type I IFN upon pathogen contact.
The observation that early IFN- production of mouse
IPCs is largely independent of IFNAR signaling indicates a
less stringently regulated IFN- expression in IPCs as com-
pared with other cell types. Further experiments will re-
veal, whether, depending on the tissue tropism and the
stimulation mechanism, different pathogens may activate
discrete cell populations to produce type I IFN, and
whether mouse IPCs do play a role in antigen processing
and presentation. A better understanding of the role of
IPCs in viral pathophysiology can have important diagnos-
tic and therapeutic implications, as exemplified by publica-
tions showing reduced IPC counts in HIV-infected AIDS
patients (44, 45).
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